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The main purpose of this thesis is the design of a polymeric 
bilayer scaffold with porous architecture for osteochondral 
regeneration. The material used for the construct fabrication 
was poly(L-lactic acid), a biodegradable polymer of the family 
of polyesters. One of the layers of the scaffold was designed to 
attend the regeneration of articular cartilage. The other layer 
serves as anchorage to subcondral bone, one difference with 
the previous layer is in the mechanical properties and the 
bioactivity. This behavior was obtained by combination of 
poly(L-lactic acid) with inorganic nanoparticles. Both layers 
are joined to each other by a thin layer of nonporous material, 
that avoids the flow of cells from one part to the other one. 
For this aim, first, scaffolds with different porous morphology 
were fabricated varying parameters of fabrication such as the 
polymer concentration and the polymer / porogen ratio, in 
order to obtain the more suitable structure for the 
regeneration of both tissues. Then they were evaluated in 
regard to their mechanical and physical-chemical properties, 
in order to select the parameters of fabrication which lead to 
greater results.  
In tissue regeneration it is essential to know how the implant 
properties will vary with time when implanted and when its 
degradation starts. Consequently we considered opportune 
studying in vitro degradation of the material in different 
conditions. The degradation study was realised by static 
degradation during 6, 12, 18, 24 weeks and 1 year and fatigue 
essay during 1, 2, 4 and 6 weeks. Then the mechanical 
properties and physical-chemical properties were evaluated 
after the different times of degradation. 
Later, and to increase the mehanical properties and 
bioactivity of the bone construct, different contents of bioactive 
ii 
 
nanoparticles of hydroxyapatite and silica were incorporated 
to the material. The influence of the incorporation of 
nanoparticles on the mechanical and physical-chemical 
properties was evaluated. Special emphasis was made in 
evaluating the increase of the bioactive potential provided by 
the inorganic filler. The bioactivity was evaluated thanks to 
the in vitro test consisting in studying the capacity of the 
material in nucleating biomimetcic hydroxyapatite crystals on 
its surface, while immersed in simulated body fluid during 
different times.  
These studies allowed selecting the optimal parameters of 
synthesis for the bilayer osteochondral construct, which was 






El objetivo principal de esta tesis doctoral es el diseño de un 
andamio polimérico bicapa macroporoso para la regeneración 
del complejo osteocondral. El material empleado para la 
fabricación del constructo ha sido el ácido poli(L-láctico), un 
polímero biodegradable de la familia de los poliésteres. Una de 
las capas del andamio ha sido diseñada para asistir la 
regeneración del cartílago articular. La otra capa sirve de 
anclaje al hueso subcondral, y se diferencia de la anterior en 
sus propiedades mecánicas y bioactividad. Este 
comportamiento ha sido logrado por combinación del ácido 
poli(L-láctico) con nanopartículas inorgánicas. Ambas capas 
están unidas entre sí por una fina capa de material no poroso 
que evita el flujo de células de una parte a otra del constructo.  
Para lograr este objetivo se realizó un primer estudio de 
diseño variando la morfología de los andamios hasta obtener 
aquella arquitectura más adecuada para la regeneración de 
ambos tejidos. Se varió parámetros de síntesis tales como la 
concentración de polímero y el ratio entre polímero y porógeno. 
Los andamios fueron evaluados mecánica y 
fisicoquímicamente y se seleccionó los parámetros de síntesis 
del ácido poli(L-láctico) que dieron mejores resultados. 
En la regeneración del tejido es esencial conocer cómo 
variarán las propiedades del material una vez sea implantado 
y comience su degradación. Por lo tanto, fue considerado 
oportuno realizar un estudio de degradación del material in 
vitro en diversas condiciones. El estudio de la degradación fue 
realizado en condiciones estáticas durante 6, 12, 18, 24 
semanas y 1 año y en condiciones dinámicas durante 1, 2, 4 y 6 
semanas. Se evaluó tanto las características mecánicas como 




Posteriormente, y para aumentar las características 
mecánicas y la bioactividad del anclaje óseo, se incorporó 
distintas cantidades de nanopartículas inorgánicas de 
hidroxiapatita y sílice a los andamios. La influencia de la 
cantidad de nanopartículas incorporadas y su naturaleza  en 
las características mecánicas y fisicoquímicas de los 
materiales fueron estudiadas. Se hizo especial hincapié en la 
mejora del potencial bioactivo proporcionado por la carga 
inorgánica. Para ello se realizó ensayos de bioactividad in vitro 
consistentes en estudiar la capacidad del material de nuclear 
hidroxiapatita biomimética en su superficie cuando es 
sumergido en fluido biológico simulado durante distintos 
tiempos.  
Estos estudios permitieron elegir los parámetros de síntesis 
óptimos para el andamiaje bicapa osteocondral, que fue 








L’objectiu principal d’aquesta tesi doctoral és el disseny d’un 
constructe polimèric bicapa macroporós (scaffold) per a la 
regeneració del teixit osteocondral. El material emprat per a la 
fabricació del constructe ha segut l’àcid poli(L-làctic), un 
polímer biodegradable de la família dels polièsters. Una de les 
capes del constructe ha segut dissenyada per a assistir la 
regeneració del cartílag articular. L’altra capa serveix 
d’ancoratge a l’os subcondral, i es diferencia de l’anterior en 
les seves propietats mecàniques i bioactivitat. Aquest 
comportament ha segut atansat amb la combinació de l’àcid 
poli(L-làctic) amb nanopartículas inorgàniques. Ambdues 
capes estan unides entre sí per una fina capa de material no 
porós, que evita el flux de cèl•lules d’una part a l’altra del 
constructe.  
Per tal d’obtenir aquest objectiu es realitzà un primer estudi 
de disseny variant la morfologia dels scaffolds fins a obtenir 
aquella arquitectura més adequada per a la regeneració dels 
dos teixits. Es varià paràmetres de síntesi tals com la 
concentració de polímer i el ràtio entre polímer i porogen. Els 
scaffods van ser avaluats mecànica i fisicoquímicament i se 
seleccionà els paràmetres de síntesi que donaren els millors 
resultats.  
En la regeneració del teixit és essencial conèixer com varien 
les propietats del material una vegada és implantat i comenci 
la seva degradació. Per tant, es considerà oportú realitzar un 
estudi de degradació del material in vitro en diverses 
condicions. L’estudi de degradació es realitzà en condicions 
estàtiques durant 6, 12, 18, 24 setmanes i 1 any i en 
condicions dinàmiques durant 1, 2, 4 i 6 setmanes. Es va 
avaluar tant les característiques mecàniques com 




Posteriorment, i per tal d’augmentar les propietats 
mecàniques i la bioactivitat de l’ancoratge ossi, s’incorporà 
distintes quantitats de nanopartícules inorgàniques 
d’hidroxiapatita i sílice als scaffolds. La influència de la 
quantitat de nanopartícules incorporades i la seva naturalesa 
en les propietats mecàniques i fisicoquímiques dels materials 
van ser estudiades. Es posà l’accent en la millora del potencial 
bioactiu proporcionat per la càrrega inorgànica. Per a això, es 
realitzà assajos de bioactivitat in vitro consistents en estudiar 
la capacitat del material de nuclear hidroxiapatita 
biomimètica a la superfície quan és submergit en fluid biològic 
simulat durant diversos temps.  
Aquestos estudis permeteren escollir els paràmetres de síntesi 
òptims per al constructe bicapa osteocondral, que va ser 








This thesis focuses on the design of a bilayer scaffold for 
osteochondral complex regeneration. The first layer presents 
similar characteristics to articular cartilage. In this layer 
mesenchymal cells will be cultivated and pre-differentiated to 
chondrocytes in vitro to promote cartilage regeneration when 
implanted in vivo. The second layer presents the bioactivity 
necessary to favour the anchorage to subchondral bone and 
mechanical properties similar to the surrounding bone. The 
two layers will be separated by an impermeable layer in order 
to avoid vascularization and migration of cells in the cartilage 
layer from the bone layer. The material selected for the design 
was poly(L-lactic acid), a biodegradable polymer approved by 
the FDA for medical devices. 
Specific purposes 
 
• Design of porous scaffolds with interconnected pores and 
a double porosity, micrometric and macrometric, able to 
reproduce the mechanical properties of artilcular 
cartilage and subchondral bone.  
 
• Evaluate the relationship between the properties of the 
scaffolds (porosity, micro and macrostructure, 
mechanical and other physicochemical properties) and 
the fabrication parameters, polymer/solvent ratio and 
polymer/porogen ratio. 
 
• Evaluate the effect of static and dynamic degradation on 
the structure, mechanical and physical-chemical 





• Modify the scaffolds to increase their bioactivity and 
mechanical properties for the bone anchorage layer. 
 
• Assembly of the cartilage and bone scaffolds into an 
osteochondral construct. 
 
• The biological response of the designed scaffolds was 
not a direct objective to this thesis but thanks to the 
collaboration with the Laboratorio de Ortopedia 
Experimental and Área de Terapia Celular of the 
Universidad de Navarra and the Group of Structural 
Mechanics and Materials Modelling, of the University 
of Zaragoza, it was possible to test samples in in vitro 
and in vivo. Some of the results are shown in the 




Chapter 1.   Introduction 
 
1.1 OSTEOCHONDRAL BIOLOGY 
1.1.1 Structure and function of articular cartilage 
 
Cartilage is a highly specialized, avascular, aneural, 
connective tissue found throughout the body. The primary 
function of this tissue in all locations is to provide structural 
support for surrounding tissues. There are four major types of 
cartilage each distinguished by specific constitutive or 
organizational components: hyaline or articular cartilage, 
elastic cartilage, and fibrocartilage.  
Elastic cartilage or yellow cartilage is a type of cartilage 
present in the outer ear, larynx and epiglottis. It contains 
elastic fibre networks and collagen fibres of type II and few 
ones of type IX, X and XI. The principal protein is elastin. 
Elastic cartilage is histologically similar to hyaline cartilage 
but contains many yellow elastic fibres lying in a solid matrix. 
These fibres give elastic cartilage great flexibility so that it is 
able to withstand repeated bending. Chondrocytes, which are 
the cartilage-specific cells, lie between the fibres.  
Fibrocartilage owes its flexibility and toughness to the former 
of these constituents, and its elasticity to the latter. 
Fibrocartilage is the only type of cartilage that contains type I 
collagen in addition to the normal type II. Chondrocytes are 
also the fibrocartilage cells. Fibrocartilage is found in the 
pubic symphysis, the annulus fibrosus of intervertebral discs, 
meniscus and the temporomandibular joint (1). 
Articular cartilage is the most prevalent type in the body and 
is distinguished by shiny white appearance. It is a tissue of 
mesenchymal origin that covers the articulating surfaces of 




the applied load onto the subchondral bone; it provides the 
articular surfaces with low friction and lubrication; it is also 
responsible for the mechanism of shock-absorption. 
Hyaline cartilage is a flexible tissue consisting of cartilage 
cells, chondrocytes, scattered through a woven network of 
collagen fibres and proteoglycans distributed within the extra-
cellular matrix (ECM) containing 60-80% of water (2).  
In humans, chondrocytes represent only about 1% of the 
volume of hyaline cartilage but are essential since it is these 
cells that replace degraded matrix molecules to maintain the 
correct size and mechanical properties of the tissue. Thus, 
chondrocytes produce and maintain components of ECM 
including collagen, glycoaminoglycans (GAGs) and 
proteoglycans (3). 
Collagen types II, VI, IX, X and XI are found in articular 
cartilage, although type II accounts for 90-95% of the collagen 
in the matrix. Type II collagen has a high amount of bound 
carbohydrate groups, allowing more interaction with water 
than some other types. Collagen types IX and XI, along with 
type II, form fibrils that interweave to form a mesh. This 
organization provides tensile strength as well as physically 
entrapment of other macromolecules. Type X is found only 
near the areas of the matrix that are calcified.  
The ECM in hyaline cartilage contains three kinds of GAGs: 
hyaluronan, chondroitin sulphate and keratan sulphate. The 
hyaluronan molecule is important in the structure of the ECM 
as it forms a linear aggregate and is interwoven with the 
network of collagen fibrils. A proteoglycan monomer consists 
of a core protein joined by GAGs. The most important 
proteoglycan monomer in the ECM is aggrecan, which is 
joined by chondroitin sulphate and keratan sulphate 
molecules. Proteoglycans are hydrophilic; this property results 
in the ability of hyaline cartilage to retain water which is 
essential to its proper function. The principal role of articular 




underlying bone. Keratan sulfate and chondroitin sulfate on 
the GAGs carry a negative charge. This negative charge 
creates a high affinity for water that helps cartilage to resist 
compressive loads and causes the aggrecans to repel one 
another, resulting in maximal volume expansion. The flow of 
water through charged regions of the proteoglycan-rich matrix 
generates piezoelectric charges that further modulate the rate 
of water flow contributing to the viscoelastic behaviour of 
articular cartilage. In addition, there is evidence that electric 
and electromagnetic fields can produce a sustained up-
regulation of growth factors in articular cartilage (4).  




Figure 1-1: Proteoglycan aggregate structure. Reproduced 
from (4). 
 
As represented in Figure 1-2, articular cartilage can be 
divided into four zones: superficial, transitional, middle and 
calcified; based on differences in matrix morphology and 
biochemistry. The superficial zone is the thinnest zone and is 






predominantly collagen fibers covers the joint. Below this, the 
second layer is composed of flattened chondrocytes with their 
long axes parallel to the articular surface. The ECM in this 
area has more collagen and less proteoglycan than the other 
zones. There are also large amounts of fibronectin and water. 
This combination of molecules imparts more tensile strength 
to this area of the matrix, which could be useful in resisting 
shear stress from the articulating surfaces. Occupying more 
volume than the superficial zone, the transitional zone 
includes chondrocytes that are spherical and contain synthetic 
organelles such as the endoplasmic reticulum, Golgi bodies 
and mitochondria. The ECM in this area has larger collagen 
fibrils, more proteoglycan and less collagen and water than in 
the previous zone. The interterritorial fibrils are aligned 
obliquely or randomly to the articular surface, as opposed to 
parallel in the superficial zone. The middle zone is usually the 
biggest and has the largest diameter collagen fibrils, the most 
proteoglycan and the least water. The cells are rounded, like 
in the transitional zone, but are stacked in columns 
perpendicular to the articulating surface. The territorial 
region of the matrix encloses each column. These cells show 
high synthetic activity, ten times that of superficial zone 
chondrocytes. Also, in this area, the orientation of the 
interterritorial fibres changes again so that they are now 
aligned perpendicular to the joint surface. The fibres extend 
into the tidemark, a basophilic line of unknown composition 
that indicates the beginning of calcified tissue. The thin 
calcified cartilage zone lies closest to the subchondral bone 
and acts as a transition from soft hyaline cartilage to bone. 
Significant shear stress can be produced in this area due to 
the interface between the soft cartilage and much stiffer bone. 
The chondrocytes here are smaller, with almost no 
endoplasmic reticulum. In some places, they seem to be 
completely surrounded by calcified ECM, indicating that they 






Figure 1-2: Three dimensional organisation of articular 
cartilage. Produced from (4). 
 
The complex network formed by proteoglycans and type II 
collagen, provides resistance to a compressive stress and high 
elasticity to the articular cartilage. The equilibrium modulus 
of articular cartilage in compression can range from 0.05 to 0.8 
MPa. The network confers to the matrix porosity between 65 
and 80%, with pores of 60 Angstroms in normal conditions, 
which could be reduced up to 20 Angstroms when cartilage is 
compressed. When a load is applied, the water flows very 
slowly out of the tissue. This slow flow is due to two factors, 
the low porosity and the presence of the negative charges 
contained in the GAGs molecules, which exert a strong 
resistance to a volume reduction. In these conditions the load 
bearing capacity is influenced mainly by liquid. The 
uncompressible water sustains the compressive stresses, 





matrix, which appears only partially involved in the 
biomechanical response. If cartilage is damaged the water 
flows out rapidly from the ECM involving significantly the 
solid component of the tissue in the biomechanical response. 
This may lead to a rapid deterioration of the whole 
cartilaginous tissue (3). Articular cartilage can reach a 
thickness of up to 7- 8 mm in human knee joint (6). 
1.1.2 Composition, structure and function of 
subchondral bone 
 
Bones are rigid organs that constitute part of the endoskeleton 
of vertebrates. Bone tissue is a type of dense connective tissue. 
The extra cellular matrix of bone comprises of both a 
mineralized inorganic component and an organic one. It is the 
mineralized osseous tissue that gives it rigidity and a 
honeycomb-like three-dimensional internal structure.  
The adult human skeleton is composed of 80% cortical bone, 
also called compact bone, and 20% trabecular bone, also called 










Figure 1-3: Hieralgical structure of bone. 
 
The hard outer layer of bones is composed of compact bone 
tissue, so-called due to its minimal gaps and spaces. Filling 
the interior of the bone is the trabecular bone tissue, an open 
cell porous network which is composed of a network of rod- 
and plate-like elements that make the overall organ lighter 
and allow room for blood vessels and marrow. Trabecular bone 
accounts for the remaining 20% of total bone mass but has 
nearly ten times the surface area of compact bone. Its porosity 
is 30–90%. Both cortical and trabecular bone are composed of 






Haversian systems are cylindrical in shape, are approximately 
400 mm long and 200 mm wide at their base, and form a 
branching network within the cortical bone. The periosteum is 
a fibrous connective tissue that surrounds the outer cortical 
surface of bone, except at joints where bone is lined by 
articular cartilage. The periosteum is tightly attached to the 
outer cortical surface of bone by thick collagenous fibers, 
called Sharpeys’ fibers, which extend into underlying bone 
tissue. The endosteum is a membranous structure covering 
the inner surface of cortical bone, trabecular bone, and the 
blood vessel canals (Volkman’s canals) present in bone. 
At the joint, the epiphysis is covered with articular cartilage; 
below that covering is a zone similar to the epiphyseal plate, 
known as subchondral bone.  
Bone is composed of cells such as osteoblasts and osteoclasts 
which control the formation or the destruction of tissue. 
Osteoblasts are located on the surface of bone or osteoid, and 
they are responsible for synthesizing the organic components 
of the bone matrix, including type I collagen, proteoglycans, 
and glycoproteins. Osteoblasts also synthesize the enzyme 
alkaline phosphatase, which is needed locally for the 
mineralization of osteoid, the matrix produced by osteoblasts. 
Osteoblasts contact their neighbouring osteoblasts 
cytoplasmically. These cells have polarity with the cytoplasm 
toward the bone and the nuclei at the opposite end away from 
the bone. Osteoblasts do not divide. They give rise to 
osteocytes, remain as osteoblasts, or return to the state of 
osteoprogenitor cells from which they derived (7, 8, 9). 
An osteoblast becomes an osteocyte when the cell is encased by 
osteoid matrix that it synthesizes itself. Lacunae and 
canaliculi form around the osteocyte and its cytoplasmic 
processes, respectively (10). Thus, an osteocyte lies in its own 
lacuna and contacts its neighbouring osteocytes 




Adjacent cells make contact via gap junctions, maintaining the 
vitality of osteocytes by passing nutrients and metabolites 
between blood vessels and distant osteocytes. Although 
osteocytes have reduced synthetic activity and are not capable 
of mitotic division, they are actively involved with the 
maintenance of the bony matrix. Some of the osteocytes die 
during remodelling, but most probably return to the state of 
osteoprogenitor cells or persist as osteocytes for a long time.  
The osteoclasts are probably derived from a monocytic-
macrophage system and are responsible for bone resorption, 
and are the only cells to resorb mineralized bone matrix.  
Similarly to cartilage, bone cells are part of the matrix. Bone 
matrix consists of organic and inorganic components. The 
association of organic and inorganic substances gives bone its 
hardness and resistance. The organic component is composed 
of collagen fibers with predominately type I collagen (95%) and 
amorphous material, including glycosaminoglycan 
(chondroitin sulphate) that are associated with proteins, with 
amino acid content rich in glycine, leucine, glutamate and 
aspartate. Osteoid is uncalcified organic matrix. Inorganic 
matter represents about 50% of the dry weight of bone matrix, 
composed of abundant calcium and phosphorus, as well as 
smaller amounts of bicarbonate, citrate, magnesium, 
potassium, and sodium. Calcium forms hydroxyapatite (HAp) 
crystals with phosphorus but is also present in an amorphous 
form. The ratio between calcium and phosphate is a way to 
characterise the type of hydroxyapatite, stoichiometric 
hydroxyapatite (Ca10(PO4)6(OH)2) has a calcium phosphate 
ratio of 1.67, and physiological HAp a Ca/P ratio of 1.65. Bone 
hydroxyapatite crystals are very small, 200 Angstroms. Matrix 
maturation is associated with expression of alkaline 
phosphatase and several noncollagenous proteins, including 
osteocalcin, osteopontin and bone sialoprotein. It is thought 




regulate ordered deposition of mineral by regulating the 
amount and size of hydroxyapatite crystals formed.  
Bone mineral provides mechanical rigidity and load-bearing 
strength to bone, whereas the organic matrix provides 
elasticity and flexibility. Bone mineral is initially deposited in 
“hole” zones between the ends of collagen fibrils. This process 
may be facilitated by extracellular matrix vesicles in bone. 
Matrix extracellular vesicles are synthesized by chondrocytes 
and osteoblasts and serve as protected microenvironments in 
which calcium and phosphate concentrations can increase 
sufficiently to precipitate crystal formation. The extracellular 
fluid is not normally supersaturated with hydroxyapatite, so 
hydroxyapatite does not spontaneously precipitate. Matrix 
extracellular vesicles contain a nucleational core that is 
composed of proteins and a complex of acidic phospholipids, 
calcium and inorganic phosphate that is sufficient to 
precipitate hydroxyapatite crystals. It is not yet certain how 
matrix extracellular vesicles contribute to mineralization 
points at the ends of collagen fibrils, because the vesicles 
apparently are not directly targeted to the ends of fibrils. 
There is no evidence that noncrystalline calcium phosphate 
clusters (amorphous calcium phosphate) form in bone before 
they are converted to hydroxyapatite. As bone matures, 
hydroxyapatite crystals enlarge and reduce their level of 
impurities. Crystal enlargement occurs both by crystal growth 
and by aggregation. Confirmed mineralization promoters 
(nucleators) include dentin matrix protein 1 and bone 
sialoprotein. Type I collagen is not a bone mineralization 
promoter. Phosphoprotein kinases and alkaline phosphatase 
regulate the mineralization process. Bone alkaline 
phosphatase may increase local phosphorus concentrations, 
remove phosphate-containing inhibitors of hydroxyapatite 
crystal growth, or modify phosphoproteins to control their 
ability to act as nucleators. Vitamin D plays an indirect role in 




After absorption or skin production of vitamin D, the liver 
synthesizes 25-hydroxyvitamin D and the kidneys 
subsequently produce biologically active 1.25-
dihydroxyvitamin D [1.25-(OH)2D]. Serum 1.25-(OH)2D is 
responsible for maintaining serum calcium and phosphorus in 
adequate concentrations to allow passive mineralization of 
unmineralized bone matrix (11). 
Bone remodelling is the process by which bone is renewed to 
maintain bone strength and mineral homeostasis. 
Remodelling involves continuous removal of discrete packets 
of old bone, replacement of these packets with newly 
synthesized proteinaceous matrix and subsequent 
mineralization of the matrix to form new bone. Remodelling 
begins before birth and continues until death. The bone 
remodelling unit is composed of a tightly coupled group of 
osteoclasts and osteoblasts that sequentially carry out 
resorption of old bone and formation of new bone. The 
remodelling cycle is composed of four sequential phases. 
Activation precedes resorption, which precedes formation. 
Remodelling sites are thought to develop mostly in a random 
manner. Activation involves recruitment and activation of 
mononuclear monocyte-macrophage osteoclast precursors from 
the circulation, lifting of the endosteum that contains the 
lining cells of the bone surface, and fusion of multiple 
mononuclear cells to form multinucleated preosteoclasts. 
Osteoclast-mediated bone resorption takes only approximately 
2 to 4 weeks during each remodelling cycle. Resorbing 
osteoclasts secrete hydrogen ions via H+-ATPase proton pumps 
and chloride channels in their cell membranes into the 
resorbing compartment to lower the pH within the bone-
resorbing compartment to as low as 4.5, which helps mobilize 
bone mineral. Resorbing osteoclasts secrete tartrate-resistant 
acid phosphatase, cathepsin K, matrix metalloproteinase 9, 
and gelatinase from cytoplasmic lysosomes to digest the 




cells after the multinucleated osteoclasts undergo apoptosis. 
At the completion of bone resorption, cavities contain a variety 
of mononuclear cells, including monocytes, osteocytes released 
from bone matrix and preosteoblasts recruited to begin new 
bone formation. The coupling signals linking the end of bone 
resorption to the beginning of bone formation are as yet 
unknown. Bone formation takes approximately 4 to 6 months 
to complete. Osteoblasts synthesize new collagenous organic 
matrix and regulate mineralization of matrix by releasing 
small, membrane-bound matrix vesicles that concentrate 
calcium and phosphate and enzymatically destroy 
mineralization inhibitors such as pyrophosphate or 
proteoglycans. Osteoblasts surrounded by and buried within 
matrix become osteocytes. At the completion of bone 
formation, approximately 50 to 70% of osteoblasts undergo 
apoptosis, with the balance becoming osteocytes or bone-lining 
cells. Bone-lining cells may regulate influx and efflux of 
mineral ions into and out of bone extracellular fluid, thereby 
serving as a blood bone barrier, but retain the ability to 
redifferentiate into osteoblasts upon exposure to parathyroid 
hormone or mechanical forces (11). 
1.1.3 Cartilage injuries 
 
Articular cartilage is a metabolically active tissue, but it has a 
poor intrinsic healing potential when damaged. It is able to 
repair but not to regenerate itself. A reparative process may 
replace the damaged cartilage by a tissue that fails. The 
cartilage response to traumas is limited for two reasons: first, 
cartilage is an avascularised tissue and therefore, when a 
cartilaginous lesion occurs, the blood clot formation cannot 
take place and the inflammation response, often accompanied 
by the migration of the undifferentiated cells to the lesion site, 
is absent. Second, there is a lack of undifferentiated cells. The 




further decline with age, making the repair process further 
difficult in adult and old patients (3). 
Globally cartilage injuries can be classified by three main 
types: matrix disruption, partial thickness defects and full 
thickness defects. In the case of matrix disruption ECM is 
damaged, but if the injury is not extreme, the remaining 
viable chondrocytes will increase their synthetic activity to 
repair the tissue. Partial thickness defects demonstrate 
disruption of the cartilage surface (fissures, etc.) but this does 
not extend to the subchondral bone. Immediately following the 
injury, nearby cells begin to proliferate. Full thickness defects 
transverses the entire cartilage thickness and penetrates the 
subchondral bone. In this case, the defect is filled with a fibrin 
clot and a classic wound healing response occurs. With this 
type of injury, progenitor cells from the bone marrow can 
migrate to fill the defect (5).  
One of the most common diseases of cartilage is osteoarthritis 
(OA), also called degenerative arthritis, involving the 
degradation of joints including articular cartilage and 
subchondral bone. It has been studied that cartilage defects 
may result in increased cartilage breakdown leading to 
decreased cartilage volume and joint space narrowing (12). OA 
is a debilitating, progressive joint disease often associated 
with aging process. It presents a combination of several 
disorders in which biomechanical properties of cartilage are 
altered leading to tissue softening and finally degradation. 
The degenerative process may be initiated with loss of 
proteoglycans from the ECM followed by disruption of 
collagenous fibrillar network leading to cell apoptosis/necrosis 
and deterioration of the functional tissue. Any synovial joint 
can develop osteoarthritis but knees, hips and small hand 
joints are the most common sites affected. Injurious and 
excessive mechanical stress can also result in reduction of 
proteoglycans and damage the collagen network. Mechanical 




joint protection and excessive loading. The first category 
comprises factors increasing joint vulnerability from 
deformation, muscle weakness, genetic predisposition and 
aging. The second implicates obesity, certain physical 
activities and trauma (13, 14). OA is a disorder affecting about 
10% of the United State of America population older than 30, 
and most of the people over the age of 65, with total costs 
estimated at $28.6 billion/year (15). 
 
1.1.4 Articular cartilage repair conventional therapies 
 
One of the first therapies used to repair cartilage injuries was 
a conservative one; medications. Unfortunately it was rather 
than a cure a temporary relief of symptoms, which lead 
clinicians to surgical strategy (16). Today, pain caused by 
advanced arthritis in joints is palliated by total joint 
replacement by a synthetic prosthesis, therapy known as total 
hip or knee arthroplasty. Recently, and in order to avoid such 
a traumatic clinical treatment, therapies based on the 
stimulation of the natural repair process of cartilage have 
started to be practiced. In this sense, one of the first methods 
proposed to repair articular cartilage involved the disruption 
of subchondral bone to induce fibrin clot formation and initiate 
primitive stem cell migration from the bone marrow into the 
cartilage defect site. The fibrin clot formation is supposed to 
stimulate mesenchymal cells to initiate a repair response and 
differentiate into chondrocytes under the biological and 
biomechanical conditions experienced in the joint. These 
techniques, called bone marrow-based repair techniques, are 
techniques such as abrasion, subchondral drilling and 
microfracture. Abrasion arthroplasty is an abrasion of the 
damaged surface down to bleeding bone. The philosophy is 
that blood vessels will nourish the damaged area and 




cover the damaged area with a new healthy surface. It is 
usually kept for smaller areas, as it has been found that the 
material which grows, fibrocartilage, is not as strong as proper 
cartilage and may break down (17). Subchondral drilling is a 
surgical technique, no longer popular, where a high-speed drill 
is used to drill down through a defect in the joint surface and 
into the underlying bone, in order to allow the release of blood 
and bone marrow cells which have the potential to form a 
protective fibrocartilage layer over the defect. Because the 
high speed drill can cause heating of the bone, and consequent 
damage, the procedure has largely been replaced with less 
damaging techniques such as microfracture (18). 
Microfracture was designed to be less invasive than drilling. 
Multiple microfractures (3 to 4 mm apart) are created in the 
subchondral bone to disrupt blood vessels and allow fibrin clot 
formation (19). Although these therapies are able to produce a 
regenerated tissue, they lead to the formation of fibrocartilage 
in the cartilage defect. Fibrocartilage lacks the structural and 
mechanical properties of the original hyaline cartilage; it does 
not produce proper compressive stiffness against applied 
mechanical load and is excessively deformed under 
physiological loading. Then, the supposed reparative tissue 
formed recurrently degenerates and fissures (16). 
More recent surgical strategies plan to replace the defect with 
patches or grafts. Cartilage allograft has problems with 
preparation and storage, and chondrocytes expire during the 
process. If implanted rapidly, cartilage allograft is supposed, 
by immune reaction from the synovial fluid, to induce tissue 
formation (20, 21). Autografting techniques, such as 
mosaicplasty with autologous osteochondral graft mimicking 
the defect dimension, lead to better results than other 
techniques. This technique is easily applied and the grafts are 
self-secure to the subchondral bone without any additional 
fixing procedure. However, simple cartilage grafts are difficult 




sutures. This is a process that takes time and which may 
damage the native tissue. Although mosaicplastic grafts are 
more firmly implanted, they are limited to a few autogenous 
donor sources in the human body meaning the therapy is only 
valid for small cartilage defects and artificially constituted 
extra cartilage is needed to repair larger defects (22).  
Solutions to the clinical problem of articular cartilage repair 
need multidisciplinary collaboration from biotechnology. In 
1994 Brittberg and collaborators (23) introduced the technique 
of Autologous Chondrocyte Implantation (ACI). This technique 
consists of harvesting a minimum amount of autogenous 
cartilage to retrieve chondrocyte, which are cultured in vitro to 
expand the population, seeded onto the defect and covered 
with a flap (13, 24-26). Periosteum or perichondrium is used 
as a sutured flap to cover the transplantation of chondrocytes 
or progenitors cells in the defect site (PACI), but problems of 
abrasion force leads to suture failure and an unsuccessful 
outcome (27-30). However, the donor site morbidity produced 
by the use of a periosteal flap and reports of the emerging 
complication of graft hypertrophy encouraged the development 
of the second generation of ACI techniques. Collagen-covered 
ACI (CACI) replaces a periosteal flap with a porcine collagen 
membrane as a graft covering, avoiding donor site morbidity 
associated with harvesting periosteum and theoretically 
reducing the risk of graft hypertrophy (31). Successful clinical 
results with CACI suggest that a periosteal membrane is not 
essential for ACI to be successful (32). PACI and CACI 
methods both require the chondrocytes suspension to be 
injected under the chosen covering and cannot ensure even 
cell distribution within the final graft. In addition, both 
methods require the graft to be sutured in place, potentially 
requiring extended operating times where multiple grafts or 
concurrent procedures are required. In an effort to address 
these issues while continuing to avoid graft hypertrophy and 




Implantation (MACI) was developed. In MACI technique the 
cells are seeded onto a biodegradable porous matrix to 
constitute cartilage. The elements of MACI have been 
improved continually to regenerate cartilage of better quality 
(33). MACI is the first step to what is known as tissue 
engineering (TE) approaches. We will dedicate the following 
sections to specific topics associated to articular cartilage TE 
and bone TE, as the main objective of this doctoral thesis is 
the development of a synthetic construct for osteochondral 
tissue engineering to repair osteoarthritic joints. 
1.1.5 Tissue engineering (TE) approach for the 
regeneration of articular cartilage  
 
A commonly applied definition of tissue engineering, as stated 
by Langer and Vacanti in 1995, is "an interdisciplinary field 
that applies the principles of engineering and life sciences 
toward the development of biological substitutes that restore, 
maintain, or improve tissue function or a whole organ" (36). In 
2006 Williams suggested that “tissue engineering is the 
creation of new tissue for the therapeutic reconstruction of the 
human body, by the deliberate and controlled stimulation of 
selected target cells, through a systematic combination of 
molecular and mechanical signals”. Most of all adult tissues 
have limited ability to regenerate. In order to develop this 
ability it is necessary to give to the tissue some cues or signals. 
Being TE a matter of creation of new tissue, the process is 
logically expected to be achieved by cells. The cells need to be 
stimulated in order to create the new tissue by factors like 
biomolecules and support. The support structure may be the 
key for proper regeneration and can be a scaffold, a matrix, or 
a membrane within or on which the cells will express the new 
tissue. And they will be persuaded to do this by the molecular 




molecules and mainly by mechanical signals transmitted 
through the support and the fluid medium (34, 35). 
One of the main concerns in cartilage TE is cell sourcing. The 
optimal cell source for cartilage tissue engineering is still 
being identified. Chondrocytes, fibroblasts, stem cells and 
genetically modified cells have all been explored for their 
potential as a viable cell source for cartilage repair. 
Chondrocytes are the most obvious choice, since they are 
found in native cartilage and have been extensively studied to 
assess their role in producing, maintaining and remodelling 
the cartilage ECM. Fibroblasts are easily obtained in high 
numbers and can be directed toward a chondrogenic 
phenotype. Recent work has focused on stem cells, which have 
multi-lineage potential and can be isolated from a plethora of 
tissues. These progenitor cells can be expanded through 
several passages without loss of differentiation potential. 
Additionally, all of these cells can be modified genetically to 
induce or enhance chondrogenesis. The goal is to find an ideal 
cell source that can be easily isolated, is capable of expansion 
and can be cultured to express and synthesize cartilage-
specific molecules (e.g., type II collagen and aggrecan).  
In cartilage TE scaffolds have an important role acting as cell 
carrier and mechanical support. The primary focus has been 
on polymeric materials, in forms of hydrogels, sponges and 
fibrous meshes. Scaffolds provide a 3D environment that is 
desirable for the production of cartilaginous tissue. Ideally the 
scaffold should:  
1) have directed and controlled degradation,  
2) promote cell viability, differentiation, and ECM production, 
3) allow for the diffusion of nutrients and waste products,  
4) adhere and integrate with the surrounding native cartilage, 
5) span and assume the size of the defect and  





Materials used to create these scaffolds can be natural 
polymers, synthetic artificial polymeric materials or 
combinations. Hyaluronic acid hydrogel is one of the most 
natural polymers used in this field. As it is naturally present 
in cartilage tissue it promotes cell proliferation, 
morphogenesis, inflammation and wound repair (37), and can 
easily fill defects and be crosslinked to increase its mechanical 
properties (38). Other natural hydrogels alternative to 
hyaluronic acid are collagen and fibrin and have been widely 
used for this aim (39-41). 
Many different scaffolds have been constructed from other 
varieties of biomaterials. Biodegradable synthetic polymers 
such as poly(glycolic acid) (PGA), poly(lactic acid) (PLA) and 
their copolymer of poly(DL-lactic-co-glycolic acid) (PLGA) are 
good material candidates. These two kinds of biomaterials 
have their respective advantages and disadvantages. These 
synthetic polymers have relatively good mechanical strength 
and their shape and degradation rate can be easily modified, 
but their surfaces are hydrophobic and lack cell-recognition 
signals. Naturally derived polymers have good cell interaction 
and hydrophilicity but they are mechanically too weak to 
maintain the desired shape until newly formed tissue 
matures. A novel kind of hybrid porous scaffolds have been 
investigated by introducing porous collagen sponge into the 
pores of synthetic polymer sponge and demonstrated its ability 
for cartilage tissue engineering (42). Biodegradable polymers 
for cartilage regeneration need to improve the hydrophilicity 
to hinder cell attachment and protein adsorption on their 
surface. It is widely accepted that if chondrocytes adhere to 
the pore walls of a scaffold, despite the 3D environment, they 
tend to dedifferentiate and produce an ECM which is more 
abundant in collagen I than in collagen II (43). For an 
adequate regeneration cell arrangement should be more 
similar to what occurs in nature, where chondrocytes are 




adhesion to scaffold pore walls is a phenomenon to be avoid. 
Several strategies have been reported to reduce cell-adhesive 
properties; plasma treatment and chemical graft of hydroxyl, 
carboxyl, or amide groups are examples of surface modifying 
in order to increase hydrophilicity (44,45).  
Not only the nature of the scaffolds has influence on the 
healing role of the implant, but also the percentage of porosity 
and the pores dimension. It has been studied that scaffolds 
with pores from 200 to 400 µm and 90% porosity provide an 
optimum environment for chondrogenesis (46,47). Surface 
roughness also affects cellular adhesion, proliferation and 
phenotype (48). 
 
Stimulating factors, such as growth factors, are another 
component of TE triad. Growth factors act on target cells by 
adhering to a specific receptor which triggers, by a system of 
signals or messengers, the activation of nuclear genes that 
determine cell proliferation, differentiation and death. Growth 
factors combine to promote cell survival and induce 
chondrocytic proliferation. A number of growth factors like 
TGF-β, FGF, BMP and IGF, along with other soluble factors 
like HA, chondroitin sulfate, and insulin, have been explored 
for their effects on cartilage tissue engineering (49).  
There is significant evidence that dynamic compressive 
loading has a stimulatory effect on cartilage, chondrocytes, 
and stem cells. Chondrocytes exhibit compressibility and 
behavioral changes with compressive load as a function of 
strain. Numerous loading regimes ranging from a single 
application to continuous loading have been investigated as a 
means to accelerate and improve tissue formation (50,51).  
Bioreactors have been employed to accelerate and improve the 
growth of engineered cartilage in vitro. They serve to enhance 
nutrient transport and provide a hydrodynamic environment 
that imposes a fluid-induced shear stress to promote the 




seeding of porous scaffolds has led to faster invasion and 
better cell distributions (52-54).  
1.1.6 TE approach for the regeneration of bone 
 
Bone and cartilage cells come from the same embryonic stem 
cells, and while studies show how bone stem cells are involved 
in cartilage repair it is first necessary to study the status of 
bone TE independently. The remodelling process of bone gives 
to bone a high ability to regenerate naturally. But some 
defects, because of the dimension or severity, cannot be cured 
naturally. In this context TE is an alternative to the limit of 
bone regeneration.  
Natural bone grafts represent one of the techniques for bone 
repair, but there are some important drawbacks. Harvesting 
the graft requires additional invasive surgical procedures that 
may lead to donor morbidity and infections. The use of 
autografts is not highly available, unlike autologous bone, 
allogeneic (from human cadaver) and xenogeneic (from animal 
source) grafts which are widely available and do not require 
additional surgery on the patient. However, allogeneic bone 
has to undergo processing techniques such as lyophilization, 
irradiation or freeze-drying to remove all immunogenic 
proteins in order to avoid any risk of immunogenic reaction. 
These processing techniques have a negative effect on the 
potential of the allografts, which consequently decrease their 
biological performance when compared to autografts (55).  
Because of the above mentioned drawbacks of natural bone 
grafts, a large number of synthetic grafts have been developed.  
As for cartilage tissue engineering, bone tissue engineering 
presents the same areas of focus, such as cell sourcing, 
scaffolds design and stimulating agents.  
One of the most common cell sources for bone tissue 
engineering is bone marrow stromal cells (bone marrow-




one other source of cells to seed scaffolds for bone repair. They 
can be isolated from the umbilical cord or from human dermis, 
for example  (57). It has been studied that human primary 
fetal bone cells could be of great interest for bone research, 
due to their fast growth rate and their ability to differentiate 
into mature osteoblasts (58). Another source of cells can be 
adipose stem cells, called lipoaspirate cells as they share the 
characteristics of human osteoprogenitor cell surface markers 
similar to bone marrow mesenchymal stem cells (59, 60). 
Scaffolds provide support in the formation of tissue, playing a 
crucial role in cell growth and differentiation. These goals are 
achieved by an appropriate chemistry, morphology and 
structure of the scaffold to accelerate cell adhesion for 
osteoblasts and osteoprogenitor cells, migration, 
differentiation and synthesis of the homogenous bone matrix 
avoiding the necrosis in the central regions. Various 
combinations of matrix materials are well studied, including 
biodegradable synthetic polymers such as poly(glycolic acid) 
(PGA), poly(lactic acid) (PLA) (61), copolymers of poly(DL-
lactic-glycolic acid) (PLGA) (62) and poly(ε-caprolactone) (PCL)  
(63), and biodegradable naturally derived polymers such as 
collagen (64), fibrin (65) or silk (66, 67).  
High porosity and large pores enhance bone ingrowth and 
osseointegration of the implant after surgery, as such, the 
higher pore surface area, interacting with the host tissue can 
accelerate degradation due to macrophages via oxidation 
and/or hydrolysis. In vitro lower porosity enhances 
osteogenesis due to cell aggregation and suppressed 
proliferation. The recommended pore size for a scaffold is 200-
500 µm. Relatively larger pores favor direct osteogenesis, since 
they allow vascularization and high oxygenation, while 
smaller pores result in osteochondral ossification (68,69). Thus 
big pores should be interconnected in order to allow the flux of 
cells and the supply of oxygen and nutrients to cells inside the 




vascularization (70). There is, however, an upper limit in 
porosity and pore size set by constraints associated with 
mechanical properties. An increase in the void volume results 
in a reduction in mechanical strength of the scaffold, which 
can be critical for regeneration in load-bearing bones (68). 
One of the important needs for scaffolds is to support load. 
However the specific mechanical requirements of the scaffolds 
from the beginning of implantation till complete healing is still 
under debate. For example, some authors have stated that 
scaffold mechanical properties should match those of natural 
bone. In the case of cortical bone the elastic modulus is from 
12 to 18 GPa and 1 to 5 GPa for trabecular bone. But some 
authors state simply that there should be enough if the 
scaffold does not collapse during handling and during the 
patient’s normal activities (71). Most of the porous scaffolds 
listed reveal insufficient mechanical properties (Figure 1-4). 
Figure 1-4 shows that some dense polymers match cancellous 
bone properties and approach cortical bones as well. Porous 
scaffolds however are at least one order of magnitude weaker 
than cancellous bone and orders of magnitude than cortical 
bone. Bioactive ceramics have less stiffness than the 
biodegradable scaffolds and the porous composites present a 
slight increase of mechanical properties compared to porous 
polymer scaffolds (72). A wide range of bioactive inorganic 
materials similar in composition to mineral phase of bone are 
used in the fabrication of composite scaffolds for bone 
regeneration, e.g. tricalcium phosphate, hyadroxyapatite, 
bioactive glasses and their combination (73). The composite is 
an alternative to generate bioactive materials which combine 
the bone nature of an inorganic phase with the toughness of a 






Figure 1-4: Elastic modulus vs. compressive strength of 
biodegradable polymers, bioactive ceramics, composites, 
cancellous bone and cortical bone. Porosities of the porous 
scaffolds are superior of 75% and mostly interconnected. 
Reproduced from (72). 
 
Cells seeded on tissue engineering constructs are often loaded 
by directly adding a cell suspension to the scaffold. Although 
this method is simple and thus widely used, it can result in 
low seeding efficiencies and non-homogenous seeding 
distributions. Seeding efficiency can be improved by placing 
porous scaffolds in a mixing cell solution. Spinner flask 
systems have been used for this purpose. Bone marrow 
stromal cell and chondrocyte loading efficiency have been 
shown to be 20% higher using a perfusion system as compared 
to static and spinner flask loading and significantly more 
uniformly distributed. Dynamic seeding yielded higher 
seeding efficiencies under most culture conditions. Perfusion 
seeding may increase seeding efficiency and reduce risk of 
contamination by decreasing the amount of time the scaffolds 
are handled outside the bioreactor system (75). 
Bone contains a cocktail of growth factors including 
transforming growth factor beta (TGF-β), platelet-derived 




insulin-like growth factors I and II (IGF-I and IGF-II) and 
fibroblast growth factors (FGFs) that have been shown to have 
important actions in bone cell function and therefore have 
been used to induce adequate bone cell response and enhance 
bone formation. Bone seems to be the largest reservoir for 
transforming growth factor-β (TGF-β). TGF-β is a secreted 
multifunctional protein that regulates many aspects of cellular 
function, including cell proliferation, differentiation and 
extracellular matrix metabolism. Insulin-like growth factors 
(IGFs) are also considered to be among the most important 
skeletal growth factors. The response to BMPs differs from the 
response to TGF-β in that BMPs (BMPs 2, 4 and 7) induce 
bone development from connective tissue perivascular cells (or 
other osteoprogenitor cells), which in the lifetime of the animal 
would not normally develop bone, i.e. they are osteoinductive 
(76, 77). The significance of enhanced osteogenic effect with 
multiple growth factors has been well established. Enhanced 
bone formation was observed with application of TGF-β1 and 
IGF-1 simultaneously. Similarly, TGF-β3 and BMP-2s loaded 
alginate scaffolds had significantly enhanced bone formation 
in mice in comparison to single growth factor loaded scaffolds. 
It has been suggested that multiple growth factor use can also 
be cost effective by yielding better results with reduced 
amounts of growth factor utilization when compared to much 
higher doses of single growth factors required for comparable 
results (78).  
Cells regularly contract and thereby deform the scaffolds, 
resulting in the generation of tension within the cells. This 
contractile activity of cells is essential for 
mechanotransduction, which in vitro is provided by the 
bioreactor. As a part of mechanotransduction, cells generate 
and experience forces which affect the kinetic rate of protein-
protein interaction. MSCs when subjected to the mechanical 
stimulations accelerate the expression of osteogenic markers 




to cells. The fate of cell proliferation and differentiation 
according to environmental stress can be induced by fluid flow 
and/or mechanical stimuli such as dynamic, static or shear 
forces, and other physical cues such as oxygen tension and pH 
effects. Several bioreactor designs have been evaluated for in 
vitro bone-tissue engineering applications: rotating wall-vessel 
bioreactor, hollow fiber bioreactor (HFBR), electromagnetic 
bioreactor, compression-perfusion bioreactor and perfusion-
compression bioreactor. The HFBR system allows high cell 
densities, preferential for the functional development of bone 
cells, while in an electromagnetic bioreactor, electromagnetic 
wave stimulation enhances cell proliferation and growth factor 
secretion. A significant extra cellular matrix synthesis is 
claimed when osteoblasts like cells are treated with an 
electromagnetic wave. The electromagnetic stimulation 
increased the net Ca2+ flux in human osteoblast like cells. 
Magnetic up-regulation of type-I collagen has been introduced 
representing the most abundant and significant structural 
protein of the bone matrix. On the other hand, compression-
perfusion stimulation enhances the metabolic activity of bone-
forming cells, including ECM synthesis (79).  
1.2 OSTEOCHONDRAL TISSUE ENGINEERING 
1.2.1 Purpose of the strategy  
 
 Osteochondral TE can be used in the case of cartilage defects 
to penetrate the subchondral bone. In cases where the lesions 
do not penetrate the subchondral bone, the pluripotent 
progenitor cells from the bone marrow cannot be recruited and 
the repair will be limited. It would be desirable to use biphasic 
constructs, which could satisfy the mechanical and biological 
requirements of both tissues. Even in chondral defects, the use 
of single scaffolds intended to regenerate cartilage may not be 
effective, as it is difficult to integrate the implant with the 




creating a full thickness defect and a posterior implantation of 
an osteochondral implant, this will help to anchor the graft 
into the defect since, as commented, bone-to-bone interface 
integrates better and faster than cartilage-to-cartilage 
interface (80). One of the main parameter to take care of is the 
interface between bone and cartilage. Indeed cartilage is a soft 
tissue compared to bone which is a hard one, so the connection 
is characterized as a soft-to-hard tissue interface. Cartilage-to-
bone interface are critical for joint motion and stabilization. It 
is characterized by gradual changes in properties and 
structural organization from one tissue to another, as from 
cartilage to bone mineralization is gradually detected. 
Interfaces of tissues are complex in structure, and they have a 
relatively small length scale; around 1 mm. For all these 
reasons and in matter of nature imitation osteochondral TE is 
widely studied in the case of cartilage defects (15, 81, 82). 
1.2.2 Layered scaffolds for osteochondral TE: an 
overview 
 
The ultimate researches in cartilage TE lead to the 
osteonchondral repair as an alternative to cartilage repair 
strategy. One approach to deal with articular cartilage repair 
from subchondral bone could be from single-layer scaffolds. 
That would be the concept of cartilage tissue engineering 
mentioned previously. An alternative strategy could include 
the construction of bilayered structures (Figure 1-5), especially 
adequate to incorporate, in a favourable environment two 
types of cells requiring different chemical surroundings, 
mechanical features and pore morphology. This would allow 
the growth of two different tissues, satisfying the different 
biological requirements. Therefore, heterogeneous structures 
should be built, in which one of the sides promotes cartilage 
regeneration and the other region, exhibiting different 




the case of bilayered scaffolds the concept of osteochondral 
engineering is the fusion of cartilage and bone tissue 
engineering, which were discussed above. One important 
parameter in the bilayered scaffold is the interface between 
the two parts (81-83).  
 
 
Figure 1-5: Schematic representation of osteochondral 
defect, of the cartilage layer (upper side) and the bone 
region (bottom) and the osteochondral implant. Reproduced 
from (15). 
 
Different techniques are used to produce osteochondral 
scaffolds and to induce tissue regeneration. The easiest way to 
construct a biphasic scaffold is to build two layers 
independently and join them prior implantation. There are 
some bilayered scaffolds commercialised such as 
“ChondromimeticTM” (Orthomimetics / Tigenix Ltd., 
Cambridge UK) (84) made from collagen and-GAG for the 
chondral part and collage-GAG and calcium phosphate for the 
bone part, which present satisfactory results after 26 weeks in 
osteochondral defects of goats. They support the repair of 
osteochondral defects, and a maturation of regenerated tissue 
towards hyaline structure. The production of gradient 
biomaterials to engineer grafts for full reconstruction of soft-




al. made biphasic scaffolds made from collagen-chitosan 
mixtures for the chondral phase and a composite of bioactive 
glass and collagen for the osseous phase. Collagen integrated 
in the two respective phases connected by cross linking (85). 
Chen et al. fabricated biphasic scaffold made of collagen 
sponge and a composite of PLGA with collagen for the 
cartilage and bone part respectively. Collagen sponge in the 
two respective layers was connected. Osteochondral tissue was 
regenerated four months after implantation in the knee of a 
one-year beagle. Previously canine bone-marrow-derived 
mesenchymal stem cells were cultivated in the biphasic 
scaffold (86). Ghosh et al, fabricated bi-layerded construct 
based on poly(L-lactic acid) and starch for osteocondral defect. 
In both side PLLA was used. A blend of starch and PLLA was 
used in the cartilage side, which was found to possess 
adequate hydratation capability. For the bone region, PLLA 
reinforced with hydroxyapatite was used. The bone like layer 
exhibited a bioactive like behaviour within 30 days in SBF. 
The two layers were not separated by a compact zone (83). Cui 
et al. studied autologous chondrocytes and osteoblasts seeded 
on scaffolds of PLGA for the cartilage part and tricalcium 
phosphate (TCP) for the bone part to generate a biphasic 
scaffold sutured by absorbable suture. The scaffolds were 
implanted in femoralmedi condyles of mini-pigs during six 
months. The cartilage regenerated was similar to host 
cartilage, subchondral bone was partly replaced by neo-
cartilage (87). As it was discussed previously, in order to 
mimic human nature it is necessary to reproduce a gradient 
cartilage-to-bone structure when oesteochondral layered 
scaffolds are designed. Kon et al. designed three layered 
scaffolds from cartilage to bone made of a first layer of 
collagen I (100%), a transitional one of hydroxyapatite (HAp) 
(40%) and collagen I (60%) and a third one of HAp (70%) and 
collagen I (30%). The scaffolds were implanted during 6 




humans as a pilot clinical study. This study showed to be 
promising, scaffolds maturation in bone and cartilage tissues 
showed normal osteochondral structure in 60% and a not 
differentiated inhomogeneous signal in the implanted area in 
the rest of the patient (88). Further, in the mimetic approach 
Lien et al. designed a four layer scaffold made of: a porous 
ceramic layer as osseous component and also as anchor, a 
dense ceramic layer to prevent blood vessel penetration, a 
porous ceramic layer for the fixation of bone to cartilage layer 
(i.e, joining the ceramic part to a porous gelatine solution into 
the porous ceramic layer) and a latter layer of gelatine as 
cartilaginous component. The joining was done by infiltration 
of gelatin solution into the porous ceramic layer, gelling and 
crosslinking. The scaffold was tested by in vitro cell culture 
with rat’s joint chondrocytes for 4 weeks, after that time 
cartilage tissue could be developped (81).  
 
1.3 BIOACTIVITY 
1.3.1 In vivo bioactivity 
 
Materials for bone tissue engineering need to be 
osteoconductive and so able to support bone growth and 
encourage the ingrowth of surrounding bone and also should 
be capable of osteointegration, which means able to integrate 
into the surrounding bone. Biocompatibility ensures that a 
biomaterial does not produce a foreign body reaction 
(continuous presence of macrophages and giant cells in its 
sorroundings) and can be used without any damage to 
surrounding tissues and organs as well as to the whole 
organism. Surface reactions in osteoinductive materials 
stimulate both intracellular and extracellular responses at the 
interface of the material with its physiological environment, 
giving rise to rapid in vivo bone regeneration. They are, thus, 




extracellular responses occurring at the interface, lead to bone 
migration along the interface of the so called osteoconductive 
materials. These materials allow only bone ingrowth, 
therefore showing osteoconductivity (55,89,90). 
The bone-bonding biomaterials, so-called bioactive or surface 
active, are biocompatible materials that form a layer of 
hydroxyapatite similar to the apatite in bone on their surface 
when implanted in the body, and bond to the living bone 
through this apatite layer (87,91). In vivo bioactivity of a 
material can be assessed in vitro. In 1991, Kokuko proposed 
an in vitro test to assess the bioactivity of a material by its 
capacity to generate a layer of hydroxyapatite (HAp) on its 
surface when immersed in simulated body fluid (SBF) (92). 
SBF is an aqueous medium containing all the salts present in 
the human plasma at physiological temperature (37ºC) and pH 
(7.4) (93). A comparison of the concentrations of ions (mmol/l) 
in human plasma and in SBF is given in Table 1-1. SBF 
simulates only the inorganic part of human blood plasma and 
does not contain proteins, glucose, vitamins, hormones, cells, 
CO2 flow, etc., which are factors influencing the solubility of 
salts, or which interact in the mineralization process of bone 
in vivo. It is interesting to know that the composition of blood 
plasma is not fixed to an amount of ions (i.e. K+, Ca2+, Cl- and 
HPO42-) and can vary depending on the person’s sex, age and 
nutrition (94,95). This test is a first step to determine the 
intrinsic ability of the material to form crystals of 
hydroxyapatite on its surface. The main quality of this test is 
that it does not require expensive equipment to give such 
information as the in vivo “mineralisation” ability of a 
material. Many researchers are using this in vitro test to 
predict the ability of the material to be in vivo bioactive (96, 
97). Kokubo et. al studied the ability of materials such as 
ceramics and metals to nucleate hydroxyapatite of its surface 
(98,99). Olmo et al. studied the biocompatibility of HAp coated 




during 7 days. It was proved that high cell attachment and 
good biocompatibility of the samples covered with biomimetic 
HAp (100). Zhang et al. could nucleate a layer of biomimetic 
HAp on the surface of poly(L-lactic acid) (PLLA) porous 
scaffolds after 2 weeks of immersion in SBF (101) . Wu et al. 
were able to observe nuclei of biomimetic HAp on the surface 
of apatite ceramic scaffolds after 3 days in SBF (102). Taddei 
et al. could nucleate a layer of biomimetic HAp inside and 
outside PCL scaffolds after 28 days in SBF (103), and 
Leeuwenburgh et al. concluded a good in vitro mineralization 
of Ti discs after 12 weeks in SBF  (104). Our research group in 
the Centre for Biomaterials and Tissue Engineering has also 
tested the nucleation ability of HAp by immersion in SBF 
different types of scaffolds. For example, Myriam Lebourg 
made similar studies on composite scaffolds of PCL and 
hydroxyapatite (105). Vallés et al, studied the ability of 
P(EMA-co-HEA)/SiO2 hybrid nanocomposites to nucleate 
hydroxyapatite on its surface and the influence of surface 
modifications on the bioactivity (106, 107).  
 
Table 1-1: Ion concentration in simulated body fluid and 
human blood plasma. 
 Ion molarity (mM) 
 Na+ K+ Mg2+ Ca2+ Cl− HCO3− HPO42- SO42- 
Blood 
Plasma 
142.0 5.0 1.5 2.5 103.0 27.0 1.0 0.5 










1.3.2 Bioactive materials and mechanism of apatite 
formation 
 
Precipitation of Ca-P phases in aqueous solutions mainly 
include dicalcium phosphate [CaHPO42H2O, DCP], 
octacalcium phosphate [Ca8(HPO4)2(PO4)45H2O, OCP] and 
hydroxyapatite [Ca10(OH)2(PO4)6, HAp]. HAp is considered the 
most thermodynamically stable in a physiological 
environment. OCP and DCPD, however, have been regarded 
as precursors of HAp or the metastable phases of Ca-P 
because they are kinetically favourable. pH is a parameter 
influencing the nature of HAp nucleated, as only in 
physiological conditions, pH=7.4 at 37ºC, HAp is favourable to 
precipitate (108). Equation (1) presents the ion units of HAp 
for precipitation in aqueous solutions. 
 
              5Ca2++3PO43−+OH−→ Ca5(PO4)3(OH)                  (1) 
 
In bone TE many materials are studied and revealed to be 
bioactive i.e. able to nucleate a layer of biomimetic 
hydroxyapatite on their surface. Most studies deal with the 
use of biodegradable polymers filled with bioactive particles 
and ceramics to enhance bioactive potential of biomaterials for 
bone TE. Poly(ε-carprolactone) (PCL) filled with nanoparticles 
of HAp materials are able to nucleate a layer of biomimetic 
HAp on their surface after two weeks in SBF, the layer 
observed presented cauliflower shape characteristic of HAp 
and physical characteristics similar to biological HAp 
(103,109-110). Similar conclusions have been made in the case 
of poly(L-lactide acid) containing bioactive glass ceramic (111) 
and also for poly(D-L-lactide and poly(lactide-co-glycolide) 
containing bioactive glass (112). Bioactive glasses and calcium 
phosphates present a good bioactivity due to their close 




brittle than polymers they are usually used to reinforce 
polymeric scaffolds and activate their bioactivity (113,114). 
The formation of a precursor of hydroxyapatite is shown in 
Figure 1-6. The surface of the polymer is negatively charged 
when immersed in SBF due to the presence of carboxylic and 
hydroxyl groups (115). Consequently the negative charge 
attracts the positive ions of the aqueous medium. First an 
amorphous calcium phosphate layer is formed. Once the 
amorphous precursors of apatite or apatite nuclei are formed, 
they can grow spontaneously by consuming the calcium and 
phosphate ions from the surrounding body fluid, because the 
body fluid is supersaturated with respect to the apatite (116). 
During this process, the amorphous calcium phosphate 
incorporates OH- CO32-, Na+, K+ and Mg2+ ions from the 
solution and finally crystallizes into HAp, which is the most 
stable calcium phosphate in aqueous media, rendering a HAp 
layer of polycrystalline agglomerates of carbonated 
hydroxyapatite on the substrate (72).  
 
 
Figure 1-6: Mechanism of apatite nucleation on PLLA surface. 





A variety of procedures have been proposed with the purpose 
of improving the bone-bonding ability of bioinert substrates or 
shortening the induction period required for apatite deposition 
from SBF. One of these procedures is the induction of the 
ability to nucleate bonelike apatite with the inclusion of 
calcium phosphate or glass ceramic nanoparticles in the 
polymeric matrix of the bioinert scaffolds. The mechanism 
proposed for this behaviour is that bioactive materials show 
negative surface potential when immersed in SBF, due to 
deprotonation at physiological pH of groups like –COOH, –
OH, –TiOH, –SiOH (106,107). This negative charge attracts 
calcium ions, then creating a Ca-rich layer with positive 
surface potential, which then attracts negative ions in solution 
like phosphate leading to the deposition of a Ca-poor layer. 
This process repeats itself generating the HAp layer on the 
surface of materials (116,117).  
Alternatively, prior to the immersion of the materials in SBF a 
technique has been developed consisting in the pre-nucleation 
of calcium phosphate elements on the surface of the material. 
This process is usually done by soaking the materials in 
aqueous CaCl2 and K2HPO4.3H2O saturated solutions 
alternately three times. The soaking permits the deposit 
nuclei of calcium and phosphate on the surface of the 
materials and so creates local precursors to apatite formation 
(118). 
Another procedure consists in the activation of the surface of 
the material itself in order to increase its intrinsic ability to 
form HAp on its surface. One technique currently used to 
activate the surface properties of polymeric materials is the 
treatment with aqueous NaOH solutions to introduce 
carboxylate groups onto the surface of the materials. The 
results of this immersion in the case of polyesters as PLLA are 
not satisfactory, as NaOH ions generate a rapid degradation of 
the material making it useless for its later implantation in 




alternative to surpass these drawbacks. Plasma surface 
treatments from functional groups such as hydroxyl and 
carboxyl groups that increase the hydrophilicity of the 
materials and so enhance their osteogenenic ability (119-121). 
1.4 SYNTHETIC POLYMERS BIODEGRADATION 
 
We will refer in this section mainly to the poly(L-lactic acid) 
(PLLA) polyester since it was the selected material for the 
design of our osteochondral construct. Similar synthetic 
materials share some concepts that will appear in the section. 
1.4.1 Mechanisms of biodegradation 
 
The purpose of porous scaffolds is to degrade in the human 
body when the targeted tissue regenerates, and that its by-
products can be assimilated or excreted by a living system.  
Synthetic polymers with ester functional groups as PLLA can 
degrade through hydrolytic way; enzymes such as pronase, 
proteinase K and bromelain accelerate the degradation 
process during the later stages of the in vivo degradation 
(122,123).  
The ester bond is a hydrolysable linkage leading to carboxyl 
endgroup and a hydroxyl one (eq. 2). The carboxyl endgroups 
formed are capable of catalysing the hydrolysis of other ester 
bonds, a phenomenon called autocatalysis. 
 
    R ~ COO ~ R’ +H2O    R ~ COOH + HO ~ R’ (2) 
 
Three types of erosion processes are related to the degradation 
of biodegradable synthetic polymers: surface, bulk and 
autocatalysis. Mainly surface erosion and bulk erosion 
compete, in which bulk erosion can be with or without 
autocatalysis (124). In surface erosion the hydrolysis process 





the surface moving to the core of the material. At the surface 
of the scaffolds no autocatalysis can occur because being in 
aqueous the medium is always buffered. As in vitro and in vivo 
the carboxyl endgroups are in presence at the surface of the 
scaffolds, they are neutralised by the medium and 
consequently lose their catalytic potency. For this to be 
possible, carboxyl endgroups release has to happen at the 
same rate as neutralisation, which in some circumstances is 
not possible and in vivo degradation is faster than expected 
(124). Bulk erosion involves instantaneous water diffusion at 
the beginning uniformly in the polymer core, it is then the 
typical mechanisms found in hydrophilic materials. Water 
diffusion is normally very slow in the surface erosion process 
and normally it is typical of hydrophobic materials. Bulk 
erosion is a mechanism where all the chains or the polymer 
are degraded at the same rate and molecular weight decrease 
and reduction of the mechanical properties and mass loss of 
the material is produced at almost the same time in the whole 
material (124). In the case of autocatalysis soluble oligomeric 
species are generated, those which are close to the surface can 
escape from the matrix before total degradation, while those 
located inside can hardly diffuse out of the matrix. Therefore, 
autocatalysis is more characteristic of bulk erosion, but cannot 
be excluded in the case of surface erosion (124). 
Enzymatic erosion is normally considered as a surface erosion 
mechanism, since enzymes are large molecules difficult to 
diffuse into the chains of the polymer (124). 
The degradation process depends on various parameters, such 
as matrix morphology, chemical composition, molecular 
weight, size, distribution of chemically reactive compounds 
and the nature of the degradation media (125, 126). Once 
placed in an aqueous medium, water penetrates into the 
scaffold leading to hydrolytic cleavage of ester bonds. PLLA 
being hydrophobic its degradation is expected to be in surface. 




bonds, and yields lactide acid, which is a normal by-product of 
anaerobic metabolism in the human body; it can also degrade 
by enzymatic reaction (127). Complete degradation of one 
material, being the degradation rate dependent on the 
medium and the characteristics of the material, can take place 
in months or even years.  
1.4.2 Effect of different parameters on the rate of 
biodegradation 
 
For aliphatic polyesters, hydrolysis rates are affected by 
temperature, molecular structure, ester group density, type of 
degradation media and mechanical stimulus. Crystallinity is 
also an important parameter as the crystalline domains are 
less permeable to water penetration, slowing down hydrolysis. 
First, hydrolysis tends to affect to the amorphous regions of 
semicrystalline polymers with random hydrolytic scission of 
ester bonds. Then, hydrolysis starts to attack from the edge 
towards the center of the crystalline domains, when most of 
the amorphous regions are degraded. The molecular weight 
plays also a very important role in the degradation rate on 
polyesters; the higher the initial molecular weight, the slower 
the degradation rate as more ester bonds have to be attacked 
and diffusion of water is slower if polymer chains are longer 
(128, 129). The pH of the aqueous medium also affects the 
degradation rate, degradation in alkaline solution occurs 
faster as oligomeric acids are dissociated into RCOO- 
presenting higher hydrophilicity which enables them to diffuse 
out in the solution, in contrast to non-dissociated oligomers 
RCOOH formed by hydrolysis in neutral or acid solution (130, 
131). The dimension and the porosity of the scaffold influence 
the degradation process. The smaller a scaffold is the less is 
the difference between surface and centre due to autocatalysis 
(132). An increase of temperature can also increase diffusion, 




1.5 POLY(L-LACTIC ACID) AND POLY(L-LACTIC ACID)/ 
INORGANIC COMPOSITE SCAFFOLDS 
1.5.1 Main properties of poly(L-lactic acid) 
 
As said before, in this work poly(L-lactic acid) (PLLA) has 
been selected in order to design porous scaffolds. Poly(L-lactic 
acid) is generated from lactic acid (2-hydroxypropanoic acid), 
which is an organic acid found in many products of natural 
origin. Lactic acid is produced by animals, in plants and by 
microorganisms in the nature. It can also be derived from 
intermediates with an origin in renewable materials or from 
chemicals derived from coal or oil. PLLA is one of the few 
polymers approved by FDA for intern biomedical applications. 
Lactic acid is composed by an asymmetric carbon atom, 
leading to two optically active configurations. It is one of the 
smallest optically active molecules, which can be either L(+) or 
D(-) stereoisomer (Figure 1-7). The L(+) isomer is the one 
naturally produced in humans and other mammals, but both 
are produced in bacterial systems (133,134). 
 
 
Figure 1-7: Stereoforms of lactic acid. 
 
From the isomers L and D of PLA is it possible to obtain the 
poly(L-lactic acid) (PLLA) (Figure 1-8), poly(D-lactic acid) 






Figure 1-8: Poly(L-lactic acid) formulation. 
 
PLLA is synthesized by ring-opening polymerization of L-
lactide. The ring-opening polymerization route includes 
polycondensation of lactic acid followed by a depolymerisation 
into the dehydrated cyclic dimer, lactide (3,6-dimethyl-1,4-
dioxane-2,5-dione), which can ring-opening polymerized into 
high molar mass polymers (135). 
PLLA is a semi-crystalline polymer, its thermal transitions, 
such as glass transition, melting and crystallization, are 
important aspects to know, since they determine the final 
properties of the PLLA chosen to fabricate the material for 
implantation. In general, it is difficult to obtain a PLLA with a 
crystallinity higher than 60%. The crystallisation process of 
PLLA can be observed in the range of 80-160ºC (136). PLLA 
exhibits a high melting temperature, around 173–178ºC (137). 
The glass transition temperature of PLLA is about 55-65ºC, 
which is not so far above room or body temperature. That 
would explain the metastable state of the amorphous fraction 
at physiological temperatures, and slow changes in molecular 
configuration. The process of physical aging, also called 
structural relaxation, is a reversible physical process, which is 
not supposed to generate any chemical changes (138, 139).  
PLLA is a polymer widely known to be biocompatible and 
biodegradable into non-toxic components which can be 
eliminated from the body in the form of carbon dioxide and 
water. The use of PLLA is also seen in biomedical applications 
such as scaffolds for tissue engineering or medical devices 
such as screws or sutures (140-143), as well as being a 




1.5.2 An overview to poly(L-lactic acid) scaffold 
fabrication techniques 
 
There are many techniques to fabricate porous scaffolds from 
poly(L-lactic acid). The main techniques used are basically 
solid free-form fabrication (SFF) techniques, electrospinning, 
moulding, freeze drying and freeze extraction. Each method 
leads to specific properties which characterise the final 
product, such as morphology, porosity, mechanical strength 
and so on. Other parameters to pay attention to at the time of 
choosing the technique of fabrication are the time it takes, its 
cost, complexity and repeatability. 
SFF techniques require a computer model of the desired 
scaffold architecture from computer-assisted design. An inkjet 
printing system is directed by the computer-assisted design. A 
thin layer of polymer powder is spread over a pistons surface, 
the inkjet dispenses a binding liquid, which is a solvent for the 
polymer, in the desired pattern of the scaffold layer. After a 
short time, the piston is lowered by the thickness of a single 
layer and the subsequent layers of powder and binding liquid 
are applied. Unbound polymer remains in the network during 
the fabrication process to support disconnected sections in the 
layer. SFF techniques present the advantages of being rapid, 
being able to control external and internal structure. It is also 
a reproducible process easy to shape. The scaffolds remain 
highly porous, 65% of porosity and with interconnected pores 
of around 500 µm and 600 µm wall thickness. It is possible to 
create smaller pores but decreasing the porosity. The elastic 
modulus observed for a porosity of 65% with square pores is 
around 6 MPa. One of the biggest disadvantages responsible 
for the rejection of this technique is its high cost due to the 
need for high technological equipment (144-146). 
Electrospinning is an easy and economical technique used to 
fabricate porous samples. The electrospinning equipment uses 




extremity, containing a polymer solution and a metal collector. 
The high voltage is employed to create a charged jet of 
polymer solution out of the tube, which accelerates, thins and 
dries in the electric filed, ultimately collecting on a grounded 
device. The use of high voltage can represent labour risk. The 
material formed are nanoscaled fibres of polymer, these fibres 
superposed create the scaffold. This scaffold possess high 
surface to volume ratio that promotes cell attachment. 
However the pore size obtained of the interfibres is around 5-
10 µm which is too small to permit cell penetration even 
though the pores are interconnected. Furthermore the 
mechanical properties are not recommendable for load support 
as the network of fibres lack rigidity, and most of them 
present elastic modulus around 200 kPa. Usually the scaffolds 
of electrospun PLLA fibres have a 2D application such as 
membranes support for cell in the case of skin or heart tissue 
engineering (147-150).  
Moulding techniques permit to modulate scaffold pore size and 
porosity. This technique involves filling a mould with polymer 
powder and then heating the mould above the glass transition 
temperature of polymer while applying pressure to the 
mixture; in this process a porogen template is performed by 
sintering the polymer powder. Compressive moulding (also 
known as melt injection moulding) requires the application of 
high processing temperature. The polymer is inserted to a 
mould, filled with the porogen template (previously shaped), in 
melting phase. The temperature of processing PLLA for melt 
injection moulding is around 180ºC. This may suppose a 
problem in the selection of an adequate porogen, as the 
template needs to be such so it does not deform at that 
temperature. Alternative materials for the template would be 
polyethylene oxide (PEO) which has a flash point from 180ºC 
to 280ºC or chloride magnesium which has a degradation 
temperature of 300ºC. In order to avoid such high processing 




option. The polymer is inserted to the mould dissolved in a 
solvent, with the aid of compression pressure. This technique 
permits to fabricate highly porous scaffold (90%) (151, 152). 
Freeze drying is one technique used to fabricate PLLA porous 
scaffolds, involving the removal of a solvent first by 
sublimation of a frozen sample and then by desorption of the 
non-frozen sorbed solvent under reduced pressure or by 
solvent leaching. In this case the main inconvenience is the 
use of a freeze dryer instrument. A similar technique able to 
generate highly porous PLLA scaffolds which does not need 
the use of a freeze dryer is the freeze-extraction process. It 
consists of the elimination of the solvent by dissolution rather 
than sublimation at polymer solution freezing state, which 
permits a gain on energy and time. Freeze-extraction 
combined with particle leaching is a simple, low cost and 
reproducible technique to fabricate highly porous scaffolds 
with interconnected pores giving the scaffolds suitable 
mechanical properties. The resulting porosity is double, micro 
and macro; micropores are formed from the leaching of the 
solvent and macropores from the leaching of the porogen. 
Freeze-extraction allows addition of inorganic components to 
the scaffolds by previous mixing nanoparticles with the 
polymer solution, in this way physiological or mechanical 
properties are increased (55, 153-156). In this process the 
temperature of polymer solution is decreased to induce phase 
separation into two phases, one having a high polymer 
concentration and one having a low polymer concentration or 
normally pure solvent crystallized phase.  
Polymer-solvent phase separation can be divided into liquid-
liquid phase separation, which may occur prior to the solvent 
freezing and solid-liquid phase separation, which is only 
observed when the solvent has been completely frozen. The 
addition of a non-solvent to the polymer solution may induce 
liquid-liquid phase separation. Two types of liquid-liquid 




solution is cooled. Between the binodal and spinodal curves of 
the phase diagram, the liquid-liquid phase separation 
proceeds through a nucleation and growth mechanism and 
gives rise to a generally dispersed structure. In contrast, below 
the spinodal curve, the original solution undergoes a 
spontaneous liquid-liquid phase separation referred to as the 
spinodal decomposition, with the formation of an 
interconnected network of two phases. In the case where the 
solvent crystallizes before liquid-liquid phase separation 
occurs, this solid-liquid phase separation is responsible for a 
final morphology that depends on the crystallization mode of 
the solvent. Schugens et al. studied that no liquid-liquid phase 
separation is observed when solutions of polylactides in 1,4-
dioxane are cooled, at least until a solid-liquid phase 
separation occurs due to solvent crystallization. Which 
corresponds to the case where the critical solution 
temperature of liquid-liquid phase separation is largely lower 
than the freezing point of the solvent (157,158). 
1.5.3 Bioactive poly(L-lactic acid)/inorganic composites 
 
Poly(L-lactic acid) and bioactive ceramics are being combined 
in a variety of composite materials for bone tissue engineering 
scaffolds. Around 60 wt.% of bone is made of HAp, Ca10 
(PO4)6(OH)2, and therefore it is evident why HAp and related 
calcium phosphates (e. g. α-TCP, β-TCP (101,159) have been 
intensively investigated as the major component of scaffold 
materials for bone tissue engineering. As expected, calcium 
phosphates have an excellent biocompatibility due to their 
close chemical and crystal resemblance to bone mineral. If the 
properties of HAp and related calcium phosphates are 
compared with those of cortical bone, bone has a reasonably 
good compressive strength though it is lower than that of 
HAp. However, bone has significantly higher fracture 




toughness of bone are attributed to the tough and flexible 
collagen fibers reinforced by HAp crystals. Hence, calcium 
phosphates alone cannot be used for load-bearing scaffolds 
despite their good biocompatibility and osteoconductivity (72). 
The composition of bioactive particles with polymers is an 
option to the pure ceramic scaffolds. Most of the ceramics used 
to fabricate composite scaffolds of PLLA are nanoparticles of 
HAp. It was possible to fabricate highly porous composites 
increasing the bioactive potential of the PLLA and the 
mechanical properties. The nanoparticles can be in needle–
like shape or more spherical (160,161). The particles of HAp 
are supposed to transmit resistance to the polymer matrix. 
This transmission of resistance depends on the adhesion 
between polymer and particles. In the case of internal 
interfaces with poor adhesion it might provide links to 
nucleation of cracks. As the superficial nature of PLLA and 
HAp does not permit a chemical bond there is a weak adhesion 
between the two substances. In order to improve the 
interfacial connection of hydroxyapatite to PLLA Wang et al. 
used silane to modify the surface of the nanoparticles of HAp, 
and so increase the mechanical properties of the PLLA/ HAp 
composites and also to prevent aggregation of HAp powder. 
The interactions between silane modified HAp particles 
surface and hydroxyl or carboxyl groups of PLLA is stronger 
as HAp instead of showing up HAp–P–OH shows HAp–P–OH–
Si(OH)2–(CH2)17–CH3. The best increase in terms of elastic 
modulus was obtained for scaffolds filled with 20% of modified 
HAp from 0.65 to 0.83 MPa, with fibers about 100-800 µm and 
93.6% porosity, the scaffolds dimension being 20.5 mm 
diameter and 5.0 mm high. For the scaffolds made by freeze-
drying with 100-300 µm pore dimension elastic modulus 
increased from 2.14 to 6.44 MPa for the scaffolds filled with 
15% of modified HAp particles in comparison to that not 
modified (162,163). Other representative bioactive ceramics 




bioactive glass. In these cases the elastic modulus could be 
increased from 5.5 to 8.0 MPa for the scaffolds with cubic form 
(10x10x10mm) and 89% porosity filled with 30% of bioactive 
bioglass. When scaffolds filled with bioactive glass are 
previously treated with silane there is an increase in the 
elastic modulus of up to 80%. The elastic modulus increased 
from 107.7 to 178.6 and up to 259.6 MPa from the scaffolds not 
filled, the ones filled with 29 vol%. of bioactive glass and the 
ones filled with 29 vol%. modified bioactive glass in the works 




Chapter 2.   Materials and methods 
 
In this chapter the techniques used to prepare and 
characterise the materials involved in this work will be 
described. As a first step porous scaffolds of poly(L-lactic acid) 
(PLLA) with different porous morphologies have been 
prepared and studied. From this evaluation a composition of 
the reactive mixture to prepare the porous scaffolds was 
selected to design the scaffold for the cartilage layer of the 
osteochondral construct. Then evolution of the physical and 
chemical properties under static and dynamic degradation of 
this scaffold was studied. In order to bioactivate the material 
for the bone anchorage, hybrid composite structures in 2D and 
3D of PLLA/ bioactive particles were fabricated. The influence 
of the content and the nature of the bioactive particles on the 
properties of the samples were studied. Finally the 
osteochondral construct was assembled. 
 
2.1 MATERIALS  
2.1.1 Micro and macro porous scaffolds. 
Micro and macroporosity are one of the main morphological 
qualities for scaffolds fabricated in this work. The macropore 
structure should host seeded cells and host the regenerated 
tissue while the network of microchannels allows the diffusion 
of water and soluble substances through the scaffold. With the 
variation and combination of these two morphological aspects 
physical-chemical properties of the scaffolds can be modified 
over a broad range. This part deals with the design of different 
morphologies for the selection of the adequate for our 
application. The techniques used to prepare these samples 




formation of micro and macropores, respectively. The design of 
these scaffolds combines the effects of two different 
parameters as polymer/ solvent concentration and polymer/ 
porogen ratio. The poly lactic acids used were from the 
commercial brands Cargill Dow (Minneapolis, USA) and Purac 
(Barcelona, Spain). The Cargill Dow lactic acid is of industrial 
use. It contains a 99.6% L-lactide isomer, its average 
molecular weight is 124 kDa, with a polydispersity index 
Mw/Mn = 1.83 (155). The PLLA from Purac (Purasorb PL 18) 
is a medical grade polymer with a viscosity of 1.8 dl/g. 1,4-
Dioxane, commonly called dioxane, has been chosen for the 
freeze extraction process because of its capacity to dissolve 
PLLA and its high melting point that permits its extraction in 
solid state when it is at -10ºC. It was purchased from Sharlau 
Chemie, S.A. (Barcelona, Spain) and used without any 
purification. The porogen used is Elvacite®2043, a low 
molecular weight acrylic resin (low molecular weight 
poly(ethyl methacrylate) (PEMA) in the form of spherical 
beads, produced by Lucite International (Southampton, UK). 
It has an average molecular weight of 50 kDa. The diameter of 
the beads is around 200 µm, with low dispersion (140-220 µm 
as claimed by the producer). In order to assure the dimension 
of the porogen, the particles of PEMA were sieved before their 
use, in that way particles below 53 µm were discarded. This 
material was chosen as porogen because of its solubility in 
ethanol; ethanol is in fact one of the few solvents, that does 
not dissolve PLLA. 
 
In order to vary the polymer concentration, a series of poly(L-
lactic) acid/ dioxane solutions with 5, 10, 15, 18 and 20 % wt. 
of polymer content were used to prepare different scaffolds. 
The obtained scaffolds will be called (5/95), (10/90), (15/85), 
(18/82) and (20/80) respectively, corresponding to the (PLLA/ 
dioxane) content. The different PLLA solutions were mixed 
with two different polymer solution and porogen ratios, 1:1 
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and 1:1.25 (w/w), with the aim to vary the polymer / porogen 
ratio. In the text the different samples are named 1:1-(5/95), 
(10/90), (15/85), (18/82), (20/80) and 1:1.25-(5/95), (10/90), 
(15/85), (18/82), (20/80) scaffolds. 
 
Consequently the five different PLLA solutions were poured 
into Teflon moulds, quickly mixed with the PEMA porogen 
with a spatula, and then immediately frozen in liquid 
nitrogen. Then, cold ethanol at -10ºC was poured on the frozen 
mixtures in order to dissolve the crystallized dioxane. Dioxane 
extraction was conducted in a cold ethanol bath at -10ºC, 
ethanol was changed until the dioxane had completely 
disappeared from the structure, and so leads to the formation 
of the micropores. It is important not to increase the 
temperature up to the melting temperature of dioxane (11.8ºC) 
until the dioxane has been totally removed as it could either 
dissolve the PLLA or swell the particles of porogen and so 
deform the porous structure. Afterwards, the extraction of the 
porogen with hot ethanol at 40ºC and slow stirring was done; 
ethanol was changed until the PEMA had completely 
disappeared from the structure, leading to the formation of the 
macropores. After extraction, scaffolds were dried firstly at 
room temperature for 24 hours, then under vacuum for 24 
hours and then under vacuum at 40ºC until constant weight. 
The scaffolds were cut into cylinders of 6 mm diameter and 4 
mm high. 
 
This part of the study led us to the selection of a scaffold 
formulation which resulted in the best candidate for the 
cartilage part of the osteochondral construct, after the 
evaluation of the influence of the macro and micro porosity on 





2.1.2 Hybrid scaffolds PLLA/bioactive particles 
The bioactivity and mechanical properties of the scaffolds were 
planned to be enhanced incorporating bioactive nanoparticles, 
such as HAp and SiO2, to the polymeric structure. First this 
study involved membranes of the samples. Varying the 
content of the filler it was possible to study the influence of the 
amount of nanoparticles to the bioactivity of the material and 
the properties of the membraness. 
2.1.2.1 Fabrication of the 2D hybrid structure 
A series of poly(L-lactic acid)/ hydroxyapatite composite 
membranes with HAp content 0, 5, 10 and 15% (w/w) were 
prepared by freeze extraction method. The fabrication process 
is the same as used in section 2.1.1, p.54, to fabricate scaffolds 
but the incorporation of porogen and particle leaching 
processes was skipped as we intended to produce flat samples 
and without macropores. Hydroxyapatite particles with 
particle size inferior to 200 nm were purchased from Sigma-
Aldrich (Spain); the nanoparticles of HAp were sieved before 
incorporation to the solvent. PLLA for industrial use was used 
for this study. The required quantity of HAp powder was 
dispersed in dioxane by sonication, then a 15% weight PLLA 
(relative to solvent weight) was added to the mixtures, and 
stirred until completely dissolved. As mentioned above, four 
solutions with different content in HAp were prepared with 0, 
5, 10 and 15% particles, this percentage is in regard to PLLA 
weight. Then the membranes were fabricated by freeze 
extraction process. The membranes were cut into squares (1 
cm x 1 cm) of 200 µm thickness. To obtain the desired 
thickness the samples were shaped in compound resin 
(O.C.T.TM) from Tissue-Tek at -30ºC and cut by cryogenic 
microtome. After removing residues of the resin, samples were 
dried during three days. The first day at room temperature, 
the second under vacuum and the third under vacuum at 40ºC.  
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2.1.2.2 Fabrication of the 3D hybrid structure 
The same type of composites as in the previous section were 
made but, in this case, in three dimension by adding the 
particle leaching step to the freeze extraction process. After 
confirming that the HAp was not as effective as expected for 
the enhancement of the mechanical properties of the 3D PLLA 
scaffolds, different inorganic filler based on silica particles was 
introduced. 
PLLA/HAp COMPOSITES 
A composite scaffold of poly(L-lactic acid)/ hydroxyapatite with 
a 5 % wt. of HAp was prepared by the freeze extraction and 
particle leaching processes following the fabrication procedure 
as presented in section 2.1.1, p.54. A pure organic scaffold was 
prepared as a reference material. The samples will be named 
PLLA and PLLA/ HAp scaffolds. The HAp nanoparticles were 
sieved before incorporation to the solvent. Briefly, the required 
quantity of HAp powder was dispersed in dioxane by 
sonication, then a 15% weight PLLA was added to the 
mixture, and stirred until completely dissolved. The PLLA and 
the PLLA/ HAp solutions were poured into Teflon moulds, 
quickly mixed with the PEMA porogen with a spatula, and 
then immediately frozen in liquid nitrogen. Then, cold ethanol 
at -10ºC was poured on the frozen mixtures in order to dissolve 
the crystallized dioxane. Dioxane extraction was conducted in 
a cold ethanol bath at -10ºC, ethanol was changed until the 
dioxane had completely disappeared from the structure. 
Afterwards the extraction of the porogen with hot ethanol at 
40ºC and slow stirring was done; ethanol was changed until 
the PEMA had completely disappeared. The scaffolds were cut 
into cylinders of 6 mm diameter and 4 mm high. Samples were 
dried firstly at room temperature for 24 hours and then under 






Unfortunately this fabrication process did not enhance the 
mechanical properties of the scaffolds. Two strategies were 
followed to improve the mechanical properties of the organic 
matrix: 
• A second sonication process was employed after 
dissolving the PLLA in the dioxane/ particles mixture 
and before adding the PEMA porogen. 
• The increase of HAp nanoparticles content (5, 10, 15, 
18, 20 wt.%). 
• The combination of HAp particles with finer inorganic 
particles based on nanoporous silicates with the aim to 
enhance the interaction area of the filler and the 
organic matrix, which could lead to an increase of the 
mechanical properties. 
PLLA/ HAP/ SIO2 COMPOSITES 
The filler used to fabricate these composites consisted of a 
mixture of the same HAp particles as before, previously 
sieved, and laboratory made particles of silicates. The silicate 
particles were nanoparticulated bimodal porous silicas (NBSs) 
with particles size of 20-30 nm; they were purchased from the 
Materials Science Institute of the University of Valencia (164). 
A series of scaffolds were prepared with (100/0/0), (95/0/5), 
(95/5/0), (90/10/0) and (90/9.5/0.5) % wt. of PLLA/ HAp/ SiO2 
respectively. Freeze extraction and particle leaching, the same 
procedure explained in section 2.1.1, p.54, were used to 
fabricate these 3D composites. In order to increase the 
dispersion of the particles in the polymeric matrix double 
sonication was applied; when the nanoparticles were added to 
the dioxane and after the PLLA, added to the HAp/ SiO2/ 
dioxane mixture, was dissolved (prior to pour the PEMA 
porogen). The scaffolds were cut into cylinders of 6 mm 
diameter and 4 mm high. Samples were dried first at room 
temperature for 24 hours and then under vacuum 24 hours 
and then under vacuum at 40ºC for 24 hours more. 
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2.1.3 Bioactivity test 
The in vitro bioactivity test was assessed as specified in 
section 1.3, p.30, to determine the ability of the samples to 
precipitate HAp from the ions in a SBF solution while they are 
in immersion. This layer was characterised to find out the type 
of HAp coating on the surface of the samples. SBF solution 
was prepared using the Müller method (95) from different 
volumes of eight salt solutions of KCl (59.64 g/l), NaCl (116.88 
g/l), NaHCO3 (45.37 g/l), MgSO4.7H2O (49.30 g/l), CaCl2 
(14.702 g/l), TRIS (tris-hydroxymethyl aminomethane; 121.16 
g/l) (used for pH adjustment, see below), NaN3 (1 g/l), KH2PO4 
(27.22 g/l) poured into 650 ml deionised ultra-pure water, in 
order to prevent salt precipitation and maintain the pH of the 
solution. The exact volume in millilitres of the different 
solutions used to fabricate the SBF (added to the 650 ml of 
water) is detailed in the Table 2-1. Then the flask containing 
the salts was filled with deionised ultra-pure water up to 1000 
ml. For pH adjustment to pH 7.6-7.7 at 25ºC (which 
corresponds to pH 7.3-7.4 at 37ºC), HCl or TRIS was added.  
 
Table 2-1: Volume of salt solutions used to prepare 1 L of 
SBF. 
Salts KCl NaCl NaHCO3 MgSO4.7H2O CaCl Tris.HCl NaN3 KH2PO4 
volume 
(ml) 
5 60 10 5 25 50 10 5 
 
Samples were soaked in SBF for different times up to 21 days. 
The SBF solution was not renewed during the first 7 days. 
Afterwards, the ion concentrations were adjusted to twice 
those of SBF (2xSBF) and the solution was renewed each 2-3 
days, in order to provide more favourable conditions for 
apatite deposition. As the hydrophobic characteristic of PLLA 
hindered its immersion in the biological fluid, the pores of the 
scaffolds were forced to fill of SBF with vacuum. The 




samples followed the recommendation that it should be above 
the Sa/10, where Sa is the apparent surface area (93). 
2.1.4 Oxygen plasma treatment 
Surface modification is one method presented in section 1.1.6 
to increase the bioactivity of a polymer. Surface modification 
of some materials was carried out before SBF immersion in 
order to form hydrophilic groups on the surface of the material 
which tend to favour the precipitation of ions in presence of 
the medium responsible for the coating of a layer of HAp (121). 
The plasma treatment was applied with oxygen plasma 
(Plasma Electronic, model Piccolo, quartz cylinder, 2.45 GHz 
generator) at 300 W in a 50 Pa vacuum, for 120 seconds for 
each side. The samples were used for experiments within 1 
hour after exposure, time enough for the radicals 
recombination on the surface of the samples. 
2.1.5 Sonication 
The dispersion of the nanoparticles in the polymeric matrix 
was done by sonication using a GM 3200 Sonoplus Ultrasonic 
homogenizers from Bandelin (Berlin, Germany). The 
sonication was applied during five minutes in pulsation mode 
(2 seconds ON, 1 second OFF), at 50% of 200 W, and at a 
frequency of 20 kHz. In order to avoid heating of the solution, 
the flask was immersed in cold water inside a Teflon mould 
with ice cubes.  
2.1.1 Static degradation 
The evolution of the properties of the 1:1-15%-PLLA-MED 
scaffold under in vitro static degradation were analysed. This 
study was done in collaboration with the Group of Structural 
Mechanics and Materials Modelling, of the University of 
Zaragoza, in Spain (under the supervision of Drs. Manuel 
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Doblaré and Ignacio Ochoa and as part of the PhD thesis of 
Dr. Victor Acosta (165). Scaffolds were shaped in cylinder of 6 
mm diameter and 4 mm thick. Then 65 samples were 
immersed in phosphate buffered saline solution, PBS, each 
one in 2 mL at 37ºC. The immersion times for this study were 
0, 6, 12, 18 and 24 weeks. Furthermore 2 samples were 
subjected to static degradation during 1 year. The PBS bath 
was renewed every 2 weeks. After the different times of 
immersion in PBS the scaffolds were analysed by several tests 
to see the influence of degradation time on the properties of 
the scaffolds. 
2.1.2 Fatigue essay 
The 1:1-15%-PLLA-MED scaffolds were also subjected to 
degradation under dynamic compression conditions. In order 
to perform the fatigue essay blocks of Teflon were fixed on the 
extremity of the arms of the compression machine (Microtest 
Universal Testing Machine) to avoid their oxidation. The 
upper side was used to apply the compression, and the lower 
side was filled with PBS and the scaffolds were placed there, 
properly ordered to identify each of them. A PBS flow was 
supplied by a peristaltic pump at 2 ml/min. In order to 
maintain the PBS temperature at 37ºC a thermostatic water 
bath at 40ºC was used. The silicon PBS circulating tube was 
immersed in the water to warm the fluid. Silicon tubes with 4 
mm external diameter and 0.8 mm internal diameter were 







Figure 2-1: Fatigue test circuit. 
 
The tested scaffold was the same as that used for the static 
degradation; in cylinder shape 6 mm diameter and 3 mm 
thick. The applied strain was 5% in compression with a pre-
deformation of 0.25%, at 1 Hz. The scaffolds were tested 
during several times: 1, 2, 4 and 6 weeks. The PBS was 
renewed every week. At each degradation time the scaffolds 
were removed from the bath, dried and analysed by several 
tests to see the influence of degradation time under dynamic 
conditions on the properties of the scaffolds  
2.1.3 Biconstruct fabrication: bilayered scaffold for 
osteochondral regeneration 
The aim of this work was to fabricate a bilayered construct 
with an impermeable junction between each macroporous 
part. The biconstruct is the combination of two scaffolds 
fabricated by freeze extraction and particle leaching. The 
scaffold formulation used in the fabrication of the cartilage 
part of the biconstruct resulted from the study of the influence 
of micro and macroporosity on the scaffold’s properties. The 
formulation used to the fabrication of the bony part of the 
biconstruct was a consequence of the results obtained after 
filling the scaffold with HAp particles. Thus, the up side of the 
biconstruct aimed at cartilage repair was a 1:1-15%PLLA-
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MED scaffold, 1 mm high (1:1-15%PLLA refers to a scaffold 
fabricated with the same mass ratio of porogen and 
PLLA/dioxane solution, containing this solution a 15 % wt. of 
PLLA). The lower side was similar to the upper side (1:1-
15%PLLA-MED scaffold), but functionalised for bone 
regeneration in the sense that it was fabricated with a 5% of 
bioactive HAp nanoparticles; and it was 6 mm high. So the 
biconstruct was a sandwich of (100/0) and (95/5)- 1:1-
15%PLLA-MED scaffold. The two parts were separately 
prepared, and once the porogen was removed and the samples 
were dried they were joined by applying a thin layer of PLLA 
solution in dioxane of 15 % wt. of PLLA. The purpose of this 
layer is to prevent blood flow from the bone to the cartilage 
area once the construct is implanted. In order to remove the 
dioxane the bilayered construct was dried during 24 h at 40ºC. 
 
2.2  CHARACTERIZATION TECHNIQUES 
2.2.1 Scanning Electron Microscopy (SEM) 
The morphology was characterised by scanning electron 
microscopy (SEM) analysis, with a JOEL JSM 6300 scanning 
electron microscope in the secondary mode under an 
acceleration tension of 15 kV and working distance 15 mm. 
The cross-section surface of each sample was sputter coated 
with a gold layer under vacuum to ensure conduction. An 
estimation of the pores sizes was determined by direct 3 
measurements of both micro and macropores from 3 SEM 







2.2.2 Elemental analysis (EDS) 
For EDS analysis, samples were mounted onto copper holders 
and carbon sputtered. Elements quantification was performed 
by Electron Dispersive Spectroscopy (EDS) with a JEOL JSM 
6300 scanning electron microscope with an acceleration 
tension of 10 kV. 
2.2.3 Porosity 
Porosity was measured by a gravimetric method. Firstly the 
dry samples were weighed, and then filled with ethanol under 
vacuum, and subsequently weighed. Porosity was calculated 
as the quotient of the volume of pores and the total volume of 
the scaffold. The volume of pores, Vpore, was deduced from the 
weight difference between the dry (mdry) and wet (mwet) 
sample, according to equation (3) – assuming that the amount 
of ethanol absorbed by the polymer matrix is negligible during 
the short time of the experiment 







pore        (3) 
where ρethOH is the density of ethanol. 
Thus, the volume of the pores equals the volume occupied by 
the absorbed ethanol. 
The total volume (equation 4) is the volume occupied by the 
pores and that occupied by the polymer. The volume of the 
polymer is: 





             (4) 
So the porosity (P) is done by the equation 5: 
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  (5) 
 
At least five measurements were carried out for each sample. 
The volume occupied by the polymer was calculated from the 
dry weight of the scaffold assuming a density of PLLA of 1.19 
g.cm-3 (155).  
2.2.4 Compressive test 
In order to study the mechanical properties of the samples, a 
compression test was done, using a Microtest Universal 
Testing Machine. A compression with a constant speed of 1 
mm/min until 500 N was applied on the dry scaffolds, at room 
temperature. For each scaffold the test was repeated five 
times for statistical analysis. In Figure 2-2 a schematic 
compressive stress-strain curve for a PLLA foam is shown. 
The stress was calculated by the delivered force divided by the 
initial area of the scaffold and the strain was determined by 
dividing the displacement of the gag by the initial sample 
height. The graph shows a linear elastic deformation at low 
stresses, followed by a long collapse plateau, truncated by a 
regime of densification in which the stress rises steeply (166). 
Linear elasticity is related to cell wall bending, and the 
apparent compressive elastic modulus, Eelastic, is the initial 
slope of the stress-strain curve; the plateau (characterized by 
yield point) is associated with the collapse of the cells by 
elastic buckling; finally, when the cells have almost completely 
collapsed, opposing cell walls touch and further strain 
compresses the solid itself, giving rise to the final region of 
rapidly increasing stress; the densification zone (characterized 






Figure 2-2: Typical regimes of compressive stress-strain 
curves of polymeric foam. A real measurement on a PLLA 
scaffold has been used as illustration. 
 
The compressive test used to study the mechanical properties 
of the scaffolds after static degradation were realised in 
collaboration with the the Group of Structural Mechanics and 
Materials Modelling, of the University of Zaragoza, in Spain. 
The protocol involved in this study was different from the 
previous one. A slower compression, with a constant speed 
deformation of 0.01 mm/s (0.6 mm/min) until 50 N, was 
applied on the scaffolds, at room temperature and immersed 
in a PBS solution in a Instron MicroTester 5548 machine. A 
pre-deformation of a 4% the initial height was applied to 
standardize the experiments. The samples were conditioned 
24 hours before the experiment by their immersion in SBF. 
For each scaffold the test was repeated five times for 
statistical analysis. 
Strain 
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2.2.5 Dynamic mechanical spectroscopy (DMS) 
The dynamic mechanical properties of the membranes (2D 
hybrids) were determined by the Seiko Instruments 
Extrar6000 Thermal Analysis and Rheology System. The 
samples were heated first from 0ºC up to 120ºC at 2ºC/min, 
maintained at 120ºC for 60 minutes, and then cooled to 0ºC at 
2ºC/min and heated again to 150ºC at the same rate. Testing 
frequency was 1 Hz and the membranes presented rectangular 
dimensions 3 x 3 x 30 mm3. 
2.2.6 Differential scanning calorimetry (DSC) 
Thermal transitions were evaluated by thermal analysis with 
the PERKIN ELMER differential scanning calorimeter Pyris I. 
Each sample was underwent to two heating cycles from 0ºC to 
210ºC at a heating rate of 10ºC/min, between the two heating 
scans there was a cooling scan from 210ºC to 0ºC at a heating 
rate of 10ºC/min. 
2.2.7 Gel permeation chromatography (GPC) 
The molecular weight of the samples was determined with gel 
permeation chromatography at 30°C, using a Water Breeze 
GPC system equipped with a 2414 refractive index detector 
and Styrage HR THF columns. Tetrahydrofuran (THF) was 
used as the eluent at a flow rate of 0.5 ml/min. The calibration 
curve was prepared by using monodisperse polystyrene 
standards from Shodex. 
2.2.8 Thermogravimetric analysis (TGA) 
Thermogravimetric analysis (Thermogravimetric analyser 
SDTQ600 from TA Instruments) was used in order to 
determine the thermal degradation profile of the samples and 




deposited HAp in the samples. The samples were subjected to 
a temperature ramp from room temperature until 800ºC at 
20ºC/min under nitrogen flow (50 ml/min). 
2.2.9 Calcination experiments  
The real content of HAp in the PLLA/HAp composites was 
determined by weighting membrane residues after calcination. 
Calcination was carried out in a Conatec HC-300 ceramic 
oven. For each composite, three samples were heated up to 
600ºC at 10ºC/min, and maintained at 600ºC for 10 minutes, in 
order to entirely thermally degrade the PLLA.  
 
2.2.10 Fourier transform infrared analysis (FTIR) 
Chemical surface changes due to the HAp nucleation were 
studied using FTIR Thermo Nicolet Nexus apparatus in a 
transmission mode. The spectra resulted from averages of 128 
scans at 4 cm-1 resolution, between 650 and 4000 cm-1. The 
sample, as a finely divided powder, was mixed with potassium 





Chapter 3.   Results  
 
3.1 SCAFFOLDS FABRICATION: PROCESSING, 
MORPHOLOGY AND PROPERTIES RELATIONSHIPS  
 
Two types of PLLA have been used in the study. A PLLA from 
PURAC for medical use, developed for use in animal models in 
collaboration with the group of Prof. F. Prosper at the Clínica 
Universidad de Navarra, was selected. In this way possible 
effect of low molecular weight substances retained in the 
material or other by-products of synthesis process could be 
discarded when analysing the in vivo performance of the 
scaffolds. Nevertheless the high cost of this material meant 
carrying out many initial trials and some of the experiments 
were done with a PLLA from Cargill-Dow, which receives 
extensive use in packaging industry. From the point of view of 
an eventual clinical study, any scaffold would need extensive 
purification and deep toxicity analysis due to the chemicals 
used in processing. PLLA for industrial use and for medical 
use will be referred to in this manuscript respectively as 
PLLA-CD and PLLA-MED. The behaviour of the two 
materials might be slightly different in several aspects due to 
differences in molecular weight and stereochemistry. The aim 
of this section is mainly to determine the influence of 
processing conditions on the morphology and properties of the 
scaffolds. Morphology, mechanical and thermal properties, and 
porosity of the scaffolds will be characterised. As a conclusion 
of this study the composition of the best construct for the 






3.1.1 Scaffold morphology 
 
The structures of the PLLA scaffolds obtained by freeze 
extraction and particle leaching processes are presented 
below. The SEM pictures are classified in order to show both 
types of PLLA, firstly the scaffolds made with industrial 
PLLA-CD and then the medical grade PLLA-MED. For each 
type of PLLA both 1:1 and 1:1.25 PLLA-solution: porogen 
mass proportions are presented in the images. Each series of 
images shows the scaffolds obtained with each of the five 
polymer concentration in the dioxane solution (5, 10, 15, 18 
and 20% in weight). The tests carried out on the different 
samples examine the influence of factors such as the polymer 
concentration, the polymer/ porogen ratio and the PLLA type 




Figure 3-1 and Figure 3-2 show the SEM pictures of cross 
sections of the scaffolds made with industrial PLLA. The 
morphology of the scaffolds is composed of two different types 
of cells. Small closed-cells called microporosity, because of its 
microdimensions, which are uniformly distributed all over the 
surface of the scaffolds. The microcells are arranged in 
undefined axes. The solid material closes off the cell faces, 
leaving the external face open. Furthermore the material 
shows a porous structure of open macrocells forming the so 
called macroporosity. The walls of the macropores are 
completely covered by microcells. Macropores are uniformly 
distributed throughout the entire scaffold. These open 
macrocells connect each other through smaller diameter 
throats. The appearance of the resulting structure is that of a 
3D cellular material with open pore structure forming an 
interconnected network which in many aspects looks like 
trabecular bone (166). Macroporosity presents some changes 




when the polymer concentration varies. The macrocells 
trabeculae are well defined with a uniform macroporosity 
when the scaffolds are prepared with solutions of intermediate 
PLLA concentration, particularly for both series, from 5 to 
15% of PLLA content. Nevertheless, for the 1:1-(20/80) scaffold 
and 1:1.25-(5/95)/ (18/82)/ (20/80) scaffolds the trabeculae are 
not well defined in certain areas or completely broken. The 
porous structure is somehow collapsed and the macropores 
appear completely deformed in the case of the 1:1-(20/80) and 
1:1.25-(5/95) scaffolds. Scaffolds 1:1.25-(18/82)/ (20/80) present 
a structure with defined macropores but with very thin 
trabeculae 
While the polymer concentration changes a variation of the 
microporosity can be seen. Micropores are uniformly dispersed 
on the surface of the scaffolds except on the surface of the 1:1-
(20/80) scaffolds and 1:1.25-(18/82)/ (20/80) scaffolds, where 
the microporosity does not show up. It can be observed that 
the micropores get bigger when the polymer content decreases, 
for both 1:1 and 1:1.25 polymer/porogen ratio series. The 
influence of porogen proportion is observed in the trabeculae 
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Figure 3-2: SEM pictures of 1:1.25-(5/95)/ (10/90)/ (15/85)/ 
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The SEM pictures of the PLLA-MED scaffolds are presented 
in Figure 3-3 and Figure 3-4. The same morphologies as 
obtained in the case of industrial PLLA are observed. 
Interconnected macropores and micropores well dispersed on 
the surface of the pore walls can be identified. Defects on the 
structure caused by the polymer concentration, as broken 
trabeculae in some points, appear only for the 1:1.25-(20/80) 
scaffold. It can be seen that the trabeculae are getting thinner 
as the polymer concentration increases. This trend is better 
observed for the 1:1.25 series. 
Micropores are well defined and regularly distributed on the 
macropore walls, except for the 1:1-(5/95)/ (20/80) scaffolds and 
1:1.25-(18/82)/ (20/80) scaffolds. On the macropore walls of this 
last composition, (20/80), microcells form an undefined relief. 


















Figure 3-3: SEM pictures of 1:1-(5/95)/ (10/90)/ (15/85)/ (18/82)/ 
(20/80)-MED scaffolds. 
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Figure 3-4: SEM pictures of 1:1.25-(5/95)/ (10/90)/ (15/85)/ 
(18/82)/ (20/80)-MED scaffolds. 
 
500 µm 50 µm 
500 µm 50 µm 
500 µm 50 µm 
600 µm 60 µm 
600 µm 60 µm 






Porosity, micropore and macropores dimensions of the 
different scaffolds are presented in Figure 3-5, Figure 3-6 and 
Figure 3-7 respectively. The porosity was determined as 
explained in section 2.2.3, p.58, the pores dimensions were 
directly determined from the SEM pictures. An average was 
made measuring five pores of three different scaffolds for both 
types of pores. Micro and macropores were both considered to 
determine the porosity. 
A slight decrease of the porosity can be seen when the polymer 
concentration increases. The porosity varies from 81% to 96%. 
The highest macropore dimensions are for the (5/95) scaffolds 
in both series; around 150 µm for the PLLA-CD scaffolds and 
between 100 and 150 µm for the PLLA-MED scaffolds. Both 
PLLA brands present the same tendency; the highest 
micropore dimension is obtained for the (5/95) in both series 
and then decreases with the polymer concentration, until 
disappearing for the (20/80) scaffolds fabricated with 
industrial PLLA, as observed on the SEM pictures. For the 
PLLA-CD scaffolds the micropore dimensions range from 8 to 






Figure 3-5: Porosity of (5/95), (10/90), (15/85), (18/82), (20/80) 


































Figure 3-6: Micropore dimensions of PLLA-CD and PLLA-
MED scaffolds, values obtained by direct measurement from 
the SEM pictures of five pores of three different scaffolds. 





































Figure 3-7: Macropore dimensions of PLLA-CD and PLLA-
MED scaffolds, values obtained by direct measurement from 
the SEM pictures of five pores of three different scaffolds. 
 
3.1.3 Mechanical properties 
 
The curves representative of the highest and the lowest elastic 
modulus for each type of PLLA and series are represented in 
Figure 3-8 and Figure 3-9, focusing on the elastic area marked 
by a dotted line. Figure 3-10 represents the compression 
curves of the 1:1-(5/95), (10/80), (15/85), (18/82), (20/80)-PLLA-
MED scaffolds in order to evaluate the mechanical resistance 
of the scaffolds with different compositions from the same 
series. This series is chosen to be represented because PLLA-
MED is the material selected for further degradation and 
implantation studies. The elastic modulus of the scaffolds can 
be calculated from the compression curves as explained in 
section 2.2.4, p.59. The compression curves of the (15/85) 
scaffolds of both PLLA are shown in Figure 3-11. Table 3-1 




scaffolds. In order to visualize the tendency of the evolution of 
the elastic modulus as a function of the formulation a graph 





The highest elastic modulus obtained for either series 
1:1/1:1.25 is for the scaffolds with 15% PLLA, corresponding to 
the 1:1-(15/85) scaffold with a modulus of 8.9±0.8 MPa. The 
lowest measured elastic moduli are for the 1:1-(5/95) and 
1:1.25-(5/95) scaffolds, 0.2±0.1 MPa and 0.1±0.1 MPa, 
respectively. In general, the elastic moduli of the 1:1 series are 
bigger than those of the 1:1.25 series, with the exception of the 




The highest moduli are obtained for the 1:1-(18/82) and 1:1.25-
(15/85) scaffolds with 6.06±0.92 MPa and 4.8±0.4 MPa, 
respectively. And the lowest correspond to those calculated for 
the (5/95) samples of both series. 
The shape of the compression curves is similar for each type of 
PLLA. In Figure 3-8 and Figure 3-9, it is possible to observe 
the difference in the shape between the elastic zones in the 
compression curves, of the (5/95) and (15/85) scaffolds for each 
series and PLLA type. It can be appreciated how the elastic 
area is inexistent and the yield point is occurring instantly for 
the 1:1-(5/95) scaffold. It can also be seen that the yield point 
for a certain strain (dotted line) increases towards higher 
stress level when the polymer content increases. Therefore, 
the plateau area is reached at higher stress level when 
polymer content increases.  




In Figure 3-11 it can be observed that the yield point of the 
PLLA-MED scaffolds is achieved at higher stress and strain 
than for the PLLA-CD scaffolds. 
 
Figure 3-8: Compression test curves of 1:1/1:1.25-











Figure 3-10: Compression test curves of 1:1/1:1.25-
(5/95)/(10/80)/(15/85)/(18/82)/(20/80)- MED scaffolds. 
 









Table 3-1: Elastic modulus of the PLLA-CD and PLLA-MED 
scaffolds from the elastic zone of the compressive curves. 
(PLLA/dioxane) 
content 
E elastic (MPa) 
PLLA-CD 
E elastic (MPa) 
PLLA-MED 
1:1 1:1.25 1:1 1:1.25 
(5/95) 0.2±0.1 0.1±0.1 0.2±0.1 0.1±0.03 
(10/90) 2.4±1.5 1.7±1.2 1.7±0.2 0.6±0.01 
(15/85) 8.9±0.8 5.3±2.7 3.5±0.6 4.8±0.4 
(18/82) 2.6±1.1 3.4±1.0 6.1±0.9 2.4±0.4 
(20/80) 1.9±1.7 1.8±1.3 5.7±0.4 2.3±0.5 
 
Figure 3-12: Apparent elastic compression modulus of the 










3.1.4 Calorimetric properties 
 
Scans of first and second heating experiments are shown in 
Figure 3-13 of the 1:1-(15/85) scaffolds of PLLA-MED and CD. 
Similar scans were obtained for the other compositions.  
Table 3-2 presents the enthalpic glass transition temperature, 
the maximum of the temperature of crystallization and the 
maximum of the melting temperature of the (15/85) of both 
PLLA after the first and the second scan of DSC test. Table 
3-3, Table 3-4, and Table 3-5 compile the enthalpic glass 
transition temperature of the first scan, the maximum of the 
melting temperature of the first scan and the crystallinity of 
the first and second scans, respectively, obtained from the 
DSC curves for each composition. In most of these tables the 
data were calculated only after the first scan in order to have 
information of the materials after their fabrication. The 
enthalpic glass transition and the maximum of the melting 
temperature were obtained for each curve by the method of 
integration of the heat flow curves. The enthalpic glass 
transition temperature was calculated and corresponds to the 
intersection of the enthalpic lines at the liquid and glass states 
in the enthalpy vs. temperature diagram. 
 
The crystallinity (χc (%)) was determined by the equation (6): 




•   (6) 
where ∆Hm and ∆Hc are the enthalpy of melting and the 
enthalpy of crystallization in the case in which a 
crystallisation peak appears, respectively. ∆Hm100% is the heat 
of melting of the 100% crystallised PLLA; a value of 93.1 J/g 
(167) was used.  
Figure 3-13 shows that any crystallisation peak appears after 
the first scan but only after the second one. In the case of the 
medical grade PLLA-MED two crystallization peaks at low 




temperature and another one at higher temperature can be 
observed in the second scan in the case of the PLLA-MED. 
Glass transition temperature occurs at lower temperature in 
the first scan than at the second one. 
The glass transition temperature is around 60ºC for all 
scaffolds (Table 3-3); there are no significant changes between 
the different PLLA used to fabricate the samples. 
The maximum of the melting temperature (Table 3-4) is lower 
for the PLLA-CD scaffolds (around 164ºC) than for the PLLA-
MED (around 180ºC) scaffolds. For both brands there are no 
significant changes between the different polymer 
concentration and polymer/ porogen ratio. The crystallinity 
(Table 3-5) of the PLLA-CD scaffolds is lower (around 40%) 
than that of the PLLA-MED scaffolds (around 50%). For both 
brands there are no significant changes in the different 
polymer concentrations and polymer/ porogen ratios. 
 
 
Figure 3-13: Normalised heat flow (J/gK) as a function of the 
temperature from the DSC first (1) and second scan (2) of 1:1-




























Table 3-2: Enthalpic glass transition temperature (Tg), 
maximum of crystallization temperature (Tc) of the second 
peak in the case of PLLA-MED and melting temperature (Tm) 
after the first and second scans of 1:1-(15/85) PLLA-MED and 
PLLA-CD scaffolds. 
 CD MED CD MED CD MED 
Nº Scan Tg (ºC) Tc (ºC)  Tm (ºC) 
First 63.0 65.3 - - 164.3 180.6 
Second 56.5 59.0 130.3 103.3 161.2 180.9 
 
Table 3-3: Enthalpic glass transition temperature of PLLA-






1:1 1:1.25 1:1 1:1.25 
(5/95) 63.7 58.3 69.0 64.4 
(10/90) 60.4 66.6 66.1 65.9 
(15/85) 63.0 60.3 65.3 72.8 
(18/82) 58.0 58.9 68.8 63.4 
(20/80) 62.7 64.7 68.6 - 
 
Table 3-4: Maximum of the melting temperature of PLLA-CD 






1:1 1:1.25 1:1 1:1.25 
(5/95) 163.8 163.6 181.3 180.4 
(10/90) 163.3 163.9 179.4 179.4 
(15/85) 164.3 163.6 180.6 181.9 
(18/82) 164.8 164.9 180.8 180.6 









Table 3-5: Crystallinity of PLLA-CD and PLLA-MED scaffolds 






1:1 1:1.25 1:1 1:1.25 
(5/95) 40 40 51 57 
(10/90) 36 37 52 51 
(15/85) 38 38 51 56 
(18/82) 44 38 51 52 
(20/80) 40 38 54 - 





3.2 DEGRADATION EXPERIMENTS 
 
PLLA, due to its ester bond, can degrade in the human body, 
the degradation process leads to the loss of mechanical and 
physical-chemical properties. One way to determine the 
degradation process of PLLA scaffolds is by simulation 
through in vitro incubation in phosphate bufferer saline 
solution (PBS) at 37ºC in order to recreate the conditions of pH 
and osmolarity of the human body. In this section, the effect of 
degradation time on the properties of the scaffolds is 
presented. Two types of degradation experiments were 
performed; first a static degradation experiment lasting 6, 12, 
18, 24 weeks and 1 year, which enables the evaluation of the 
effect of the hydrolytic degradation on the PLLA scaffolds. To 
maximise the simulation of degradation of PLLA in the human 
body, in such parts as joints, it is necessary to pay attention to 
the mechanical solicitation which can affect the degradation 
process. For this aim a second degradation experiment was 
performed; a fatigue assay, under a compressive dynamic 
loading in PBS at 37ºC, was applied during 1, 2, 4 and 6 weeks 
on the scaffolds. These in vitro degradation experiments were 
performed on the scaffold formulation (1:1)-(15/85)-PLLA-
MED selected for the fabrication of highly porous scaffolds in 











3.2.1 Static degradation 
3.2.1.1 Morphology 
 
As can be seen in the SEM micrographs in Figure 3-14, the 
macro and microstructure of the different scaffolds submitted 
to different periods of degradation do not present significant 
changes up to 24 weeks. The trabeculae remain intact and the 
macropores are still highly interconnected. Table 3-6 shows 
the average macropores size determined by microtomography. 
The microtomography was carried out by the Group of 
Structural Mechanics and Materials Modelling, of the 
University of Zaragoza, in Spain, to determine the average 
macropores size. 
The pore dimension increases with degradation time as it can 
be demonstrated in Table 3-6. But it was not really possible to 
appreciate a change on the micropore dimension even after 1 
year of incubation in PBS. However a significant change was 
observed after 1 year when most of the trabeculae appeared 
broken in the SEM pictures. When, after 1 year, the scaffolds 
are manipulated they disaggregate easily. 




















Figure 3-14: SEM pictures at different magnifications and 
degradation times of the section of the (1:1)-(15/85)-PLLA-
MED scaffold showing the effect of static degradation in PBS 
on scaffolds morphology. 
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3.2.1.2 Mass evolution 
 
The evolution of the mass of the samples as a function of the 
degradation time was determined. Figure 3-15 shows how the 
mass loss of the different scaffolds changed with time of 
degradation. The mass loss of the samples was evaluated 









=    (7) 
where mi is the initial mass and mf the final mass of the 
samples. 
Contrary to what was expected it seems that the scaffolds 
mass loss is hardly observed. Furthermore it can be observed 
that the mass residue increase after 6 and 18 weeks of 
degradation. This can be due to the precipitation of some salts 
on the surface of the materials as observed in the dynamic 
degradation. Elemental analysis was performed after the 










Figure 3-15: Percentage of mass remaining after 0, 6, 12, and 
18 weeks of static degradation for the 1:1-15%-MED scaffold.  
 
 
3.2.1.3 Mechanical properties 
 
The influence of the static degradation experiment on the 
mechanical properties of PLLA scaffolds was evaluated by 
compression test from which the elastic modulus was 
calculated. The compression test was performed by the Group 
of Structural Mechanics and Materials Modelling, of the 
University of Zaragoza, in Spain. The protocol used for this 
study is detailed in section 2.2.4, p.59 . The stress-strain 
curves obtained from the compression test are represented in 
Figure 3-16 and the elastic moduli are compiled in Figure 3-17 
and Table 3-6. The curves show the three specific zones 
characteristic of a porous material. The plateau area, 
representing the collapse of the pores, is affected by 
degradation time. The slope of the pore collapse zone 
decreases with degradation time, and at 24 weeks was almost 




degraded. The stress and strain curves show that pores 
started to collapse at lower stresses when the degradation 
time increased and this effect was particularly marked after 
18 and 24 weeks. When degradation time increases the 
scaffolds hold the load less and less, so that less stress is 
required to deform more. The elastic moduli present a slight 












Figure 3-16: Stress – Strain curves of the compression test 












Figure 3-17: Apparent Young’s modulus of the PLLA-1:1-15%-
MED scaffold as a function of the degradation time under 
static in vitro conditions. 
 
Table 3-6: Evolution of the apparent Young’s modulus, 
permeability and macropore dimension as a function of the 











0 w 3.43 ± 0.25 1.2.10-7 ± 0.1.10-7 88 ± 7 
6 w 3.41 ± 0.14 1.2.10-7 ± 0.1.10-7 179 ± 3 
12 w 3.06 ± 0.12 1.7.10-7 ± 0.3.10-7 184 ± 10 
18 w 2.94 ± 0.33 3.10.10-7 ± 0.3.10-7 206 ± 8 











Permeability tests allowed evaluation the effect of the 
degradation time on the water flow rate through the porous 
structures of the scaffolds. The permeability test was done by 
the Group of Structural Mechanics and Materials Modelling, 
of the University of Zaragoza, in Spain. The permeability test 
was performed accordingly to the Darcy’s law (8) and valid for 




    (8) 
Where k is the intrinsic permeability, t the specimen 
thickness, A the cross-sectional area, Q is the volumetric flow 
rate, ∆p is the pressure difference across the sample and µ the 
dynamic fluid viscosity (deionized water at 10-3 Pa). All the 
samples were immersed in PBS solution during 48 hours 
before testing. According to the experimental protocol, the 
fluid flow through the scaffold was increased at different rates 
(20, 40, 60 ml/min) and for each case the pressure difference 
between the exit and entrance to the scaffold was measured. 
The obtained results were averaged and the intrinsic 
permeability of the material was determined. Five replicates 
of each sample were measured for the sake of precision. The 
results of the permeability test are shown in Figure 3-18 and 
Table 3-6. It can be clearly observed that the permeability 







Figure 3-18: Evolution of the permeability of PLLA-1:1-15%-
MED scaffold as a function of static degradation time in PBS. 
 
3.2.1.5 Calorimetric properties 
 
The influence of the static degradation process on the 
calorimetric properties of PLLA-1:1-15%-MED scaffold were 
evaluated using DSC tests. The samples corresponding to 
different time of degradation (0, 6, 12, 18, 24 weeks and 1 
year) were submitted to three temperature scans: two from 
0ºC to 210ºC at 10ºC/min and the cooling between them from 
210ºC to 0ºC at 10ºC/min. The results from the DSC test are 
represented in Figure 3-19 and Figure 3-20. The curves of the 
first scan (1) present two differences between the non-
degraded scaffolds and the degraded scaffolds. The degraded 
scaffolds present a double peak typical of double melt 
behaviour. An exception has to been made for the scaffolds 
degraded for 1 year. The double melting behaviour of PLLA is 
explained by the melting of originate crystals and the second 
peak by the melting of recrystallized crystals that can be 
caused by the degradation process. The cooling peaks shift 




towards a lower temperature as the scaffolds degrade. The 
second heat scan presents differences from the first one; two 
crystallization peaks appear, one with a maxima at low 
temperature (around 100ºC), and a smaller one with a maxima 
of around 160ºC. The second peak is explained to be the 
recrystallization process (137). The trend is the same for all of 
the scaffolds tested. The double melting peak does not appear 
at the second heating. The maximum of the melting process 




Figure 3-19: Normalised heat flow of the DSC first (1) and 
second (2) heating scans after 0, 6, 12, 24 weeks and 1 year of 
static degradation of PLLA-1:1-15%-MED scaffolds. The heat 
flow was normalised by the mass of the samples and the 
heating rate at (10ºC/min). The arrow mark represents a unit 











Figure 3-20: Normalised heat flow of the DSC cool scans after 
0, 6, 12, 24 weeks and 1 year of static degradation of PLLA-
1:1-15%-MED scaffolds. The heat flow was normalised by the 
mass of the samples and the heating rate at 10ºC/min. The 
arrow mark represents 5 units of normalised heat flow in 
J/gK. 
 
From these curves the enthalpic glass transition temperature 
(determined as the intersection temperature of the enthalpic 
lines at the liquid and glass states in the enthalpy vs. 
temperature diagram) and the crystallinity (see equation (1) in 
section 3.1.4, p.78) are compiled in Figure 3-21, Figure 3-23 
and Table 3-7. Crystallinity measured after the first heating 
scan (1) is representative of the state of the sample after 
degradation and the one measured from the second heating 
scan (2) is representative of the ability of crystallization from 
the melt of the samples, previously degraded and melted. It 
K 




can be observed that the glass transition temperature (Tg2) 
and the crystallinity (χc2) of the scaffolds at the second heating 
are smaller than those corresponding to the first one, for all 
the degradation times. The glass transition temperature at 
day 0 shifted from 72ºC in the first scan to 58ºC in the second. 
The crystallinity of the scaffolds after the different 
degradation times remained almost constant around 50%, for 
the first heating. In the second heating scan it was smaller 
than in the first and increased with the time of degradation; 
the crystallinity is 13% for the non-degraded sample and 
increased up to 38% for the 1 year degraded sample.  
 
 
Figure 3-21: Glass transition temperature after the first (Tg1) 
and second (Tg2) DSC scan as a function of static 
degradation in PBS at 37ºC after 0, 6, 12, 24 weeks and 1 year 






Figure 3-22: Melting temperature after the first (Tm1) and 
second (Tm2) DSC scan as a function of static degradation in 




Figure 3-23: Crystallinity after the first (χc 1) and second (χc 2) 
DSC scan as a function of static degradation in PBS at 37ºC 
after 0, 6, 12, 24 weeks and 1 year of PLLA-1:1-15%-MED 
scaffolds. 





Table 3-7: Crystallinity (χc) and glass transition temperature 
(Tg) after the first (1) and second (2) DSC scan of the 







χc 1 χc 2 Tg1 Tg2 
0 w 48 13 72 58 
6 w 50 24 71 57 
12 w 46 22 72 58 
24 w 51 27 73 54 
1 y 49 38 75 54 
 
3.2.1.6 Gel permeation chromatography 
 
From the GPC curves (Figure 3-24), it is possible to know the 
fraction (%) of polymer chains length as a function of log(M). 
Consequently it is possible to evaluate the effect of 
degradation of the PLLA scaffolds on the molar mass 
distribution function. The weight average molar mass (Mw) is 
represented in Figure 3-25, and the polydispersity index 
Mw/Mn in Figure 3-26, Mn being the number average molar 
mass. The distribution of the molar masses of the PLLA 
samples is described in Figure 3-24. Initially the non-degraded 
PLLA scaffold presented a narrow molecular mass distribution 
with weight average molar mass of almost 200 kDa. With time 
a higher fraction of short chains appear and average molar 
mass decreases (Figure 3-25). However, the GPC curve shows 
that a major fraction of chains keeps its molecular weight as 
the principal peak (Figure 3-24) does not change of position 
but lowers its intensity. The polydispersity index increases as 
the GPC curve shows that fraction of lower molecular weight 




of polymers that degrade in surface (from outside to the 
interior of the material). The longer the degradation time the 
more the peak shifts towards a lower molecular weight as the 
entire volume of the material becomes affected by the 
degradation process, especially for one year. 
 
Figure 3-24: Gel permeation chromatography curves 
representing the fraction in percentage as a function of 
log(MPLLA) of PLLA-1:1-15%-MED scaffolds after 0, 6, 12, 18, 24 
weeks and 1 year of static degradation. 
 
 





Figure 3-25: Evolution of the weight average molecular 
weight (Mw) as a function of degradation time of PLLA-1:1-
15%-MED scaffolds after 0, 6, 12, 18, 24 weeks and 1 year of 
static degradation. 
 
 Figure 3-26: Evolution of the polydispersity index (Mw/Mn) 
as a function of degradation time of PLLA-1:1-15%-MED 






3.2.1.7 Thermogravimetric analysis 
 
The PLLA scaffolds were thermally degraded in order to 
evaluate the effect of the static degradation in PBS on the 
thermal stability of the polymer chains. The TGA curves 
represented in Figure 3-27 represent the residual mass of the 
scaffolds when they are thermally degraded. The first 
derivative of mass as a function of the temperature (dw/dT) 
curves is shown in Figure 3-28. They allow us determining 
that decomposition of PLLA takes place in mainly only one 
step; the temperature of the maximum of this step shifts to 
lower temperatures as the degradation time increases. 
Persenaire et al. (173) describes the pyrolysis reaction of the 
ester bond as the first step of thermal degradation of PCL 
during which volatile components are formed as H2O, CO2 and 
5-hexenoic acid. A second thermal degradation step is also 
described as the formation of cyclic monomer as a result of an 
unzipping depolymerisation process occurring caused by the 
presence of hydroxyl group (173). In the case of PLLA 
pyrolysis of the ester bond produces shorter chains that 
immediately are degraded producing a rapid mass loss 
traduced in only one peak on the derivative curve. The 
maximum of this peak for the non-degraded scaffolds takes 
place at 360ºC and for the scaffolds one year degraded at 
315ºC. This shift could be a consequence of two phenomena: on 
one hand the presence of a higher proportion of carboxylic and 
hydroxilic groups in the degraded samples may act as 
catalyzers of the scission of the ester bonds. On the other 
hand, as the degraded samples have shorter chains the 
diffusion of volatile species should be easier and the onset of 
mass loss is produced at lower temperatures. Indeed, 
molecular weight distribution curves Figure 3-24 show that as 
degradation time increases the number of high molecular 
weigh chains decreases (demonstrated by the lowering of the 
intensity of the peak) giving place to lower molecular weight 




chains (as shows the broadening to low molecular weight of 
the distribution curve). The non-hydrolytically degraded 
scaffolds therefore start to thermally degrade around 300ºC, 
and those hydrolytically degraded during 1 year start to 
thermally degrade around 210ºC (Figure 3-27).  
 
 
Figure 3-27: Residual mass as a function of temperature of 
PLLA-1:1-15%-MED scaffolds after 0, 6, 24 weeks and 1 year 









Figure 3-28: First derivative curves of residual mass with 
temperature (dw/dT) as a function of the temperature of 
PLLA-1:1-15%-MED scaffolds after 0, 6, 24 weeks and 1 year 
of static degradation. 
 
3.2.2 Fatigue essay 
3.2.2.1 Morphology 
 
The SEM micrographs, Figure 3-29, show the external surface 
and the cross section of the scaffolds after several weeks of 
degradation. The deformation of the macroporous structure is 
most evident in the solicitation direction on the cross-section 
micrographs. The trabeculae are more and more collapsed as 
they are degraded. After 6 weeks of dynamic degradation the 
scaffolds present a compact structure. 



















Figure 3-29: SEM micrograph of the PLLA-1:1-15%-MED 
scaffolds external and internal surface after 0, 1, 2, 4 and 6 
weeks of dynamic degradation. 
600 µm 600 µm 
500 µm 500 µm 
500 µm 500 µm 
500 µm 500 µm 




3.2.2.2 Mass evolution 
 
The evolution of the mass of the samples as a function of the 
degradation time was determined following equation 7, p. 86. 
Figure 3-30 shows the mass residue of the different scaffolds 
after various times of degradation. The mass residue 
decreases with degradation time only after 2 weeks of 
degradation. Due to the fact that the observed gain in mass 
after 1, 4 and 6 weeks of degradation could be due to the 
precipitation of some salts on the surface of the materials we 
performed an elemental analysis of the samples after the 
degradation tests. 
 
Figure 3-30: Mass residue of the PLLA-1:1-15%-MED scaffolds 











3.2.2.3 Elemental analysis 
 
In order to explain why the mass of the sample increased with 
the degradation process we analysed the surface of the 
material to detect the eventual nucleation of salts from the 
PBS. Figure 3-31 presents the results of the elemental 
analysis carried out on the surface of the scaffolds after 6 
weeks of dynamic degradation, where the atomic percentages 
of the salts detected are represented. The samples were 
properly rinsed with distilled water before analysis; the same 
procedure was practiced before weighing them for the 
determination of the mass after each degradation time. A 
large amount of NaCl was found on the surface of the scaffold 












Figure 3-31: (up) Atomic percentage of the element detected 
on the surface of the samples after 6 weeks of dynamic 
degradation of the PLLA-1:1-15%-MED scaffolds and (down) 
signal obtained during the corresponding elemental 
analysis. 
 
3.2.2.4 Mechanical properties 
 
The evaluation of the dynamic degradation on the mechanical 
properties of the scaffolds was done by compression test. In 
Figure 3-32 and Figure 3-33 it can be observed that there is no 
elastic zone as the curves start directly in the plateau zone, 
with a short pore collapse zone. The precision of the 
equipment used to apply the deformation during the 
degradation could not avoid the partial pore collapse. 




Consequently, no values of the elastic modulus were obtained. 
Nevertheless, the effect of degradation on the scaffolds’ 
mechanical properties can be observed. In Figure 3-33 
following the horizontal line at a stress of 0.04 MPa it can be 
determined the corresponding strain as a function of the 
degradation time. The strain increases from 0.04 for the 
scaffolds no degraded to 0.13 after 1 week of degradation to a 
maximum of 0.15 after 2, 4 and 6 weeks of degradation. The 
pore collapse as the scaffolds degraded. After 1 week this zone 
is shorter and the densification zone is reached at smaller 
strain (Figure 3-32 and Figure 3-33).  
 
Figure 3-32: Stress – Strain curves of the compression test 







Figure 3-33: Stress – Strain curves of the compression test 
after 0, 1, 2, 4 and 6 weeks of dynamic degradation of the 
PLLA-1:1-15%-MED scaffolds. The vertical line limiting the 
elastic zone of the curves of the samples no degraded. 
 
3.2.2.5 Calorimetric properties 
 
Representative curves of the calorimetric properties are 
represented in Figure 3-34 and compiled in Table 3-8. In these 
DCS spectra first (1) and second scans (2) can be observed. 
The curves representative of the first scan shown only glass 
transition temperature and melting. The second scan shows, 
in addition to Tg and Tm, crystallization process around 110ºC 
a recrystallization at higher temperature around 160ºC. This 
phenomenon was also observed in the static degradation 
study. It also can be observed that the crystallization peak at 
110ºC increases with degradation time. From these curves it 
was possible to evaluate the evolution of the glass transition 
temperature (Figure 3-35), the melting temperature maximum 
(Figure 3-36) and the crystallinity (Figure 3-37). It can be 
noticed that the glass transition temperature, melting 




temperature and the crystallinity of the second heating is 
smaller than the first one. The glass transition temperature 
for both scans remains constant when the scaffolds get more 
and more degraded. The decrease of the melting temperature 
when the time of degradation increases is more pronounced 
during the second heating than the first one, in particular 
after the first week of degradation; falling from 183 to 179ºC 
after the first scan, between 0 and 6 weeks of degradation. 
 
 
Figure 3-34: Comparison of the DSC first (1) and second (2) 
heat scans after 0, 1, 2, 4 and 6 weeks of dynamic 
degradation. of the PLLA-1:1-15%-MED scaffolds The heat 
flow was normalised by the mass of the samples and the 
heating rate at 10ºC/min. The arrow mark represents 3 units 






Figure 3-35: Glass transition temperature after the first scan 
(Tg1) and the second scan (Tg2) of the PLLA-1:1-15%-MED 
scaffolds after 0, 1, 2, 4, 6 weeks of dynamic degradation. 
 
 
Figure 3-36: Maximum of melt temperature after the first 
scan (Tm1) and the second scan (Tm2) of the PLLA-1:1-15%-
MED scaffolds scaffolds after 0, 1, 2, 4, 6 weeks of dynamic 
degradation. 
 





Figure 3-37: Crystallinity after the first scan (χc 1) and the 
second scan (χc2) of the PLLA-1:1-15%-MED scaffolds after 0, 
1, 2, 4 and 6 weeks of dynamic degradation. 
 
Table 3-8: Crystallinity and glass transition temperature 
after the first (1) and second (2) DSC scan of the PLLA-1:1-
15%-MED scaffolds after different time of dynamic 






χc 1 χc 2 Tg1 Tg2 
0 w 48 13 77 62 
1w 45 11 70 59 
2 w 45 19 70 59 
4 w 47 18 71 57 










3.2.2.6 Gel permeation chromatography 
 
 A small fraction of the polymer chains are affected by the 
dynamic degradation as the molecular weight decreased 
slightly after one week and then remains constant (Figure 
3-39) and the polydispersity index increased (Figure 3-40). 
This phenomenon was also observed in Figure 3-38 as the 
principal peak was reduced between week 0 and 1 week. The 
small decrease in molecular weight was similar to the one 
observed for the static degradation at 6 weeks.  
 
 
Figure 3-38: Gel Permeation Chromatography curves 
representing the fraction of polymer chain as a function of 
log(Mw) after 0, 1, 2, 4 and 6 weeks of dynamic degradation. 
 
 




Figure 3-39: Average molecular weight of the PLLA-1:1-15%-
MED scaffolds after 0, 1, 2, 4 and 6 weeks of dynamic 
degradation. 
 
Figure 3-40: (Mw/Mn) of the PLLA-1:1-15%-MED scaffolds 





3.2.2.7 Thermogravimetric analysis 
 
As noticed in the static degradation study, thermal 
degradation was performed in order to determine the effect of 
the fatigue essay on the thermal resistance of the polymer 
chains. The results of this test are shown in Figure 3-41 and 
Figure 3-42. The derivative mass loss peak lowers its intensity 
and shifts from 360ºC to 315ºC after 1 week of dynamic 
degradation (Figure 3-42), a phenomena that already occurred 
on the static degradation experiments. Furthermore the 
thermal degradation stability is decreased as the degradation 
curves onsets (Figure 3-41) lower from 320ºC to 240ºC after 6 
weeks of degradation. This indicates the formation of smaller 
polymer fragments when scaffolds degraded in PBS. 
 
 
Figure 3-41: Mass residue percentage as a function of the 
temperature of the PLLA-1:1-15%-MED scaffolds after 0, 1, 2, 









Figure 3-42: Evolution if the first derivative of weight as a 
function of the temperature curves of the PLLA-1:1-15%-MED 
scaffolds after 0, 1, 2, 4 and 6 weeks of dynamic degradation. 
 





3.3 REINFORCEMENT AND BIOACTIVITY OF THE 
MATERIAL 
 
The polymeric scaffolds selected on section 4.1.2, p.176, which 
will be the basis for the design of the construct for 
osteochondral scaffolds, are much more compliant than bone. 
This constraint is not only due to the polymeric character of 
PLLA but also to its high porosity. The aim of this chapter is 
to look for the best strategy to reinforce the scaffolds and at 
the same time to confer an adequate bioactivity to the bony 
part of the construct. The aim is to try to have a part of the 
construct with mechanical properties more similar to 
subchondral bone, with a good anchorage to the host tissue 
due to its high bioactivity. The strategy we followed was to add 
bioactive nanoparticles to the organic PLLA matrix. First, we 
prepared 2D composite membranes as an easy way to test the 
viability of our approach, and then 3D scaffolds were produced 
in order to approximate working conditions. The same brands 
of PLLA as in section 3.1, p.63, were used: industrial PLLA 
and the medical PLLA. The influence of the inherent 
properties and the concentration of the nanoparticles used as 
filler on the hybrid structure were studied. The fabrication 
protocol was optimized for our specific objectives. Two kinds of 
fillers have been incorporated: commercial hydroxyapatite 
(HAp: Ca10(PO4)6(OH)2) nanoparticles and laboratory produced 
nanoporous silica (SiO2) particles. HAp is naturally present in 
bone tissue and its bioactive properties have been widely 
tested. More recently the use of bioactive silicates has been 
proposed as an alternative to apatites due to the interesting 
mechanical properties obtained with them (152,153). The 
hybrids were thoroughly characterized with emphasis on the 
reinforcement and bioactive potential of these inorganic fillers.  
Membranes from a solution of PLLA in dioxane with a 15 % 
wt. of PLLA-MED and different quantities of HAp 
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nanoparticles (0, 5, 10 and 15 % wt. referred to the mass of 
PLLA) were fabricated. Then a bioactivity test was performed 
by soaking them in a simulated body fluid solution (SBF) for 0, 
7, 14 and 21 days. The effect of a surface pre-treatment with 
oxygen plasma on the bioactivity of pure PLLA and composites 
was also studied. 
Then this study was extrapolated to scaffolds. Scaffolds in 
which nanoparticles of HAp and silicate were incorporated to 
the polymeric matrix to enhance their bioactivity were 
fabricated. The bioactivity test used in the case of the scaffolds 
is the same as the one used for the membranes. In addition 
the effect of a new type of filler is evaluated on the bioactivity 
of the samples. Sonication is the method used to incorporate 
the filler to the matrix. In this way the effect on the 
interaction between the filler and the polymeric matrix on the 
mechanical properties can be studied. 
3.3.1 2D hybrid structure 
3.3.1.1 Morphology 
 
Figure 3-43 and Figure 3-44 present the surface of the 
membranes observed by scanning micrograph. Figure 3-43 
shows the membranes filled with 0, 5, 10 and 15 % wt. in HAp 
nanoparticles with and without plasma exposure. Figure 3-44 
shows the surface of the membrane filled with 15% of HAp 
particles at two different magnifications. Figure 3-45 shows 
the surface of the membranes with and without exposure to 
plasma, as the pictures were done at high magnification it is 
possible to evaluate the effect of the plasma treatment on the 
surface of the membranes. 
The membranes were fabricated using freeze-extraction 
process to generate the microporosity. No porogen was added 
as the plan was to build a 2D structure. The nanoparticles of 
filler were added to the solvent before dissolving the polymer 
in dioxane. The morphology observed in Figure 3-43 is similar 




to that observed on the pore walls of the scaffolds prepared in 
section 3.1, p.63, by freeze-extraction and particle leaching. 
The micropores are homogenously dispersed on the surface of 
the membranes. To confirm repeatability of the technique, 3 
different membranes were fabricated and observed by SEM. 
All membranes exhibited the same morphology. The pores are 
produced by the phase separation when both dioxane and 









































Figure 3-43: Scanning electron microphotographs of the 
surface of the PLLA membrane prepared with a 
PLLA/dioxane solution with a 15 % wt. of polymer by freeze 
extraction and filled with 0, 5, 10 and 15 wt. % of 
nanoparticles of hydroxyapatite after plasma treatment 
(right) and without (left). 
60 µm 50 µm 
60 µm 50 µm 
60 µm 100 µm 
60 µm 60 µm 




The micropore dimension was measured for the membranes 
exposed to plasma 12.3 ± 4.6µm and 12.9 ± 4.1µm for those 
that were not. They present a pore dimension greater than the 
one obtained for the scaffolds but of the same order of 
magnitude. The dimensions of the pores are not influenced by 
the content in filler. The structure of the microporosity as 
shown in Figure 3-43 does not present any significant changes 
when the filler content increases. The pictures present some 
differences but due to the way the membranes were cut. It was 
not possible to cut the membranes through the same angle. 
 
 
Figure 3-44: Scanning electron microphotographs of the 
surface of the PLLA membrane prepared with a 
PLLA/dioxane solution of with a 15 % wt. of polymer by 
freeze extraction without plasma: (left) low magnification 
micrograph and (right) high magnification micrograph. 
 
The morphology of the membrane seems to not be affected by 
plasma treatment. After oxygen plasma treatment, as shown 
in Figure 3-45 some kind of abrasion defects can be seen on 
the surface of the membranes, which does not appear in the 
membranes without plasma treatment. Surface abrasion was 
already found in plasma treated PLLA by Qu et al. (120) and 
in our study this abrasion allows HAp particles to appear at 
the pores walls. HAp nanoparticles cannot be clearly seen by 
SEM, especially in the untreated membranes, probably 
because a layer of PLLA covers them. However, EDS analysis 
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was able to show Ca and P peaks, characteristic of the HAp 
components, as shown by the insets in Figure 3-45. The EDS 
analysis was repeated three times in different zones for three 
different samples, and all the signals present the same 
behaviour, showing that particle dispersion is homogenous. 
 
 
Figure 3-45: Scanning electron micrographs and Energy 
dispersive spectroscopy analysis (as inset in the 
micrographs) of PLLA/HAp nano-composites with 10 % wt. of 
HAp: (a) without plasma treatment, (b) after plasma 
treatment. 
 
3.3.1.2 Nanoparticles content evaluation 
 
In order to evaluate the effective content of nanoparticles 
incorporated in the membranes, 3 membranes of each 
composition were calcinated up to 1000ºC. In this way, the 
mass of the polymer was eliminated from the composite 
membrane, allowing the residual mass to be used to evaluate 
the real content of nanoparticles in the membranes. In Table 
3-9 results of the content of measured nanoparticles are 
compiled and compared to the nominal ones. The calcination 
experiments showed that the amount of HAp incorporated into 
the membranes is similar to but lower than the amount of 
HAp dispersed in the PLLA solution. The more HAp was used 
to fill the membranes the less is really incorpoarated. The 




membranes that are filled with 5 % wt. of HAp are really filled 
with 4.45 ± 0.10 % wt., and those supposed to be filled with 15 
% wt. are really filled with 11.82 ± 1.12 % wt. The more HAp 
that is incorporated to the membranes, the more difficult it is 
to control the exact content in filler. 
  
Table 3-9: Effective nanoparticles mass content derived from 
the calcination experiments compared to the nominal ones in 
the PLLA/HAp membranes. 
Nominal 
HAp content (%) 
% of HAp 
incorporated 
Deviation (%) 
to the mass of 
HAp 
incorporated 
0 - - 
5 4.45 ±0.10 -10.9 
10 8.85 ±0.74 -11.5 
15 11.82 ±1.12 -21.2 
 
3.3.1.3 Differential scanning calorimetry 
 
Figure 3-46 shows the first and second heating of the diferent 
membranes filled with nanoparticles of HAp, and Table 3-10 
compiled the transition temperature obtained from the DSC 
scans. The first heating scan shows the glass transition with a 
large overshoot characteristic of the physical ageing (or 
structural relaxation) process suffered by the polymer during 
annealing at 40ºC while drying in vacuum. The cold 
crystallisation peaks appear after glass transition. These cold 
crystallisation peaks do not appear in the case of the scaffolds 
as it was observed in section 3.2.1.5, p.92, one factor that can 
explain this peak appearance is that the membranes are not 
dipped in ethanol at 40ºC as non porogen particle is 
incorporated in the fabrication process. The ethanol bath at 
40ºC permits crystallization of the polymer. These exothermal 
peaks appear at lower temperatures as the HAp nanoparticle 
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content increases (Figure 3-46 - left). Another crystallisation 
process appears at higher temperatures that is characteristic 
of highly nucleated samples that crystallize at very low 
temperatures (130). Finally the melting process takes place at 
a temperature independent of sample composition. The second 
scan is representative of the samples crystallized after 
melting. Here the endothermal overshoot due to physical 
ageing disappears since the sample was not annealed below 
the glass transition (Figure 3-46 - right). The crystallization 
and melting follow a trend similar to that of the first scan, 
although the crystallization peaks are clearly shifted towards 
higher temperatures. 
The determination of crystallinity was done by an integration 
of the heat flow trace with respect to a linear baseline that 
intersects a point immediately above the glass transition and 
another one after melting. If the sample was completely 
amorphous at the beginning of the heating scan the area 
between the thermogram and the baseline would be zero. The 
calculus becomes quite uncertain since the temperature 
interval to which it is extended is very broad and can easily 
lead to small errors in the determination of the baseline used 
in the integration (for instance for small curvatures in the 
baseline of the calorimeter). This difficulty is especially clear 
in the first scan when the thermogram starts deviating 
towards the exothermal side immediately above the glass 
transition (Figure 3-46 - left), which impedes any enthalpy 
calculation, and so the determination of the crystallinity after 
the first scan. The melting behaviour does not present any 
changes between the different samples and both scans; the 
peaks appear at the same temperature. 
The data relative to the glass transition temperature of the 
first and second scans and the crystallinity calculated after 
the second scan are compiled in Table 3-10. Other researchers 
have studied the effect of freeze-extraction on PLLA/ PCL 
mixture and the crystallinity obtained was 19% for the 




samples of the same PLLA used in our case (177). In the 
second scan crystallinity values between 6 and 20% were 
found but the HAp content dependence was non-systematic. 
The onset of the glass transition seems to be independent to 
the filler content (Figure 3-45). A slight decrease of the 




Figure 3-46: First DSC heating scan of PLLA/HAp 
nanocomposites with different filler content (left), and 
second DSC heating scan (right), both obtained at a heating 
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Table 3-10: (onset) Glass transition temperature and 
crystallinity of the membranes filled with 0, 5, 10 and 15 % 
wt. of nanoparticles of HAp. 
HAp content (%) 
Tg onset (ºC) Enthalpic Tg (ºC) χc (%) 
first scan second scan second scan 
0 51 36 10.4 
5 48 38 6.2 
10 51 38 19.9 
15 49 37 5.9 
 
3.3.1.4 Dynamic mechanical spectroscopy 
 
The dynamic mechanical properties at tension mode of the 
membranes were determined. The samples were first 
subjected to heating from 0 to 120ºC in the first measuring 
scan. The graph on the left DMS curves in Figure 3-47 show 
the temperature dependence of the storage modulus (E’) for 
the first and second scans of the membrane with a 10 % wt. of 
HAp and the curves on the right show E’ of the second scan for 
all the composites. The E’ curve for the first scan shows a 
sharp decrease starting close to the calorimetric glass 
transition. The shape of the curve with a change of slope in the 
middle of the relaxation indicates that crystallization starts 
during the scan itself. This makes the values measured at 
temperatures above Tg quite dependent on thermal history in 
the scan itself. The modulus in the glass region measured in 
the first scan increases with the HAp content of the 
composites (Table 3-11). To compare the behaviour of the 
different nano-composites with a more reproducible structure, 
samples were annealed at 120ºC for one hour to allow 
crystallization and cooled to 0ºC to start the second scan. 
Thus, the second scan corresponds to higher crystallinity 
samples. The main relaxation in the second scan is shifted to 
higher temperatures with respect to the first scan. This 
behaviour is expected due to the increase of glass transition 




temperature of the amorphous phase with the increase of 
crystal fraction. The value of E’ in the glassy region increases 
with respect to the first scan due to the higher fraction of 
PLLA crystals. The second scan shows that the value of E’ 
increases with the content of filler incorporated to the matrix 
both at low temperatures when the amorphous phase is in the 
glassy state and  after the main relaxation when it is in the 
rubber-like state (Table 3-11). Nevertheless, the increment 
although systematic and significant is not the one expected for 
a nanocomposite with a stiff nano reinforcing filler. In fact, as 
shown in Table 3-11, the value of the elastic modulus in the 
membrane with the highest HAp content does not reach twice 
that of the PLLA matrix. This fact must be ascribed to a poor 
interface adhesion between polymer matrix and filler, and 



























Figure 3-47: Dynamic-mechanical storage modulus as a 
function of temperature, E’(T), obtained at 1 Hz and a 
heating rate of 2ºC/min: (a) first and second heating scan of 
10 % wt. HAp membrane, (b) second heating scan of 0, 5, 10 








Table 3-11: Dynamic-mechanical storage modulus of the 
membranes filled with 0, 5, 10 and, 15 % wt. of nanoparticles 
of HAp after the first and the second scan. 
HAp content 
(%) 
E' glass (Pa) E' glass (Pa) 
E' (Pa) 








0 1.81.108 2.03.108 1.20.107 
5 2.02.108 2.30.108 1.43.107 
10 2.37.108 2.68.108 1.61.107 




Figure 3-48 shows the surface of the membranes of PLLA 
without nanofiller after the maximum time of immersion in 
SBF (21 days). It is possible to evaluate the influence of the 
plasma treatment on the bioactivity of the samples over this 
time. Figure 3-49 shows the surface of the membranes filled 
with 0, 5, 10 and, 15 wt. % of HAp with and without plasma 
treatment after 7 days in SBF. In this way it is possible to 
evaluate the influence of the plasma treatment and the 
content of nanofiller on the bioactivity of the membranes at 
short time since the membranes are not affected too much by 
hydrolysis in SBF. 
SEM analysis shows the influence on the kinetics of HAp 
deposition during increasing immersion times in SBF. As can 
be seen in Figure 3-48 PLLA is able to nucleate HAp in its 
surface, without any special treatment but at very slow rates 
compared to plasma-treated PLLA or PLLA reinforced with 
HAp. Over short time periods few nuclei can be observed in 
the SEM pictures, they increase in number to form a rough 
layer of cauliflower-shaped crystals. The surface of the 
micropores needs less time of immersion to be uniformly 
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coated with HAp as the content of nanofiller increases and 
with previous exposure to plasma. Figure 3-48 shows the 
surface of a PLLA membrane after 21 days of immersion in 
SBF, a time at which coating is still not complete, whereas the 
sample treated with plasma show a smooth layer of 
biomimetic HAp deposited on the surface. 
 
 
Figure 3-48: Scanning electron micrographs of pure PLLA 
membranes, without plasma treatment (left) and with 
oxygen plasma treatment (right), after 21 days in SBF. 
 
Figure 3-49 shows the effect of the HAp nanofiller content 
after 7 days of immersion. After this time the PLLA samples 
show no signs of apatite layer even when treated with plasma, 
but the rate of deposition increases with HAp content and 
samples containing more than 10 % wt. HAp nano-particles 
show a smooth coating of the composite surfaces. Plasma 
treatment further enhances the rate of deposition and the 
thickness of the layer increases in such a way that biomimetic 
apatite fills the whole volume of the micropores (Figure 3-49). 
After 21 days of immersion in SBF as it can be seen in Figure 
3-48 a layer of biomimetic HAp covers all the surface of the 
membranes. As can be seen on Table 3-12 Ca/P atomic ratio of 
the biomimetic HAp layer has been calculated from EDS 
analysis. This ratio has been compared to the one of 
stoichiometric hydroxyapatite (Ca10(PO4)6(OH)2) Ca/P = 1.67, 
or physiological HAp = 1.65. Globally the Ca/P atomic ratio 




calculated for all the samples is higher than the physiological 
HAp one, ranging from 1.63 to 2.54. The membranes with HAp 
incorporated at day 0, in which the Ca/P atomic ratio 
measured corresponds to the HAp nanoparticles added as 
filler, have the highest ratio, and the ratio observed does not 
match that of stoichiometric hydroxyapatite claimed by the 
supplier. For the same immersion time membranes previously 
exposed to plasma present a ratio closer to the physiological 
one in comparison with membranes that had not been exposed 
to plasma. In general, the ratio that is closest to the 
physiological one is for the plasma treated membranes 
prepared with nano-filler after 7 days in SBF. 
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Figure 3-49: Scanning electron micrographs of 0, 5, 10 and 15 % wt. HAp membranes without and with 
oxygen plasma treatment, after 7 days in SBF. 
50 µm 60 µm 
60 µm 60 µm 60 µm 60 µm 
60 µm 50 µm 









Table 3-12: Ca/P atomic ratio reported from the energy dispersive spectroscopy analysis 
Immersion time (days) 0 7 14 21 
HAp content (%) Plasma 
treatment 
no yes no yes no yes no yes 
0  0 ±0 0±0 0±0 0±0 - - 2.18 ±0.6 1.77 ±0.4 
5  2.54 ±0.5 2.15 ±0.4 1.82 ±0.1 1.66 ±0.1 - - 2.55 ±0.7 1.77 ±0.3 
10  2.1 ±0.2 2.38 ±0.4 1.68 ±0.05 1.67 ±0.05 2.25 ±0.7 1.95 ±0.2 2.2 ±0.3 2.48 ±1.3 
15  2.21 ±0.3 2.33 ±0.4 1.63 ±0.1 1.69 ±0.2 - - 2.08 ±0.2 2.62 ±1.4 
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3.3.2 3D hybrid structure 
 
The influence of the incorporation of HAp nanoparticles when 
fabricating 3D scaffolds and the influence of plasma treatment 
will be now discussed. The material used to fabricate this 
scaffolds was PLLA for industrial use; PLLA-CD. This was in 
order to lower the cost of the study as it is a first step in 3D. In 
this first section the nanofiller used is nanoparticles of HAp. 
3.3.2.1 PLLA/HAp composites 
MORPHOLOGY 
 
Figure 3-50 shows the surface of the scaffolds only made with 
PLLA and those filled with 5 % wt. of HAp. It can be observed 
that the morphology of the scaffolds is not affected, neither 
macro nor microstructure show differences when the nanofiller 
is incorporated to the polymer matrix. Although it will be 
discussed more thoroughly later in the section on mechanical 
properties, it is worth mentioning now that the elastic 
modulus of the scaffolds filled with HAp decreases - see Figure 
3-57 and Figure 3-58. The viscosity of the polymeric matrix 
used to produce composite porous scaffolds of PLLA is one of 
the main difficulties to permit a uniform distribution of the 
filler inside the polymeric matrix and avoid aggregates of 
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Figure 3-50: Scanning electron micrographs of the surface of 
the scaffolds of 1:1-(15/85)-CD scaffolds and 1:1-(15/85)-CD 




In Figure 3-51, Figure 3-52 and Figure 3-53 the surface of the 
scaffolds filled and not filled with nanoparticles of HAp after 
7, 14 and 21 days in SBF are shown. It is possible to evaluate 
the influence of immersion times and the incorporation of the 
nanofiller after 21 days in SBF (Figure 3-53) and the influence 
of plasma treatment after 14 days in SBF (Figure 3-52) on the 
bioactivity of the scaffolds. Figure 3-54 shows the morphology 
of the biomimetic HAp coated on the surface of the scaffolds 
and its distribution in the macropore scale. Figure 3-55 is a 
micrograph of the scans made during elemental analysis on 
the surface of the scaffolds filled with 5 % wt. of nanoparticles 
of HAp and exposed to plasma after 21 days in SBF. It also 
shows the corresponding scan of the signal obtained during 
800 µm 800 µm 
80 µm 100 µm 
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the elemental analysis. Table 3-13 compiles the calcium 
phosphate ratios on the surface of the scaffolds filled with 0 
and 5 % wt. HAp nanoparticles and treated or not by plasma 
treatment after 14 and 21 days in immersion in SBF. Figure 
3-56 is a histogram showing the calcium and phosphate ratios 
in the biomimetic layer coating on the surface of the scaffolds 
after 21 days (when bioactivity tends to be the most 
satisfactory. No nuclei of HAp were detected on the surface of 
the scaffolds after 7 days in SBF. It can be appreciated the 
influence of the nanofiller and the plasma treatment on the 
nature of the layer of HAp nucleated on the surface of the 
samples. 
Apatite layer formation in the surface of the pores of the 
scaffolds is observed after different times of immersion in 
SBF. Nanoparticles of HAp were added and a previous oxygen 
plasma treatment applied as a mean for studying their 
influence on in vitro bioactivity of the samples. The scaffolds 
were carefully dipped in SBF using vacuum to remove all the 
air trapped in the pores. SEM analysis in Figure 3-51 and 
Figure 3-53 shows the progression of the nucleation of HAp on 
the surface of the scaffold. The layer nucleated on the surface 
of the scaffolds is denser than the one in the inside of the 
scaffolds. It was possible to nucleate a uniform HAp layer 
inside the matrix for scaffolds with 5% HAp nanoparticles and 
a previous plasma treatment after 21 days in SBF. Only 
plasma treatment after 21 days in SBF allows the formation of 
some nuclei of HAp inside the scaffolds. The scaffold without 
filler is able to nucleate HAp on its surface after being 21 days 
in SBF, but not before this time, as observed in Figure 3-51 
and Figure 3-53. These kinetics are accelerated when scaffolds 
without filler particles are plasma treated (Figure 3-52) or 
when it is mixed with 5% of HAp nanoparticles. This is 
because a uniform layer is already nucleated after 14 days in 
SBF when one of these processes is applied (Figure 3-51). 
After 14 and 21 days in SBF the layer of HAp precipitated on 




the surface of the sample, is more uniform for scaffold 
previously treated with plasma than the ones filled with 
nanoparticles. As can be seen in Figure 3-51 and Figure 3-52, 
the combination of plasma and nanoparticles as filler, allows 
the bioactivity of the scaffolds increase. After 14 days in SBF, 
plasma modified hybrid scaffolds filled with 5% of nanofiller 
are able to nucleate a second hydroxyapatite layer on the 
surface of the scaffolds (Figure 3-51). After 21 days in SBF the 
nucleation is also produced on the pore walls in the inside of 
the scaffolds (Figure 3-52). 
 
0% HAp 5% HAp 
  
Figure 3-51: Scanning electron micrographs of the 
surface of the scaffolds filled and not filled with 
nanoparticles of HAp after 7 days in SBF. 
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Figure 3-52: Scanning electron micrograph of the surface and the section of the scaffolds of PLLA-CD 
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Figure 3-53: SEM micrographs of the surface and section of hybrid scaffolds of PLLA-CD filled with 0 
and 5 % wt. of nanoparticles of HAp after 14 and 21 days of immersion in SBF and previous plasma 
treatment. 
50µm 
0 % HAp 
5 % HAp 
14 days 14 days 21 days 21 days 
Surface Section 




The layer of HAp coated on the scaffold matrix presents the 
typical cauliflower shape, like hemispherical-shaped apatite 
granules characteristic to biomimetic HAp from SBF ions 
precipitation. The granules contain numerous nano-sized 
apatite needle – like crystals (Figure 3-54) (156). The 
nucleation of HAp on the surface of the scaffold does not 
obstruct the macrostructure.  
Figure 3-54: SEM micrographs of a) HAp coating on the 
surface of the scaffolds filled with 5 % wt. of nanoparticles 
after 14 days in SBF b) same surface but at higher 
magnification, c) macrostructure of the scaffolds filled with 
5% of nanoparticles after 21 days in SBF. 
 
The Ca/P this ratio also was calculated using the EDS signals 
corresponding to Ca and P elements; the spectra of 3 replicates 
of each sample in 3 different zones were employed and the 
mean value was calculated. Figure 3-55 corroborates that the 
EDS detected peaks of the nucleated HAp correspond mainly 
to calcium and phosphate; the spectra show other peaks 
corresponding to sodium and chloride, but their signals are not 
significant enough to be considered. Figure 3-56 shows the 
Ca/P ratio of the hydroxyapatite nucleated on the surface and 
section of pure PLLA scaffold and PLLA/HAp hybrid scaffold, 
with and without a previous plasma treatment after 14 and 21 
days in SBF. Scaffolds with previous plasma treatment are 
named (PLLA-P), these filled with 5 % wt. HAp nanoparticles 
are named (PLLA-5%), and these filled with 5% wt. HAp 
nanoparticles exposed to previous plasma treatment are 





named (PLLA-5%-P). As shown in Table 3-13, the Ca/P ratio 
oscillates between 3.23 and 1.52 for the scaffolds immersed in 
SBF 14 days and between 1.58 and 3.98 for those in SBF 
during 21 days, for all the scaffolds (plasma/no-plasma, 0 and 
5 % wt. of nanofiller). In the section of the scaffolds it can be 
observed that Ca/P is nearer to physiological one after 14 and 
21days in SBF for the scaffolds without filler and previously 
exposed to plasma treatment. But those filled with 5% of 
nanofiller present a Ca/P nearer to the physiological one when 
they were not exposed to plasma. In the surface of the 
scaffolds the Ca/P nearer to the physiological one is for the 
scaffolds after 14 days in SBF filled with 5% of nanofiller and 
without plasma exposure, but after 21 days it is for the 
scaffolds filled with 0 and 5 % wt. of HAp, both exposed to 
plasma. In some cases, as after 14 days in SBF, little 
biomimetic HAp is nucleated on the section of the scaffolds, 
but the calcium phosphate ratio can be close the physiological 
one (Figure 3-52 and Figure 3-53). These values are highly 
accurate, demonstrated by an error less than 0.4. Globally the 
Ca/P ratio is nearer to that of the physiological HAp for the 




Figure 3-55: On the left Scanning electron micrograph from 
the elemental analysis of the surface of a scaffold filled with 
nanoparticles of HAp exposed to plasma and immersed for 21 
days in SBF. On the right the corresponding scan of the 
signal of the elemental analysis. 
 
50 µm 




Table 3-13 Ca/P ratio after 14 and 21 days in SBF calculated 
for the section and the surface of scaffolds of PLLA-CD filled 
with 0 and 5 % wt. of nanoparticles of HAp. These ratios have 
been calculated from the EDS signal of analysis on the 
surface and cross-section of the samples. 
 14 days 21 days 
section 
0% HAp 
No Plasma 3,23 ± 3,4 2,3 ± 1,2 
Plasma 1,81 ± 0,4 1,58 ± 0,1 
5% HAp 
No Plasma 1,52 ± 0,1 1,70 ± 0,2 
Plasma 2,95 ± 2,7 2,39 ± 1,6 
surface 
0% HAp 
No Plasma 2,28 ± 1,7 3,98 ± 3,2 
Plasma 2,63 ± 1,5 1,67 ± 0,2 
5% HAp 
No Plasma 1,63 ± 0,1 1,92 ± 0,4 
Plasma 2,69 ± 2,6 1,59 ± 0,1 
 
 
Figure 3-56: Ca/P ratio after 21 days in SBF calculated for the 
cross-section and the surface of scaffolds of PLLA-CD filled 
with 0 and 5 % wt. of nanoparticles of HAp. These ratios have 
been calculated from the EDS signals of analysis on the 







The apparent Young’s modulus measured in compression 
mode was obtained from 5 measurements of different scaffolds 
with the same dimensions under the same conditions. In 
Figure 3-57 the stress vs. strain curves resulting from the 
compression test is shown. The elastic modulus was calculated 
for the elastic zone. In Figure 3-58 the various moduli 
obtained are compared. From the curves it can be observed 
that the elastic zone is clearly reducing towards lower stress 
and strain after 14 and 21 days in SBF independently from 
the content of filler These measurements show that the elastic 
modulus decreases from 8.9±0.4 MPa for the original pure 
PLLA scaffold to 4.5±1.1 MPa for the one filled with 
nanoparticles. Figure 3-58 also shows that the modulus is also 
decreasing with the time of immersion in SBF. However, it can 
be seen that the modulus is not decreasing as much for the 
scaffold composites (PLLA-5%) after 14 and 21 days in SBF in 
comparison to those without filler. Indeed, the modulus of the 
composite is 0.9 MPa higher than that of the pure PLLA 
scaffold both after immersion in SBF for 21 days, when the 
bioactivity is supposed to be the highest. That difference is 
lower at 14 days of immersion, 0.2 MPa difference. The 
possible hydrolysis degradation of polymer chains in SBF 
could explain the decrease of mechanical properties of the 
scaffolds after immersion in SBF. 




Figure 3-57: Stress and strain representation of the scaffolds 
filled with 5% of HAp and not filled after 0,14 and 21 days in 
SBF. Graph obtained from compression test. 
 
 
Figure 3-58: Young’s modulus obtained from the compressive 
curves of the scaffolds filled with 0 and 5 % wt. of 





GEL PERMEATION CHROMATOGRAPHY 
 
Figure 3-59 and Figure 3-60 show the molecular weight and 
the polydispersity index of the scaffolds not filled and filled 
with nanoparticles of HAp after 0, 14 and 21 days in SBF, 
with and without plasma treatment. The molecular weight 
decreases with immersion time, in all cases. These results are 
consistent with the above mentioned decrease of the 
mechanical properties with the time of immersion in SBF, the 
cause of which being the degradation of the polymer matrix. 
After 14 days the molecular weight decrease is higher for the 
scaffolds previously exposed to plasma, decreasing from 237 to 
190 kDa. After 21 days the scaffolds presenting less decrease 
in molecular weight are those filled with nanoparticles. The 
smaller molecular weight observed after 21 days of immersion 
is for the scaffolds made with just PLLA; 66kDa, which is 
similar to the molecular weight observed for the same 
scaffolds after 1 year of static degradation in PBS (see the 
results in section 3.2.1.6, p.97). The polydispersity index 
increases after 14 days in SBF, except for the scaffolds filled 
and exposed to plasma. After 21 days the polydispersity index 
decreased to values smaller than the scaffolds not immersed. 
The possible hydrolysis degradation of the polymer in SBF 
could cause the scission of the polymer chains. As PLLA is 
hydrophobic the scission of the polymer chains is not uniform. 
This can explain the increase of the polydispersity index with 
time of immersion. 
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Figure 3-59: Weight average molecular weight of the 
scaffolds filled with 0 and 5 % wt. of nanofiller previously 
exposed (P) or not to plasma after 0, 14 and, 21 days in SBF, 
obtained by the integration of the curves from the GPC test.  
 
 
Figure 3-60: Polydispersity index of the scaffolds filled with 0 
and 5 wt% of nanofiller previously exposed (P) or not to 
plasma after 0, 14 and, 21 days in SBF, obtained by the 






The influence on the porosity of the HAp layer nucleated in 
the scaffolds when immersed in SBF was evaluated; the 
results of the test are compiled in Figure 3-61. The 
measurements were repeated 3 times for each sample. The 
global porosity meaning micro and macro-porosity calculated 
according to equation (5) seems to be not affected by the HAp 
layer, even when the samples were pre-treated with plasma or 
charged with nanoparticles. The porosity is still high, about 
90%. These results were as expected as the inside of the 
scaffolds do not present a thick layer of HAp coating. Despite 
after 21 days in SBF the inside of the scaffolds contain some 
HAp crystals, the micropores are still clearly observed by 
SEM, Figure 3-53, and those crystals do not have an influence 
on the measured porosity. 
 
 
Figure 3-61: Porosity of the scaffolds filled with 0/5% of 
nanofiller previously exposed (P) or not to plasma after 14 
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MASS OF HYDROXYAPATITE COATING 
 
Figure 3-62, Figure 3-63 and Figure 3-64  show the TGA 
results for the hybrids scaffolds after 0, 14 and 21 days in 
SBF. This way it is possible to evaluate the influence of the 
incorporation of the filler or of the plasma treatment on the 
quantity of biomimetic HAp coated on the surface of the 
scaffolds. In Figure 3-65 histograms present the percentage of 
the biomimetic HAp coating on the surface of the scaffolds 
after 14 and 21 days. The quantity of hydroxyapatite coating 
the surface of the pores samples was evaluated from the 
weight percentage representation. The residual percentage of 
inorganic component obtained after thermal degradation to 
1000ºC corresponds to the total percentage of HAp present, 
including the percentage nanofiller incorporated and the 
percentage of HAp coating on the surface of the scaffolds. To 
obtain the content of biomimetic HAp coated it is necessary to 
rest the content of nanofiller incorporated during fabrication 
process. It is observed that the layer of HAp is getting thicker 
with time since the percentage of residue increases. The 
higher amount of HAp nucleated on the surface of the 
scaffolds, almost 23% of the mass of the sample, is observed 
for the scaffolds filled with nanoparticles of HAp and 
previously exposed to plasma treatment. Only by filling the 
scaffolds with nanoparticles it is possible to nucleate around 






Figure 3-62: Weight percentage as a function of the 
temperature obtained from TGA test of the scaffolds filled 
with 0 and 5 wt% of nanofiller  and the scaffolds filled with 
5% of nanofiller and previously exposed to plasma after 0, 14 
and, 21 days in SBF. 
 




Figure 3-63: Weight percentage as a function of the 
temperature obtained from TGA test of the scaffolds filled 







Figure 3-64: Weight percentage as a function of the 
temperature obtained from TGA test of the scaffolds filled 
with 5% of nanofiller previously exposed to plasma (P) or not 
after 0, 14 and, 21 days in SBF. 
 
 




Figure 3-65: Percentage of biomimetic HAp formed on the 
surface of the scaffolds filled with 0 and 5 % wt. and the 
scaffolds filled with 5% of nanofiller and previously exposed 
to plasma (P) obtained from the TGA residue curves. 
 
FOURIER TRANSFORM INFRARED ANALYSIS 
 
The FTIR curves of Figure 3-66 and Figure 3-67 are shown in 
order to compare the influences of the immersion time and the 
influence of the incorporation of nanoparticles on the 
characteristics of the HAp coating on the surface of the 
scaffolds when immersed in SBF. The chemical groups 
corresponding to each detected stretching band are detailed on 
the figures. The curves of the commercial HAp nanopowder 
incorporated in the scaffolds as nanofiller can be used as 
reference curves to analyse the nature of the HAp coating on 
the surface of the scaffolds. The main peaks representative of 
HAp appear in all scaffolds, indicating that all of them can 




the main peaks of the nanoparticles from the HAp powder are 
the same as those obtained for the scaffolds after their 
immersion in SBF. Furthermore the transmittance peaks are 
more pronounced for the scaffolds filled with nanoparticles 
(Figure 3-67) than those without filler (Figure 3-66), probably 
indicating that the nucleation is more effective in the hybrids 
than in pure PLLA.  
 
 
Figure 3-66: Wavenumber vs. transmittance representation 
obtained from the FTIR analysis of the scaffolds without 



















Figure 3-67: Wavenumber vs. transmittance graph obtained 
from the FTIR analysis of the scaffolds filled with 5% of HAp 
particles after 0, 14 and, 21 days in SBF, and of HAp 
nanopowder. 
 
3.3.2.2 Improvements in the mechanical properties of the PLLA/HAp hybrid 
scaffolds. 
 
In the previous section PLLA was mixed with a 5% wt. of HAp 
particles for two purposes: to increase the bioactivity of the 
scaffolds and to improve their Young’s modulus at 
compression. This was in order to better approximate the 
properties of natural bone. Although the nanoparticles have 
increased the bioactivity of the materials, the mechanical 
modulus has been greatly reduced. There are two reasons for 
this. Firstly, inorganic phase content may not have been 
sufficient to form a continuous phase in the organic matrix, 















Secondly, poor dispersion of the nanoparticles would produce 
agglomeration of large particles.  
Two different experiments were designed in order to improve 
the mechanical properties of the scaffolds. First, the content of 
nanoparticles was increased and second the sonication 
procedure, normally applied to disperse the nanoparticles (one 
sonication when mixing with the dioxane), was duplicated and 
applied again after the complete dissolution of the polymer in 
the dioxane/nanoparticles mixture. 
INCREASE OF THE HAp NANOPARTICLE CONTENT 
 
In this part of the study PLLA-MED was used instead of 
PLLA-CD, which was used up until this point. As the final 
scaffolds will be fabricated with medical grade PLLA, the 
reinforcement of the nanofiller on the scaffolds made with 
PLLA-MED was studied. 
Figure 3-68 and Figure 3-69 show the stress and strain curves 
from the compression test. Figure 3-70 shows the values of the 
apparent Young’s modulus in compression of the different 
samples calculated from the elastic zone, identified by their 
HAp content. It can be seen that the elastic modulus of the 
scaffolds remains almost constant with the increase of the 
HAp content. Even when PLLA was mixed with a 20% wt. of 
nanoparticles it did not increase in comparison to pure PLLA. 
The stress and strain graphs follow a similar trend, showing 
little influence from the content in nanofiller incorporated to 
the polymeric matrix. The measures were repeated for 5 
samples of each composition. Since previously it was seen that 
storage modulus of the hydrid membranes increased with the 
incorporation of nanofiller, the same result was expected for 
the hybrid scaffolds. Unfortunately this was not the case. 
 




Figure 3-68: Stress vs. strain curves of the scaffolds filled 
with 0, 5, 10, 15 and, 20 % wt. of HAp. Representation 






Figure 3-69: Stress vs. strain curves focused on the elastic 
zone of the scaffolds filled with 0, 5, 10, 15 and, 20 % wt. of 
HAp. Graph obtained from compression test. 
 
 
Figure 3-70: Apparent elastic modulus of compression of the 
scaffolds filled with 0, 5, 10, 15 and 20 % wt. of HAp 
nanoparticles. 




The lack of improvement of the mechanical properties of the 
scaffolds when they are filled with particles of HAp, may be 
due to a weak dispersion of the particles in the matrix. 
Sonication is used in order to enhance the nanoparticles 
dispersion and consequently increase the mechanical strength. 
Figure 3-71 shows the influence of a double sonication on the 
mechanical properties of the scaffolds. Unfortunately the 
scaffolds filled with 5 and 10 % wt. of HAp particles do not 
show any increase in the elastic modulus. 
 
 
Figure 3-71: Values of the elastic modulus of compression of 
the scaffolds filled with 0, 5, 10 and, 15 % wt. of nanoparticles 
of HAp after one sonication cycle (5% HAp and 10% HAp) and 
two sonication cycles (5% HAp-2 son and 10% HAp-2son). 
 
The hybrid composites made from PLLA and nanoparticles of 
HAp presented in this section were bioactive. But, as shown 
their mechanical properties did not improve compared to pure 
PLLA. One of the major challenges in the design of these 
scaffolds is that they should retain the ability to sustain loads 
while tissue regenerates. In order to enhance the mechanical 
strength of the scaffold and maintain or even improve the 
material’s bioactivity, we changed the filler and used finer 
bioactive particles based on silica, alone or in combination 





Five types of hybrid scaffolds were fabricated with different 
filler contents. The different scaffolds will be named as 
(100/0/0), (95/0/5), (90/10/0), (90/9.5/0.5) corresponding to the 
(PLLA/HAp/SiO2) content. The influence of different nanofiller 
contents and its effect on the properties of the scaffolds and its 
bioactivity in SBF during 7, 14 and 21 days was studied. The 
effect of sonication was also studied in order to improve the 
dispersion of the filler and therefore the mechanical 
properties. 
3.3.2.3 PLLA/HAp/SiO2 composites 
SONICATION TO DISPERSE HAP / SIO2 PARTICLES 
 
In order to increase the surface of interaction between the 
filler and the polymeric matrix, the effect of sonication on the 
dispersion of the nanofiller in the scaffolds was studied. This 
was expected to increase the mechanical properties of the final 
hybrid scaffolds. Firstly we analysed the effect of a double 
sonication on the dispersion of silicate and HAp particles on 
the polymer matrix. Figure 3-72 shows the elastic modulus of 
the different scaffolds after two fabrication processes: single 
sonication and double sonication. Unlike what happened with 
HAp, when silica was used as reinforcement the double 
sonication was able to properly disperse the filler and the 
elastic modulus increased, as seen in Figure 3-72. The highest 
elastic modulus observed is for the scaffolds filled with both 
HAp and silicate particles and double sonication. In this case 
the combination of both filler increased the Young’s modulus 
from 4.7±1.0 for pure PLLA to 6.9±1.0 for the sample 
(90/95.5/0.5)-2son. 
 




Figure 3-72: Values for the elastic modulus of compression of 
the PLLA-(95/0/5)-(90/10/0)-(90/9.5/0.5) scaffolds without 




The morphology of the hybrid scaffolds can be seen in the 
micrographs in Figure 3-73. As expected, they are similar to 
what described in section 3.1.1, p.64 . They possess a 
macrostructure, with interconnected macro pores of about 150 
µm diameter. Microporosity can also be observed at higher 
magnification, the micropores (~5µm) are uniformly spread on 
over the surface of the scaffold. The macro and micro structure 
is similar for all kinds of hybrid composite, and are similar to 
the scaffold not filled or filled just with nanoparticles of HAp. 
The nanoparticles used to fill the polymeric matrix do not 
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Figure 3-73: Scanning electron micrographs of the (100/0/0)-
(95/0/5)-(90/10/0)-(90/9.5/0.5) scaffolds. 
 
DIFERENTIAL SCANNING CALORIMETRY 
 
Figure 3-74 shows the DSC curves of the scaffolds. In this 
way, the effect of the characteristics of the filler on the 
calorimetric properties of the composites can be analysed. The 
enthalpic glass transition temperature (Tg), melting 
temperature (Tm) and crystallinity after their fabrication 
process, are all shown in Table 3-14. The determination of 
crystallinity was done by an integration of the heat flow trace 
with respect to a linear baseline. The first DSC heat scan 
(Figure 3-74) does not show significant differences between 
the different samples. As shown on Table 3-14 Tg, Tm and 
crystallinity vary little between samples.  
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Figure 3-74: Normalised heat flow of the DSC first (1) and 
second (2) heating scans of the (100/0/0)-(95/0/5)-(90/10/0)-
(90/9.5/0.5) scaffolds. The heat flow was normalised by the 
mass of the samples and the heating rate at (10ºC/min). The 
arrow mark represents a unit of heat flow in J/gK. 
 
Table 3-14: Tg, Tm and crystallinity of the (100/0/0)-(95/0/5)-
(90/10/0)-(90/9.5/0.5) scaffolds after the first scan. 
(PLLA/HAp/Si) 
content 
Tg (ºC) Tm (ºC) χc (%) 
(100/0/0) 74 181 60.4 
(95/0/5) 77 180 52.5 
(90/10/0) 81 180 47.8 













No significant dependence of the scaffold porosity on the 
characteristics of the filler was found, as seen in Table 3-15. 
The global porosity, meaning micro and macro-porosity, 
calculated according to equation (5) seems be unchanged for 
the different scaffolds, regardless of the filler type. The 
porosity is still high, about 90 %. The measures were repeated 
3 times for each case.  
 
Table 3-15: Porosity of the diferent hybrid scaffolds. 








In Figure 3-75 the SEM micrographs of the surface of the 
scaffolds after 21 days in SBF at high magnification are 
shown. A layer of HAp coating is observed on the scaffold. It 
has the typical cauliflower shape, like hemispherical-shaped 
apatite granules characteristic to biomimetic HAp from SBF 
ion precipitation. The granules contain numerous nano-sized 




Figure 3-75: Scanning electron micrograph of a) (90/10/0), b) 
(90/9.5/0.5) and c) (95/0/5) scaffolds after 21 days in SBF 
60 µm 
c) 




In Figure 3-76 the micrographs of the internal and external 
surface of the (90/10/0) and (90/9.5/0.5) scaffolds after 14 and 
21 days in SBF are shown. One can clearly see the influence of 
the filler on the ability of the samples to nucleate 
hydroxyapatite on its surface. As observed previously in the 
PLLA-CD scaffolds the nucleation of HAp coating on the 
surface of the scaffold does not cover the macrostructure. The 
layer nucleated on the surface of the scaffolds can be observed 
on the outside of the scaffolds after 14 days in SBF for both 
types of filler. The (90/10/0) samples do not show any 
significant HAp layer on its inside but only some nuclei (small 
white spots) appear on the microstructure after 14 and 21days 
in SBF. This contrasts with the inside of the (90/9.5/0.5) 
scaffolds where the layer of HAp gets bigger with time 
immersion (Figure 3-76). The microstructure of the (90/9.5/0.5) 
scaffolds cannot be seen, the HAp layer coating on its inside is 
dense and perfectly uniform. The (90/10/0) scaffolds present 
more HAp nucleated on the external surface of the scaffolds 
than in its inside, in particular after 14 days in immersion. 
Both types of scaffolds show, on the internal and external 
surface, a dense uniform layer of HAp hiding the 
microstructure. An exception has to be made for the external 
surface of the (90/9.5/0.5) scaffold which presents a uniform 















Figure 3-76: Scanning electron micrographs of the different 
hybrid scaffolds after 14 and 21 days in SBF. 
 
Figure 3-77 shows the Ca/P ratio of the different scaffolds 
after 14 and 21 days in SBF. The Ca/P ratio oscillates between 
1.10 and 1.14 for the scaffolds immersed in SBF 14 days and 
between 2.06 and 2.36 for those in SBF during 21 days. 
Globally the Ca/P ratio is higher after 21 days immersion than 
after 14 days. The scaffolds filled with HAp nanoparticles have 
a HAp layer coating on its inside and on its surface, with 
calcium and phosphate content similar to the physiological one 
(see the reference line Figure 3-77) after 14 days and 21 days 
in SBF.  
In 14 days 
In 21 days 
Out 14 days 
Out 14 days 





Figure 3-77: Ca/P ratio of the layer of HAp coating on the 
surface of the (90/10/0) and (90/9.5/0.5) scaffolds after 14 and 
21 days in SBF. 
 
CONTENT OF HYDROXYAPATITE COATED 
 
The content of HAp nucleated on the surface of the scaffolds as 
a function of the type of filler used to fabricate the composites 
was also evaluated by TGA analysis; Table 3-16 shows the 
percentage content of biomimetic HAp coating. Figure 3-78 
shows the curves of the TGA experiment after 14 days in SBF. 
From these curves the percentage of residue is calculated, 
subtracting the percentage of nanofiller incorporated from the 
final content of inorganic component after thermal 
degradation. The percentage of HAp coating during the 
bioactivity test is the higher for the (90/10/0) scaffolds than 
then (90/9.5/0.5). When nanoparticles of HAp are incorporated 






Figure 3-78: TGA curves of the different hybrid scaffolds 
after 14 days in SBF. 
 
Table 3-16: Percentage content of biomimetic HAp coating on 
the surface of the scaffolds after 14 days in SBF. 










3.4 OSTEOCHONDRAL BILAYER CONSTRUCT 
 
The main goal of this project is to design a bilayer scaffold 
each part functionalised to regenerate cartilage and bone 
tissue. The previous studies have permitted to get the 
optimum formulation of each part. Each part, consequently, 
has been characterized previously, only the morphology and 
mechanical properties of the biconstruct are presented. 
The biconstruct is the combination of two scaffolds fabricated 
by freeze extraction and particle leaching. They are joined by a 
thin layer of polymer solution of 15 % wt. of PLLA avoiding 
blood flow from the bone to the cartilage area. The up side of 
the biconstruct functionalised for cartilage repair is a 1:1-
15%PLLA-MED scaffold, 1mm high. The bottom side is similar 
to the upside, functionalised for bone regeneration it has been 
incorporated 5% of bioactive nanoparticles of hydroxyapatite 
and is 6 mm high. So the biconstruct is a sandwich of (100/0) 
and (95/5)- 1:1-15%PLLA-MED scaffold.  
 
The SEM micrographs, Figure 3-79, permit to appreciate how 
the two scaffolds are joined. Upside is the (100/0) scaffolds (1 
mm high) and down the (95/5) scaffolds, bioactivated with 
nanoparticles of HAp. The biconstruct keep the macro and 
microstructure observed previously in the separated scaffolds  
The layer of polymer used to separate the two constructs do 
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Chapter 4.   Discussion 
 
4.1 SCAFFOLDS FABRICATION: PROCESSING-
MORPHOLOGY-PROPERTIES RELATIONSHIPS 
 
It can be seen how the PLLA concentration and porogen 
quantity influence the properties of the scaffolds. 
4.1.1 Effect on the scaffold properties 
 
Both micro and macro morphology are affected when the 
proportion of PLLA and dioxane is modified. The micropore is 
physically formed when dioxane crystals are leached by the 
ethanol. Indeed the dioxane crystals are formed due to the 
contact with the liquid nitrogen bath at -180ºC in the polymer-
poor phase. The dispersion of the micropores depends on the 
affinity of the polymer and the solvent. A good solvent for 
PLLA, such as dioxane, allows good dissolution of the PLLA, 
and uniformly disperses the solvent molecules among the 
polymer chains. When phase separation occurs at low 
temperatures (it is produced during the freezing process with 
liquid nitrogen) dioxane crystals are formed separate from a 
polymer-rich phase, well distributed in this phase. The 
polymer-rich phase forms a low percentage of the solvent 
crystals due to the semicrystalline property of the polymer. 
The formation of the micropores due to the leaching of dioxane 
occurs uniformly distributed on the scaffold walls (148,168). 
The more dioxane that is added to the reagent mixture the 
more the microporosity should be, as the polymer and solvent 
contents affect the process of separation of both by changing 
the viscosity of the mixture. Thus scaffold (5/95) has bigger 
micropores than scaffold (15/85). Microporosity is proportional 




process. The more dioxane is used the greater the quantity of 
micropores that are formed and the bigger they are. Dioxane 
increases microporosity through an increase in micropore 
dimensions. This effect is due to the fact that more molecules 
of solvent diffuse among the polymer chains as the solvent 
content increases (169-170). The limit of the micropores 
formation seems to be achieved at 20% of polymer content for 
the 1:1 scaffolds and at 18% of polymer content for the 1:1.25 
scaffolds. It should be also noted that dioxane is also a good 
solvent to the porogen. As it comes into contact with the 
PEMA macrospheres they experience swelling. This 
absorption process leads to a reduction in the content of 
dioxane involved in the polymer/ solvent separation. If the 
microspheres of porogen swell until losing their spherical 
geometry and deform for being in contact with the neighbours 
then the trabeculae disappear and the macrostructure loses its 
regularity. That is the phenomenon observed principally for 
the (5/95) scaffolds with higher dioxane content. The dioxane 
content absorbed by the PEMA spheres depends on the time 
duration of the mixing of the polymer solution and the 
porogen. The more dioxane present, the easier it is for the 
microsphere of porogen to come into contact with the solvent. 
Consequently, the microspheres will swell more rapidly, which 
would suggest the mixing process should be completed more 
quickly in order to avoid the deformation of the structure of 
the final scaffolds. As this time parameter is not exactly the 
same for all the samples and polymer concentration solutions 
it is not possible to know how much dioxane has been absorbed 
by the porogen. Consequently it is easy to understand why the 
maximum micropore formation is achieved at the lower 
concentration of polymer for the 1:1.25 scaffolds compared to 
the 1:1 scaffolds, as they present a higher content of porogen 
susceptible to absorb more dioxane. These observations can be 
made for both brands of PLLA. PLLA-CD and PLLA-MED 




3-6. Through the freeze extraction process we have been able 
to produce macropore walls with well controlled dimensions, 
as dioxane crystals were eliminated once PLLA-rich phase was 
frozen. The normal process followed in literature is the solvent 
casting. The main disadvantage of this technique is that the 
resulting scaffold does not have a uniform microporosity on its 
macropore walls because the polymer contracts as the solvent 
evaporates, leaving defects in the micropores. 
 
Macroporous structure depends on another parameter, the 
porogen quantity. The porogen macrospheres (average 
diameter of 100 to 150 µm) were incorporated to the polymer 
solution. After dioxane has been removed the temperature of 
the ethanol bath is increased to make the PEMA removal 
easier. As ethanol is able to dissolve the porogen, the spaces 
occupied by the porogen macrospheres are replaced by 
macropores. The higher the polymer/ porogen ratio the more 
viscous is the mixture. Consequently the homogenization with 
PEMA will be difficult, and the dioxane solution and porogen 
will spend more time in contact with one another. As was 
previously noted, the greater the time during which the 
porogen and the dioxane are in contact, the more the 
microspheres will swell and increase in size. That explains 
why the macropores are larger than the initial porogen 
dimension. It also explains why the scaffolds with the highest 
content of porogen, series 1:1.25 presents a macroporous 
structure with very thin pore trabaculae or hardly existing. 
The macrospheres of porogen had so much time to swell that 
they are in contact one with another. That also explains why 
the (5/95) scaffolds present the biggest macropore dimension; 
it has the highest dioxane content in the polymer solution, so 
the quantity of solvent available to cause the microspheres of 
porogen to swell is also highest. The same observations can be 
made for both brands of PLLA. Furthermore PLLA-CD and 





The calorimetric properties do not seem to be affected by any 
change of parameters such as the polymer concentration of the 
polymer solution or the polymer / porogen ratio. In fact Tg, Tm 
and crystallinity are almost the same in the different scaffolds. 
The differences among the samples observed for the Tg 
measurements are due to the error in determining the glass 
transition temperature. However, each type of PLLA has a 
different Tg, Tm and particularly crystallinity after the freeze 
extraction process. Medical use PLLA scaffold is more 
crystalline than the industrial use PLLA scaffold. In order to 
facilitate the processing in industry some additives, such as a 
small quantity of PDLA units, are normally added to the 
PLLA. Those industrial additives are to impede PLLA 
crystallisation which would explain the higher crystallinity 
found in the purest PLLA-MED (134,171,172). However, the 
exact nature of the used additives is unknown as the 
manufacturers try to protect their fabrication protocols.  
In the second scan for both PLLAs a crystallisation peak, or 
even two, appears. It can be concluded, that, when the cooling 
process is fast the material cannot crystallise up to maximum 
capacity, and it continues with its crystallisation after the 
glass transition temperature. The same should happen in the 
freeze extraction process and we would expect to have 
scaffolds with very low crystallinity. However, the absence of 
any crystallisation peak in the first scan means that the 
process of fabrication of the scaffolds permits them to 
crystallise up to the maximum capacity. In fact, when we put 
them in the ethanol baths at 40ºC, to remove porogen spheres, 
we are close to the Tg of PLLA, ethanol plasticises the PLLA 
and facilitates the incorporation of polymer chains to ordered 
crystalline structures. Thus, changes of scaffolds mechanical 
properties are due to the different porosities and morphologies 





These differences of macro and micro structure according to 
the changes in polymer/ solvent or polymer/ porogen content 
have, as expected, an influence on the mechanical properties. 
As observed on the SEM pictures (see Figure 3-1Figure 
3-2,Figure 3-3,Figure 3-4) the scaffolds with the smaller pore 
throats between macropores present the highest elastic 
compression modulus, due to the support of the pore walls. 
The bigger the cell walls, the more they are able to sustain the 
compression solicitation. The microstructure has also an 
influence on the mechanical properties, as micropores can be 
considered as closed-cells (166). The greater the proportion of 
cells on the surface walls of the scaffolds, the less they are able 
to sustain the compressive forces. The dimension of the cells 
can also influence the mechanical properties. It has been 
observed that the evolution of the morphology of the scaffold is 
related to the composition, which has a direct effect on the 
mechanical properties. The (5/95) scaffold has a 
macrostructure with thin pore walls or no wall. The yield point 
for these scaffolds occurs at the smallest strain (Figure 3-8 
and Figure 3-9). When the polymer content increases more 
material is used to form the structure, and consequently the 
pore walls are thicker. Then, the scaffolds are more resistent 
to compressive forces. As a result the yield point of the scaffold 
(15/85) is shifted toward higher strain and the elastic modulus 
is higher than the ones of the (10/80) scaffolds. One of the 
major differences between PLLA-CD and PLLA-MED is in the 
mechanical properties. Scaffolds made with industrial PLLA 
present higher elastic modulus but lower yield point limits 
than the medical PLLA (Figure 3-11). The PLLA in some point 
seems to be more resistant to deformation than industrial 
PLLA. Medical grade PLLA is more crystalline than industrial 
PLLA. More crystallinity means a greater quantity of 





4.1.2 Selection of a composition 
 
The best candidate for both cartilage and bone regeneration 
could be the (15:85) scaffold. One of the main requirements for 
scaffolds in bone and cartilage tissue engineering is to sustain 
the load applied, while the tissue repairs itself. In this study 
the scaffolds presenting the highest elastic moduli are the 
scaffolds with 1:1 polymer / porogen ratio and particularly that 
with a 15% of PLLA content. The elastic modulus obtained for 
this scaffold (~9 MPa) is of the same order of magnitude of 
that of cartilage (5). However, it is smaller than that of bone 
(89). It is a useful study to determine how to increase the 
mechanical properties of PLLA. Especially for the scaffolds 
made with PLLA-MED, the one expected to be used in the 
biological experiments due to its medical grade, but presenting 
a smaller elastic modulus (~4 MPa). 
4.1.3 Partial conclusions 
 
Freeze-extraction combined with particle leaching is one 
method to obtain highly porous scaffolds, with double porosity. 
The freeze-extraction leads to the formation of microporosity 
and the particle leaching leads to a well interconnected 
macroporosity. PLLA is easily shaped by this technique to 
obtain scaffolds with high mechanical properties with an 
elastic modulus close to that of articular cartilage. It is 
possible to adjust the micro and macropore size (5 and 150 µm) 
by changing parameters such as polymer concentration in the 
polymer solution and the polymer/ porogen ratio. Decreasing 
the polymer content in the polymer solution results in the 
proportion of solvent being higher, and so the microporosity 
dimensions increase. Increasing the porogen content it was 
possible to generate more macropores. In this study two types 
of PLLA have been used, one for industrial process and 




medical use PLLA are higher than those of the industrial 
PLLA. Otherwise the calorimetric properties are not affected 
by the changes of polymer concentration or polymer/ porogen 
ratio. The scaffold 1:1-(15/85)-PLLA-MED is a good candidate 
for a possible use in osteochondral regeneration as its 
morphology is adequate for cells and nutrients flow and it has 
the ability to sustain the required load. 




4.2 DEGRADATION EXPERIMENTS 
 
In the static case the degradation of the polymer chains can be 
detected by GPC analysis from the first week (Figure 3-24 
p.98). The degradation seems to be superficial and should 
start from the pores on the surface of the scaffolds. It is not 
clearly observed that the degradation starts from the surface 
of the micropore (Figure 3-14, p. 85). Nevertheless, microCT 
images show that the macropore dimension changes which is 
consistent with the observed because permeability increase 
with degradation time from the first week (Figure 3-18, p.92). 
Usually the effects of degradation of PLLA can be observed 
between 10 month and 4 years (174). Of course this result 
depends on parameters such as the initial crystallinity or the 
porosity of the sample. But it has been found that porous 
scaffolds degrade more rapidly than bulk samples (175). 
The mechanical properties are also affected. As shown in 
Table 3-6, p.90, the Young’s modulus slightly decreases with 
the time of degradation. However, changes in the pores 
collapse zone were the most notable effects of the degradation 
process observed in this study, as the yield point occurs at 
lower strain with degradation (Figure 3-16 p. 89). This is 
certainly due to the degradation occurring in surface, leaving 
the interior of trabeculae not degraded, which, consequently 
gives resistance to the structure. As demonstrated in the GPC 
curves at low degradation times the molecular weight had not 
yet decreased significantly (Figure 3-25, p.99). Kang et al. 
observed a linear decrease in the compressive strength from 
10.5 MPa to 7 MPa in 6 weeks of degradation in SBF of porous 
PLLA scaffolds (176). Tsuji et al. studied the hydrolytic 
degradation of PLLA films in PBS as a function of their 
crystallinity. It was observed that the Young modulus of the 
PLLA specimens decreased monotonously in the first 8 month 
(128, 129).  
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The evolution of the mechanical curves changes clearly in the 
dynamic case. In the dynamic study the curves start from the 
plastic zone as the dynamic load applied during the test start 
to deform plastically the samples (Figure 3-32, p.107). As the 
time of degradation increases the densification zone occurs at 
lower stress. 
The weight loss is the less notable effect in the degradation 
test (Figure 3-15, p.87), as it could not be seen in this case, 
also due to the deposition of salts from the medium (Figure 
3-31, p.106). 
The scission of the polymer chains can be observed as the 
samples get less and less thermally stable when degradation 
time increases (Figure 3-27 and Figure 3-28, p102). This result 
is also related to the decrease of molecular weight and the 
narrow molecular weight distribution. 
The crystallinity of the scaffolds after the first heating being 
higher than the second one permits us to say that the freeze 
extraction process generates highly crystallized scaffolds 
(50%) (Table 3-7 and Table 3-8, p.111). It is known that 
degradation of PLLA starts with the amorphous region (129). 
During degradation due to the scission of the ester group 
leading to the formation of carboxyl and hydroxyl endgroups 
their density increases in the amorphous region 8 (114, 124). 
These functional groups are able to catalyse the degradation 
process of the amorphous region. Density of hydrophilic 
terminal groups increasing can stimulate the diffusion of 
water in the material, making faster the degradation of the 
amorphous regions. The presence of a higher fraction of 
carboxylic and hydroxilic groups could act as plasticizers of the 
main chains lowering Tg of the degraded samples. It is not our 
case, as the decrease of Tg cannot really be observed. Neither 
the Tg decrease in Tsuji et al. studies is remarkable after one 
year of hydrolytic degradation in PBS (128). The effect of the 
degradation during the first DSC isotherm cannot be seen but 




amorphous region degraded remain without any mobility, 
entrapped between the crystalline regions, as our materials 
are quite crystalline. Then, we do not observe any increase in 
the crystallinity as the time of degradation increases However, 
the second heat permits to observe the degradation as 
crystallinity increases when the time of immersion increases. 
In the second heat scan we calculate the ability of the material 
to crystallise from the melt. As the density of short chains 
increases, their organization into crystallites is easier. This 
phenomenon is better observed in the static case as this 
experiment was performed over a larger time period. 
4.2.1 Partial conclusions 
 
Static and dynamic degradation of PLLA affects the 
mechanical properties as the yield point decreases with 
degradation time furthermore the robustness of the scaffolds 
decreased in the permeability test. However, in the static case, 
the elastic modulus decreases very slightly with degradation 
time. The effect of dynamic degradation is only seen in the 
densification zone as during the experiment the scaffolds were 
collapsed. 
The micro and macro porosity seemed to be affected by the 
degradation. However, changes in morphology are quite slight 
as corresponds to surface erosion. 
The degradation attacks the amorphous phase that keeps 
entrapped in the samples confined in the crystalline region, 
and no changes in crystallinity or mass are observed during 
the degradation experiment. Freeze extraction fabrication 
process leads to scaffolds highly crystalline that are able to 
maintain their morphology after 24 weeks of static 
degradation and 6 weeks of dynamic degradation. 




4.3 REINFORCEMENT AND BIOACTIVITY OF THE 
MATERIAL 
4.3.1 Effect of the filler content on the membrane’s 
properties 
 
The freeze extraction process produces membranes with 10 µm 
micropores as shown in Figure 3-44, p.121. The micropores are 
homogenously dispersed on the surface of the membranes. All 
membranes exhibited the same morphology, regardless of the 
filler content. The pores are produced by the phase separation 
when both dioxane and PLLA crystallise from the solution.  
 
When producing a composite, the HAp nanoparticles are 
suspended in the solution. Crystallisation of PLLA traps some 
of these particles but other particles are expected to remain 
between different dioxane crystals or at the interfaces between 
dioxane and PLLA in the solid sample when immersed in 
liquid nitrogen. DSC experiments included a heating scan that 
gives information about the crystalline structure obtained 
after freeze extraction process. This scan was performed 
between 0 and 210ºC. At the end of this scan the sample is 
melted. The second heating scan was carried out to 
characterize the structure of the polymer crystallized from the 
melt. The differences between the second and the first scan 
can be explained by the formation of crystalline nuclei during 
physical ageing at temperatures below Tg that has been 
proven in PLLA and in other semicrystalline polymers as well 
(128). An increased number of nuclei at the beginning of cold 
crystallization speeds up the process; as a result the observed 
crystallisation peak is sharper and shifted towards lower 
temperatures. The changes in shape and position, in Figure 
3-46, p.125, for cold crystallisation peaks with increasing HAp 
content demonstrate the nucleating effect of the HAp 
nanoparticles.  
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The deviations of the calcination test (Table 3-9, p.123) can be 
an indication of an imperfect dispersion of particles, or the 
leaching of a part of the particles that remained in the solvent 
during phase separation. Dynamic-mechanical experiments 
(Figure 3-47, p.128) are also highly dependent on the thermal 
treatment to which the sample is subjected. The increase of 
the storage modulus with HAp content shows the reinforcing 
role of the HAp particles. The reinforcing effect of the 
nanoparticles is clearly shown in the semicrystalline samples 
both below and above the main relaxation of the amorphous 
phase. 
 
The morphology of the membranes seems not to be affected by 
plasma treatment. After oxygen plasma treatment, as shown 
in Figure 3-45, p.122, some kind of abrasion defects can be 
seen on the surface of the membranes, and do not appear on 
the membranes without plasma treatment. Surface abrasion 
that was already found in plasma treated PLLA by Wang et al. 
can allow HA particles to appear at the pore walls. 
The biomimetic layer of HAp nucleated on the surface of the 
scaffolds present the typical cauliflower with needle like 
granules (Figure 3-54, p.140). Although plasma treatment 
increases the bioactive potential of pure PLLA, as shown in 
figure 5.6, its effect is not seen before 21 days in SBF. A faster 
process is needed to avoid degradation of the polymer before 
its osteo-integration. After 21 days in SBF or in the 
implantation site PLLA starts the degradation process (as 
seen in the case of the scaffolds) and consequently its 
mechanical properties start to decrease too early making the 
material useless for bone tissue engineering. Consequently it 
is interesting to generate a layer of HAp at shorter time of 
SBF immersion (7 days in SBF), an effect that has been 
obtained in the membranes by the addition of the HAp 
particles. Figure 3-49, p.132, shows the effect of the HAp 
nano-filler content after 7 days immersion. After this time the 
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PLLA samples show no signs of apatite layer even when 
treated with plasma, but the rate of deposition increases with 
HAp content and samples containing more than 10 % wt. HAp 
nano-particles show a smooth coating on the composite 
surfaces. Plasma treatment further enhances the rate of 
deposition, and the thickness of the layer increases in such a 
way that biomimetic apatite fills the whole volume of the 
micropores. Results obtained after different immersion times 
in SBF (7, 14 and, 21 days) are similar. Plasma treatment 
increases the wettability of the material (179), which increases 
the interaction between the ions present in SBF and the 
surface of the material. Consequently plasma treatment 
accelerates the process of precipitation of the ions on the 
surface of the material. This effect is more pronounced when 
HAp is mixed with PLLA. Surface abrasion produced by 
plasma permits the particles to show up on the surface of the 
composite. The Ca2+ and PO42- ions release within the SBF 
solution speeds the process of HAp nucleation by creating 
positive or negative charges on the surface due to the 
formation of ions in the aqueous medium.  
The Ca/P atomic ratio of the biomimetic apatite calculated for 
all the samples is higher than the physiological HAp one, 
ranging from 1.63 to 2.54 (Table 3-12, p.133). The membranes 
with HAp incorporated at day 0, in which the Ca/P atomic 
ratio measured corresponds to the HA nanoparticles added as 
filler, have the highest ratio, and the ratio observed does not 
match that of stoichiometric hydroxyapatite claimed by the 
supplier. For the same immersion time membranes previously 
exposed to plasma present a ratio closer to the physiological 
one in comparison with membranes that had not been exposed 
to plasma. In general, the ratio that is closest to the 
physiological one is for the plasma treated membranes 
prepared with nano-filler after 7 days in SBF. 
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4.3.2 Effect of the filler content on the scaffold’s 
properties 
 
As can be seen on SEM micrographs in Figure 3-73, p.161, the 
morphology of the scaffolds is not affected by the variation of 
the filler content. The macro and micropores still present the 
same dimension, around 120 µm and 5 µm, respectively. The 
porosity is high, around 80%, regardless of the filler content. 
The macropores are well interconnected which could provide 
cells and nutrients flow to promote tissue regeneration. 
 
Globally the Young’s modulus is decreasing or maintained 
constant when filling the scaffolds with nanoparticles of HAp, 
in spite of the increase of the storage modulus with the 
increase of HAp nanoparticles in the membranes. This could 
be explained by possible aggregation of the particles of 
nanofiller in the polymeric matrix. However, an improvement 
of the mechanical properties of the scaffolds was expected with 
the incorporation of the nanoparticles as previously described 
in literature (161). The particles act as reinforcement in all 
direction, provided that the previous sonication of the particles 
in the polymer solution disperses them uniformly in the 
scaffolds. The chemical, physical and mechanical interface 
properties between the matrix and the filler have very strong 
influence on the properties of the final composite material. 
This depends on the wettability of the particles and the 
interaction between the filler and the polymeric matrix. As the 
superficial tension of PLLA and the particles are both negative 
it cannot be expected a good interaction between them (184). 
The aggregation of the nanoparticles of HAp can lower the 
surface interaction between the filler and the matrix. This can 
explain the decrease of the elastic modulus of the scaffolds 
filled with particles of HAp. 
After 14 and 21 days in SBF the Young’s modulus decreases 
even more than that corresponding to the scaffolds filled with 
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nanoparticles not immersed in SBF. This is due to the 
degradation of the PLLA by hydrolysis in SBF. It can be seen 
that the PLLA degrades by hydrolysis through the presence of 
esters where scissions take place. In the crystallized PLLA 
materials the chains in the amorphous regions are 
predominantly hydrolysed (180, 181). However, an increase of 
the elastic modulus is observed for the scaffolds with filler 
immersed 14 and 21 days in SBF. The modulus is higher after 
21 days than 14 days. This may be due to the effect of the HAp 
coating which acts as reinforcement. So the filler increases the 
bioactivity of the material. The layer of HAp coating on the 
surface of the material acts as a framework. This framework 
protects the matrix from more degradation as it isolates the 
material from the medium.  
 
It seems that the coating obtained is hydroxyapatite. The Ca/P 
ratio is close to the physiological one after 21 days in SBF. The 
variations obtained for the Ca/P ratio is due to the crystals 
activity in the aqueous medium. The precipitation of ions 
present in SBF can lead to the formation of combinations 
other than Ca/P. Ions can proceed from an intermediate 
precursor phase with a transitory existence like octacalcium 
phosphate or tricalcium phosphate, but these transitory 
precursors present a Ca/P ratio smaller than 1.67 (Table 3-13, 
p.142). This deviation is due to the presence in the crystal 
lattice of vacancies and ion substitutes such as chloride (182). 
Small zones were carefully selected to avoid measuring the 
gaps between cauliflowers where the electron ray is not 
coherently dispersed. However, the possibility that the 
dispersion values are a result of imprecision in the 
measurement accuracy cannot be discounted. The formation of 
HAp becomes the most kinetically favorable phase in SBF 
with time (117). The signals detected by EDS analysis present 
small peaks of Na/Cl but their concentrations are not 
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significant. The FTIR corroborates that the layer coated on the 
scaffolds is HAp (Figure 3-66 and Figure 3-67, p.154). 
It is clear that with increasing immersion time, the layer 
coating increases. Previous works in this field yielded the 
same conclusion (102). The layer is clearly denser on the 
surface than inside the scaffold due to difficulty in the 
diffusion of ions inside the pores. Furthermore in some areas 
the microporosity structure can still be observed. This is a 
consequence of the precipitation of the ions which is generated 
by the contact with the matrix. Indeed the hydrolysed COO- 
groups of the PLLA or the HAp nanoparticles incorporated 
present a negative charge leading to the attraction of the 
positive ions and so initiate the formation of the layer of HAp. 
This combination is made via ionic and/or polar interactions 
(183). The surface of the scaffolds presents a denser layer of 
HAp, because of a better surface contact. Plasma treatment 
increases the bioactive potential of pure PLLA (120). The 
plasma attacks the surface of the material and so creates an 
abrasive surface, increasing the roughness and so permit the 
precipitation of ions. This causes nanoparticles of HAp to show 
up (Figure 3-45, p.122) on the surface, promoting the 
formation of charges on the surface of the sample (184). 
Plasma treatment and incorporation of nanoparticles of HAp 
are effective processes in improving the bioactivity of PLLA. 
After 21 days in SBF or in the implantation site PLLA starts 
the degradation process and consequently its mechanical 
properties start to decrease too early making the material 
useless for bone tissue engineering. Consequently it is 
interesting to generate a layer of HAp with a shorter 
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4.3.3 Effect of filler type 
 
The nature of the different type of filler used as 
hydroxyapatite nanoparticles, silicates or the mixture of both 
does not affect the morphology of the scaffolds. 
 
The crystallinity presented here is the consequence of the 
reorganization of the polymer-rich phase during the phase 
separation and also the reorganization of the polymers chains 
in ethanol at 40ºC during particle leaching. Even if the 
particle leaching was done below glass transition temperature 
the ethanol helps to the chains to reorganize acting like a 
plasticiser. The crystallinity decreases from 60% to 50% with 
incorporation of the nanoparticles. That means that a part of 
the crystallization of the polymer-rich region is not occurring 
because of the presence of the nanoparticles due to physical 
hindrance. The crystallinity does not seem to be influenced by 
the type of nanofiller. 
 
It can be observed, in Figure 3-72, p.160 , how the double 
sonication results in the enhancement of the elastic modulus 
of the scaffolds filled with 10% of HAp and both HAp and 
silica. Thus, the elastic modulus increased significantly, in the 
order of a 30% when the silica nanoparticles are combined 
with the HAp particles. It is hypothesised that the silica 
nanoparticles interact with the nano particles of HAp. The 
agglomerates of HAp bond with smaller particles of silicates. 
Consequently the surface of interaction between the filler and 
the polymer matrix increases. The surface interaction is even 
higher if the silicates are hollow nanoparticles. 
The modulus obtained for these scaffolds, considering the very 
high porosity (90%) and its polymeric nature, is high (around 
10 MPa). This modulus compared to other porous scaffolds is 
similar or higher. Wagoner et al. reviewed polymer calcium 
phosphate scaffolds compressive strength as a function of 
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porosity and did not report any research presenting an elastic 
modulus higher than 4 MPa (71). Wang et al. present PLLA/ 
silane modified hydroxyapatite porous scaffolds with a 
compressive modulus not greater than 1 MPa (162). The 
scaffolds do not really need to present the mechanical 
properties of bones as it is intended as a support for the 
regenerating tissue. Attention should also be paid on the 
enhancing bone binding efficiency of the scaffold. 
 
Pure PLLA is not bioactive as it does not present any HAp 
nucleated on its surface (Figure 3-49, p.132). In order to 
increase the bone binding of the scaffolds bioactive 
nanoparticles such as HAp and silicate have been added 
(162,185). The incorporation of SiO2 or HAp only increases the 
bioactivity of the scaffolds on the outside surface. The 
combination of both SiO2 and HAp contributes to nucleate 
HAp after 21 days in SBF on all the surface of the scaffold 
(Figure 3-75, p.163). The thermogravimetry allows 
quantification of the amount of HAp nucleated on the surface 
of the samples. The layer accumulates in greater proportions 
for the scaffolds filled with 10% of HAp nanoparticles than 
those with both HAp and silica. The scaffolds (90/9.5/0.5) 
accumulate less proportion of HAp but the layer is observed on 
the internal surface and the external surface of the scaffolds. 
The layer observed is similar to physiological hydroxyapatite 
as Ca/P ratio is close to 1.67. On the internal surface this ratio 
is bigger because the inside of the scaffold is difficult to rinse 
after SBF soaking, and so some residue interferes with the 
measure. 
4.3.4 Partial conclusions 
i. Freeze extraction results in PLLA/ HAp membrane 
composites with a good dispersion of HAp particles and 
bioactive properties. The storage modulus increases 
with the filler content at temperatures above and below 
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the glass transition of the amorphous phase. Particles 
act as a nucleating agent for PLLA modifying the 
crystallisation kinetics whereas glass transition 
temperature of PLLA is independent of the filler 
content. The bioactivity is enhanced by the presence of 
the HAp particles more than by plasma treatment; 
indeed the nucleation of a biomimetic HAp layer on the 
surface of the nano-composites when immersed in SBF 
is more effective than on PLLA membranes. This study 
examines two independent ways to increase the 
bioactivity of PLLA membranes: nanoparticles of HAp 
content and plasma treatment. Our results show that 
membranes demonstrating the best properties for use 
in bone regeneration are that with a 15% of HAp 
nanoparticles and previously exposed to plasma. These 
membranes demonstrate good bioactivity, they are able 
to nucleate a layer of HAp with a Ca/P ratio similar to 
the physiological one, after only 7 days in SBF, and so 
avoid a possible degradation of the material.  
ii. Despite the decrease of the Young modulus of the 
scaffolds when incorporating only 5% of HAp, and the 
degradation of PLLA in SBF, it is observed that when 
immersion time in SBF increasing, the thickness of the 
layer of HAp coating also increases. Combining the 
incorporation of nanoparticles and a previous plasma 
treatment it is possible to obtain a uniform layer of 
HAp coating on the surface after only 14 days in SBF. 
The formation of some nuclei on the internal surface is 
observed after 21 days in SBF. 
iii. The sonication process reduces the particle 
agglomeration and increases the specific surface with 
the polymer matrix and therefore a better interaction 
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between the particles and the matrix is obtained. The 
utilisation of SiO2 particles in low quantity together 
with an amount of HAp particles results in an increase 
of the elastic modulus in compression. This was due to 
an augmentation of the specific surface between PLLA 
and nanofiller, due to the silica nanoparticles 
incorporation. The composite material made with PLLA 
as matrix and reinforced with 10% (HAp/SiO2) wt. with 
the ratio (HAp/SiO2) of (95/5) showed a bioactivity on 
the surface after 21 days soaking in SBF. This study 
led to the fabrication of a highly porous scaffold, with a 
bioactive surface, an elastic modulus of nearly 10 MPa, 
and with a morphology that allows cell and nutrients 
flow. 
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4.4 BILAYER CONSTRUCT 
 
The join observed between the two functionalised sides is 
greatly assembled to both scaffolds. This is due to the dioxane 
used in the polymer solution to bond both side. The dioxane 
dissolved the PLLA in the scaffolds consequently permits to 
combine the PLLA of the scaffolds and the join when the 
dioxane is removed.  
This bi-layer scaffold presents a similar elastic modulus 
according to the cartilage phase. Bioactivity of the bone layer 
is improved by filling the PLLA matrix with HAp 
nanoparticles. The bi-construct has a very high porosity over 
80% with macro and micropores, 100% biodegradable. The 
nanoparticles of HAp do not increase the elastic modulus but 
bring to PLLA a better bone bounding ability. This design was 
one signed for, but it does not exclude other combination such 
as including SiO2 particles for the bone part. 
At present, the viability of the final osteocondral construct is 
being studied in vivo; several replicas were implanted in 
femoral condyle of sheep by our collaborators at the 
Laboratorio de Ortopedia Experimental Área de Terapia 






Chapter 5.   Conclusions 
 
• Freeze-extraction combined with particle leaching was a 
method with which it was possible to fabricate porous 
scaffolds of PLLA with a microstructure around 5 µm and 
macrostructure around 150 µm. The porosity obtained was 
high, over 80% with spherical pores interconnected. 
 
• It was possible to evaluate the influence of the 
microporosity dimension on the properties of the scaffolds 
varying the polymer/solvent ratio between the limits of 
fabrication 5% and 20% wt. of PLLA. Macroporosity and 
pores throats were varied by changing the polymer/ 
porogen ratio. The limits of this ratio were established 
between 1:1 and 1:1.25. 
 
• The calorimetric properties were not affected by the 
changes of polymer concentration or polymer/ porogen 
ratio, as in the porogen leaching PLLA crystallized up to 
its maximum. The observed changes in morphology had 
influence mainly in the elastic modulus of the scaffolds 
that varied from 0.1±0.1 to 8.9±0.8 MPa for industrial 
PLLA and from 0.01±0.03 MPa to 6.1±0.9 MPa for medical 
grade PLLA and in a lesser extent in the porosity.  
 
• The scaffolds made with 15 % wt. of PLLA and 1:1 
polymer ratio with an elastic modulus of 8.9±0.8 MPa, for 
industrial PLLA and 3.5±0.6 MPa for medical grade PLLA 
was selected for the final design of the osteochondral 
construct. 
 
• Static and dynamic degradation of PLLA produces the 




of low molecular weight chains. The evolution of the 
molecular weight distribution function indicated that 
PLLA suffers surface erosion as for almost all the 
degradation times there is still a quite big fraction of long 
chains. Chain scission affects mostly the mechanical 
properties. In the static case, the elastic moduli decreased 
very slightly while the yield point decreased to a bigger 
extent. Furthermore the robustness of the scaffolds 
decreased in the permeability test. The effect of dynamic 
degradation is only seen in the densification zone as 
during the experiment the scaffolds were collapsed. 
 
• The micro and macro porosity seemed to be affected by the 
degradation. However, changes in morphology are quite 
slight as corresponds to surface erosion. 
 
• The degradation attacks the amorphous phase that keeps 
entrapped in the samples confined in the crystalline 
region, and no changes in crystallinity or mass were 
observed during the degradation experiment. This is due 
to the highly crystallinity that had the materials after 
freeze extraction. 
 
• PLLA/ HAp membrane composites were fabricated and 
showed an increase of the storage modulus with the filler 
content. Particles affect PLLA thermal behavior acting as 
nucleating agents for PLLA crystals modifying the cold 
crystallisation kinetics whereas glass transition 
temperature of PLLA is independent of the filler content. 
The bioactivity is enhanced by the presence of the HAp 
particles more than by plasma treatment. Membranes 
demonstrating the faster kinetics of apatite deposition 
with a Ca/P ratio similar to the physiological one are that 
with a 15% of HAp nanoparticles and previously exposed 
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to plasma which also presented the higher value of storage 
modulus. 
 
• Scaffolds filled with nanoparticles of HAp and silicate 
were fabricated. The increase of HAp did not permit to 
increase the mechanical properties even when double 
sonication was applied to disperse the nanofiller to the 
polymer solution. The combination of 9.5 % of 
nanoparticles of HAp and 0.5% of silicate permitted to 
increase the mechanical properties of the medical grade 
scaffolds till 6.9±0.1 MPa, as double sonication permitted 
effective dispersion of nanofillers and silica augmented 
the specific surface between PLLA and nanofiller. 
 
• The bioactivity of the scaffolds increased when 
incorporating only 5% of HAp and more if materials are 
exposed to plasma. It was possible to observe biomimetic 
apatite on the internal surface after 21 days in SBF. The 
composite material reinforced with 10% wt. of HAp/SiO2 
in proportion (95/5) showed a better bioactivity on the 
surface and interior after 21 days soaking in SBF.  
 
• It was possible to fabricate an osteochondral bilayer 
scaffold by the combination of two scaffolds fabricated by 
freeze extraction and particle leaching. The two layers 
were joined by a thin non-porous layer to avoid blood flow 
from the bone to the cartilage area. The up side of the 
biconstruct functionalised for cartilage repair was a 1:1-
15%PLLA-MED scaffold, 1 mm high. The bottom side 
made with the same composition (6 mm high) was 
functionalised for good bone anchorage with a 5% wt. 







Chapter 6.   Appendix. In vitro and in vivo 
biological response 
 
In vitro and in vivo biological response of the different 
materials fabricated is described in this section. This study 
was made in collaboration with the Group of Structural 
Mechanics and Materials Modelling, of the University of 
Zaragoza and the Laboratorio de Ortopedia Experimental Área 
de Terapia cellular of the University of Navarra. My 
participation on this work consisted in the fabrication of the 
materials for their biological evaluation. Furthermore I add 
the opportunity to participate to the coordination meeting 
organised during the project in which each group worked on.  
6.1 IN VITRO CULTURE 
 
Human mesenchymal stem cells (hMSCs) were loaded into 1 
and 6 mm scaffolds, as fabricated in section 2.1.1, p. 47, in 
order to establish the optimal conditions for cell seeding. 
Loading of scaffolds was performed as follows: for 6 mm thick 
scaffolds cells resuspended in 20 µL were seeded by needle 
injection. Scaffolds of 1 mm thick were placed in a pipette tip 
and connected to an aspiration syringe and hMSCs were 
aspirated. Cells were finally allowed to attach for 3 hours and 
then the efficiency of seeding and the cell density achieved 
were used as the parameters to determine the optimal loading. 
Seeding efficiency was determined by quantification of DNA 
using spectrophotometry. Cell density was measured with 
DAPI and visualized using a fluorescence microscope. Cell 
count was performed using ImageJ software. For chondrogenic 
differentiation, hMSCs loaded scaffolds were maintained in 
culture with differentiation media for up to 21 days and then 





The seeding of hMSCs yielded a percentage of cells retained in 
the scaffold of 80.8 ± 4.1 and 71.6 ± 9.4% for the 6 and 1 mm 
scaffolds respectively (p>0.05). Cell distribution was 
quantified using immunofluorescence against β-actin, as the 
percentage of scaffold area occupied by cells (Figure 6-1B). 
Images are shown in Figure 6-1C. Cells were unevenly 
distributed in 1 mm scaffolds, with areas covered up to 60% 
with cells (center of the scaffold) with lower occupation in the 
outer part of the scaffold. Cells accumulated around the needle 
track and the center of the 6 mm scaffolds (Figure 6-1C); 
however concerning the percentage of the area occupied by 
cells, in 6 mm scaffolds it reached only 3% in those zones with 
higher cell concentration. Finally, SEM images obtained from 
the loaded scaffolds showed the presence of cells inside the 





Figure 6-1: (A). Cell distribution was visualized by 
immunofluorescence. (B). Some representative images are 
shown in (C) for 6 (left panels) and 1 mm scaffolds (right 
panels). Scanning electron microscopy was performed to 
confirm the distribution of cells and to visualize the 
topography of the material (D). The arrows show the channel 
perforated by the syringe during the loading process. Results 
represent the mean ±SD of at least 3 different experiments in 






Scaffolds (1 and 6 mm) were maintained for 21 days in either 
expansion media (EM) or chondrogenic media (CM) after 
which cell number, spontaneous as well as induced 
chondrogenic differentiation were examined. The number of 
hMSCs in 6 mm scaffolds remained stable during the 21 days 
in expansion and chondrogenic media while there was a 
reduction in cell number in 1 mm scaffolds with EM 
throughout the 21 days of the experiment. When 1 mm 
scaffolds were cultured with chondrogenic medium there was a 
reduction similar to those treated with EM (Figure 6-2A). In 
both cases (EM and CM), the reduction in the cell number in 
the scaffolds was not due to an increase in apoptosis, as 
demonstrated by the negative immunostaining of caspase 3A 
(Figure 6-2B left). These results suggest that the decrease in 
cell number is produced by the loss of unbound cells. Finally, 
immunostaining with Ki67 antibody did not reveal any 





Figure 6-2: Scaffolds were seeded with hMSCs and culture for 
up to 21 days in EM or CM and the number of cells quantified 
(A). (B) Cell apoptosis and proliferation was determined by 
immunfluorescence staining using antibodies against 
caspase 3A and Ki67 respectively. DAPI was used for nuclei 
staining. Results represent the mean ±SD of at least 3 








The histological comparison between scaffolds maintained in 
expansion media showed that MSCs did not produce a 
significant amount of extracellular matrix components or fiber 
deposition either in 1 or 6 mm scaffolds (Figure 6-3A). 
However, in those scaffolds maintained in differentiation 
media, hMSC were surrounded by collagen fibers as 
demonstrated by Masson’s trichrome that was particularly 
intense in certain areas. While cell distribution varied 
between 1 and 6 mm scaffolds, fibers were similarly 
distributed around the cells (Figure 6-3A).  
 
Immunfluorescence analysis demonstrated the presence of 
collagen type X in both 1 and 6 mm scaffolds and to a lesser 
extent type I collagen. Type II collagen, specifically associated 
with hyaline cartilage was poorly detected in either scaffold, 
with some slight staining in areas with a high density of cells. 








Figure 6-3: (A) Masson’s trichrome staining of sections from 
6 mm (left panels) and 1 mm (right panels) thick scaffolds 
showing the presence of matrix fibers. (B) The composition 
of the matrix fibers in the scaffolds after differentiation was 
assessed by immunofluorescence against aggrecan, and 
collagens type I, II and X (B). DAPI was used for nuclei 
staining. A representative study of at least three 
experiments is shown. 
 
hMSC into the 6 mm thick scaffolds provided a poor 
distribution of cells confined in the center of the material, but 
with high density in the site of the injection. In the 1 mm thick 
scaffolds, the higher quantity of cells seeded achieved better 
distribution spreading over the scaffold, with a high density in 
the entire volume of the material that would eventually lead 






In vivo osteointegration of the scaffolds was analyzed after 
their implantation in the femoral condyle of 3 month aged 
healthy sheep. Three types of scaffolds were implanted: 
scaffolds only made from PLLA-MED, scaffolds filled with 5% 
wt. of HAp nanoparticles and scaffolds filled with 5%wt. of 
HAp and covered by a layer of biomimetic HAp after 21 days 
in SBF. Osteochondral lesions, 6 mm in diameter and 6 mm in 
depth were performed in the load bearing area of the medial 
femoral condyle, and scaffolds placed during the surgery time 
fixed by press-fit in the site of the lesions. Animals were 
allowed to evolve for 6 weeks and then, the complete knee 
joint extracted and the lesioned area isolated and subjected to 
histological analysis. Masson’s trichrome was used for the 
evaluation of bone integration. Finally the study was 
completed with an immunofluorescence analysis for the 
detection of the bone molecular markers collagen type I, 
osteopontin and osteocalcin. 
 
Images of Figure 6-4 show the presence of regenerated tissue 
inside the pores of the 3 kinds of implanted scaffold. On the 
first hand, PLLA with and without HAp was invaded by a 
fibrous-like tissue according to Masson’s Trichrome staining, 
with abundance of collagen fiber that surround the PLLA 
fragments. On the other hand, the scaffold implanted with a 
layer of hydroxyapatite covering its pores was invaded by a 
tissue that showed zones with an aspect very similar to 
osteoids (Figure 6-4), which suggests that the regenerated 
tissue has characteristics of a mature bone and pointing to a 
more intense integration for these scaffolds. 
Immunofluorescence analysis, Figure 6-4, showed differences 
among the materials in expression of type I collagen, a clearly 
higher expression of collagen I is found in the scaffold covered 




characteristics of fibroblastic tissue and so fails to 
demonstrate the capacity of the material to regenerate a 
tissue similar to natural mature bone. The expression of both 
osteopontin (marker for bone remodeling) and osteocalcin 
(marker for bone calcification) was similar in the three kinds 
of scaffolds showing that processes of bone remodelling and 
formation occurred in the 3 scaffolds here used. 
 
 
Figure 6-4: Masson’s trichrome, collagen I, osteocalcine and 
ostepontin. 
 
The presence of nuclei of HAp on the material’s surface caused 
the appearance of osteoid-like structures very similar to those 




PLLA/ HAp-treated lesions. The lower elastic modulus for 
scaffolds filled with 5% wt. nanoparticles of HAp or the 
scaffolds filled with nanofiller and those covered by a 
biomimetic layer of HAp nucleated after 21 days in SBF 
should be also taken into account, as a weaker material could 
be not adequate for implantation in bones that need 
mechanical resistance after the surgical procedure. The HAp 
nuclei formed over the HAp molecules would facilitate the 
differentiation of cells that penetrate inside the scaffold once 







ACI    autologous Chondrocyte Implantation 
BMP   bone morphogenetic proteins 
CACI    collagen-covered ACI 
χc    crystallinity 
CM    chondrogenic media  
DAPI   4',6-diamidino-2-phenylindole 
DCPD   dicalcium phosphateFDA 
DMS    dynamic mechanical spectroscopy 
DSC    differential scanning calorimetry 
ECM    extra cellular matrix 
EDS    elemental analysis 
EM    expansion media 
FDA   food and drug administration 
FGF   fibroblast growth factors 
FTIR   fourier transform infrared analysis 
GAGs   glycosaminoglycans 
GPC    gel permeation chromatography 
HA   hyaluronic acid 
HAp    hyadroxyapatite 
HFBR   hollow fiber bioreactor 
hMSC   human mesenchymal stem cells 
IGF   insulin-like growth factors 





MSC    hesenchymal stem cells 
NBSs    nanoparticulated bimodal porous silicas 
OA    osteoarthritis 
OCP    octacalcium phosphate 
PACI   periosteum ACI 
PBS    phosphate bufferer saline solution 
PCL    poly (ε-caprolactone) 
PDGF   platelet-derived growth factor 
PDLA    poly (D-lactic acid) 
PDLLA   poly (D, L-lactic acid) 
P(EMA-co-HEA)  poly(ethyl methacrylate-co-hydroxyethyl 
acrylate) 
PEMA   poly(ethyl methacrylate) 
PEO    polyethylene oxide 
PGA    poly(glycolic acid) 
PLA    poly (lactic acid) 
PLGA    poly (DL-lactic-glycolic acid) 
PLLA    poly (L-lactic acid) 
SBF    simulated body fluid 
SEM    scanning Electron Microscopy 
SFF    solid free-from fabrication 
TCP   tricalcium phosphate 
TE    tissue engineering 
Tg    glass transition temperature 
TGF-β   transforming growth factor beta 
THF   tetrahydrofuran 
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